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Metzincins are a ubiquitously expressed family of multi-domain zinc (II)-dependent 
endopeptidases1 whose members include well-known metalloproteases such as the Matrix 
Metalloproteases (MMPs)2, the A Disintegrin And Metalloproteases (ADAMs)3, the 
ADAMs with a thrombospondin motif (ADAMTS)4, the bacterial serralysins5 and proteases 
such as the astacins (including the meprins)6,7. This superfamily of proteases is defined by 
the presence of a Zn2+ ion at the catalytic centre which is coordinated by three histidine 
residues in the zinc binding consensus sequence HExxHxxGxxH that is present in all 
proteolytically active metzincins, and a characteristic, strictly conserved methionine 
containing tight 1,4 beta turn forming a hydrophobic cleft for the catalytic zinc ion8. 
Catalysis of protein substrates is (most probably) carried out via a general base mechanism 
involving activation of a zinc-bound water molecule by the carboxylate group of the 
conserved glutamate residue in the catalytic pocket followed by attack of water on the 
polarized carbonyl group in the substrate’s scissile bond9. 
The main physiological function of these proteases lies in the modulation and regulation of 
extracellular matrix (ECM) turnover by either direct proteolytic degradation of the ECM 
proteins (e.g. collagen, proteoglycans and fibronectin)10 or by liberation of biologically 
active proteins such as cytokines, growth factors and chemokines from their membrane-
anchored proforms (so-called shedding). 
 
1.2 Matrix metalloproteinases 
 
The largest human subfamily of the metzincins is the matrix metalloproteases or matrixins 
(see table 1) which consists of 23 distinct proteases in human (24 in mouse). The first MMP 
identified in 1962 as the protease responsible for the degradation of fibrillar collagen in 
tadpole tails during metamorphosis was dubbed interstitial collagenase11. After 
identification of a similar collagenase in human skin, this protease was renamed MMP-1. 
MMPs have since been identified as the major enzymes responsible for turnover of 























Schematic representation of the domain structure of metzincin proteases 
A: signal peptide; B: prodomain; C: catalytic domain; D: hemopexin-like domain; E: fibronectin type 
II insert; F: transmembrane domain; G: cytoplasmic tail; H: disintegrin domain; I: cysteine-rich 
domain; J: EGF-like domain, K: thrombospondin type I-like repeat, L: spacer region. 
 
MMPs are largely excreted proteins with several conserved domains (see figure 1). All 
MMPs contain the catalytic domain, which is shielded off in the inactive form of the 
enzyme by the prodomain. This propeptide interacts with the catalytic region through a 
conserved cysteine residue and the Zn2+ ion in the catalytic pocket (the so-called cysteine 
switch)12,13. Except for MMP-7, MMP-23 and MMP-26 all MMPs contain a C-terminal 
hemopexin-like domain which functions primarily as a recognition sequence for the 
substrate14. Although MMPs retain catalytic activity towards a wide range of substrates 
when missing this domain, the hemopexin domain, which is structured like a four-bladed 
propeller structure with each blade consisting of 4 antiparallel β-sheets and 1 α-helix, is an 
absolute necessity for the degradation of triple helical collagens15. The gelatinases (MMP-2 
and -9) further contain a series of three fibronectin type II inserts in the catalytic domain 






Table 1: Overview of the 23 identified human matrix metalloproteinases and their common names.  
 
MMP Alternative name MMP Alternative name 
1 Collagenase-1 
Interstitial collagenase 
16 Membrane type-3 MMP 
2 Gelatinase A 
72 kDa type IV collagenase 
17 Membrane type-4 MMP 
3 Stromelysin-1 
Transin-1 







21 Human orthologue of Xenopus 
xMMP 
9 Gelatinase B 
92 kDa type IV collagenase 
23 Cysteine array MMP 
Femalysin 
MMP-22 
10 Stromelysin-2 24 Membrane type-5 MMP 
11 Stromelysin-3 25 Membrane type-6 MMP 
Leukolysin 
12 Macrophage metallo-elastase 26 Matrilysin-2 / endometase 
13 Collagenase-3 27 None 
14 Membrane type-1 MMP 28 Epilysin 
15 Membrane type-2 MMP   
 
MMP function is regulated at several levels. Firstly induction of gene expression is 
controlled by a number growth factors and cytokines, and may be suppressed by 
transforming growth factor β and glucocorticoids2,17. Besides soluble factors, MMP 
expression may also be regulated by cell-cell contact or interaction of cells with ECM 
components such as EMMPRIN (extracellular matrix metalloproteinase inducer or 
CD147)18. The expressed MMPs are largely excreted as inactive zymogens with the 
propeptide effectively limiting entrance into and catalysis of a substrate in the catalytic 
pocket by blocking the catalytic zinc (II) ion via the cysteine-switch mechanism. Activation 
of proMMPs can occur through several mechanisms (reviewed in 19) that all lead to 
disruption of the cysteine switch. Perhaps the most important mechanism is proteolytic 
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removal of the prodomain by other endopeptidases such as furin20. Removal of the 
prodomain of MMPs, which contains a furin-like proprotein convertase recognition site 
(RRKR or RxKR), has been described for 9 MMPs including all membrane-type MMPs. 
Alternatively the prodomain can be proteolytically removed by plasmin and other serine 
proteases, or even other MMPs. This mechanism is well described for MMP-2 where the 
proMMP2 binds the endogenous MMP inhibitor TIMP-2 (tissue inhibitor of 
metalloproteinases 2). This complex in turn functions as a ligand for the membrane-bound 
MMP-14 (or membrane-type 1 MMP) leading to activation of MMP-221. 
The cysteine switch may also be broken by chemical reactions, either physiologically by 
oxidation of the cysteine by reactive oxygen species, or artificially by mercury-containing 
compounds such as 4-aminophenylmercuric acetate (APMA) or denaturing surfactants such 
as sodium dodecyl sulphate (SDS). This disruption of the thiol-zinc interaction leads to 
allosteric relocation of the prodomain leading to active forms of the enzyme with the 
propeptide still attached or to autoproteolytic removal of the relocated prodomain. 
MMPs are inhibited by the general protease inhibitor α2-macroglobulin and a small family 
of natural inhibitors specifically geared towards inhibiting metalloprotease activity. These 
TIMPs are a group of 4 proteins (21-30 kDa in size) that as a group effectively inhibit all 
MMPs in vivo22.   
Excreted MMPs are generally classified according to their substrate specificity, leading to 
four classes: the collagenases (MMP-1, -8 and -13), the gelatinases (MMP-2 and -9), the 
stromelysins (MMP-3, -10 and -11) and a heterogeneous rest group containing matrilysin 
(MMP-7), metallo-elastase (MMP-12), enamelysin (MMP-20), endometase (MMP-26) and 
epilysin (MMP-28). In this nomenclature the membrane anchored MMPs (MMP-14, -15, -
16, -17, -24 and -25) are considered a separate class. An alternate classification arranges the 





MMP-1 or collagenase-1 was the first described matrix metalloprotease and has sparked a 
large volume of research on the physiological and pathological role of MMPs. MMP-1 is a 
secreted enzyme and contains the hemopexin-like domain necessary for degradation of 
triple helical collagens. ProMMP-1 is probably activated via a two-step proteolytic process 
involving either mast cell tryptase24 or urokinase25 and MMP-3. Mature collagenase-1 can 
be found as two distinct forms: a major 57 kDa species and a minor, glycosylated 61 kDa 
form26. The active enzyme is inhibited by TIMP-1. 
MMP-1 has a wide substrate specificity and is capable of degradation of aggrecan, versican, 
perlecan, casein, nidogen, serpins and tenascin-C27. Since MMP-1 does contain the 
hemopexin domain, it is one of the MMPs capable of proteolytic cleavage of fibrillar 
collagen leading to unwinding of the triple-helical structure leaving the collagen (or 
gelatine) highly susceptible to degradation by other proteases. Proteolysis by MMP-1 has 
been implicated in release of membrane-anchored proforms of insulin growth-factor 




Since mice lack a clear orthologue of human MMP-1 definition of the physiological role by 
creating knock-out mice has not been possible, but transgenic mice which express human 
MMP-1 are known to develop lung emphysema, indicating a possible role for MMP-1 in 
development of this disease28.  Other experiments with transgenic mouse strains have 
revealed development of skin disorders such as hyperkeratosis, and bone growth 
retardation29,30. Since MMP-1 appears to play a key role in turnover of ECM, deregulation 
of MMP-1 activity has been hypothesized to be involved in various diseases where 
excessive or insufficient ECM turnover is involved, such as arthritis31,32, cancer33,34, wound 
healing disorders35, and fibrotic diseases36. Although many studies have found a positive 
correlation between MMP-1 expression and disease it has proven difficult to clearly 
identify MMP-1 as a systemic marker of the investigated disease. Experiments with local 
sampling have proven more accurate, for instance in analysis of MMP-1 in synovial fluid of 
rheumatoid arthritis patients where MMP-1 level correlated with inflammatory activity37,38. 
 
MMP-8 
MMP-8 (neutrophil collagenase or collagenase-2) is very similar to MMP-1 in structure and 
physiological function, although subtle differences in substrate selectivity exist. MMP-8 
has a stronger affinity towards type I collagen than MMP-1, while MMP-1 preferentially 
cleaves type III collagen39. Neutrophil collagenase was first described in 1990 when it was 
cloned from neutrophils obtained from a patient with granulocytic leukaemia40. Contrary to 
MMP-1, MMP-8 is not released immediately after synthesis, but rather stored in specific 
granules that release the active enzyme upon stimulation41. As with MMP-1, MMP-8 can be 
activated by proteolytic removal of the propeptide by stromelysin-1 (MMP-3), but also by 
matrilysin (MMP-7)42. The mature enzyme is 64 kDa in size, with glycosylation increasing 
the size to 75 kDa. Autoproteolytic degradation has been described, yielding a 40 kDa 
fragment, which retains catalytic activity, but does not cleave fibrillar collagen. MMP-8 
activity can be inhibited by both endogenous inhibitors TIMP-1 and TIMP-243. 
MMP-8 seems to have an important function during embryogenesis and postpartum 
remodelling of uterine tissue, as demonstrated by expression studies in mice39. Collagenase-
2 has also been implicated as one of the major contributors to connective tissue turnover in 
inflammation due to oxidative auto-activation of the enzyme44. Experimental evidence has 
shown that purified MMP-8 is capable of degrading α1-proteinase inhibitor which could 
imply increased MMP-8 activity in the pathology associated with pulmonary emphysema45. 
The role of MMP-8 in cancer is interesting, since recent findings have suggested this MMP 
to have a protective effect by suppressing tumour metastasis46,47, and by aiding therapy by 
increasing the susceptibility to oncolytic viruses48. On the other hand studies have identified 
MMP-8 as a promoter of ovarian tumour proliferation49 and high MMP-8 expression seems 
to be an indicator for poor prognosis50. This contradicting evidence of the role of MMP-8 in 
cancer is an indication of the complex, and so far still poorly understood biological roles of 
MMPs. MMP-8 is further involved in various inflammatory processes, such as 
atherosclerosis, where both the expression as well as the protease activity is higher in 
vulnerable plaques than in stable plaques51,52, indicating that MMP-8 may be useful as a 
marker for plaque instability in atherosclerosis. 




MMP-13 (collagenase-3) is the latest human collagenase described in the literature. This 
enzyme exhibits preference towards cleavage of type II collagen, effectively completing the 
substrate spectrum of the collagenases. Collagenase-3 was first cloned from breast cancer 
tissue in 199453. MMP-13 expression can be influenced by a wide range of hormones and 
cytokines, such as parathyroid hormone (indicative of the important role of MMP-13 in 
bone development), insulin-like growth factors I and II, platelet derived growth factor, 
basic fibroblast growth factor, transforming growth factor β1 (interestingly both up- and 
downregulates MMP-13 expression depending on the tissue), interleukin-1 and -6, tumour 
necrosis factor α and many more54.  ProMMP-13 can be activated by auto-proteolysis or 
propeptide removal by various other MMPs like stromelysin-1 (MMP-3), yielding a mature 
enzyme of 48 kDa which in turn can be inhibited by TIMP-1, -2 and -355. Active MMP-13 
is a key factor in the activation pathway of several MMPs. Besides the TIMP route of 
inactivation, MMP-13 can bind to a specific receptor on the surface of osteoblasts and 
fibroblasts resulting in internalisation and degradation of the protease56. 
MMP-13 plays an important role in bone development and remodelling, as may be 
anticipated from its capability to cleave type II collagen (a major component of cartilage). 
This rather specific function is reflected in a limited expression profile of MMP-13 during 
development and adulthood, which is restricted to developing skeletal tissue.  
Contrary to the other collagenases, MMP-13 has a relatively high specific activity towards 
gelatine, indicating that the proteolytic role of MMP-13 expands past the first-step of 
cleavage of triple-helical collagens. Further identified substrates of MMP-13 include 
aggrecan and perlecan, TGFβ, biglycan, the large isoform of tenascin-C, fibrillin-1 and -2, 
fibrinogen and two serpins (α2-antichymotrypsin and plasminogen activator inhibitor-2)54. 
MMP-13 expression has been regularly described in literature as indicative of various 
cancerous processes including chondrosarcoma, breast cancer, head and neck tumours and 
melanoma57. In all cases high expression of MMP-13 seems to be related to aggressiveness 
of the tumour. 
Regarding the important role of MMP-13 in bone turnover it is not surprising that this 
enzyme has been linked to various bone-related diseases. Since MMP-13 degrades both 
type II collagen and aggrecan, it has been linked to cartilage destruction in rheumatoid and 
osteoarthritis58. The specialized role of MMP-13 in bone development and disease have 





MMP-2 (gelatinase A, 72 kDa type IV collagenase) is one of the two described human 
gelatinases in the MMP family, named for their ability to proteolytically degrade gelatine 
(denatured collagen). MMP-2 is ubiquitously expressed as a 72 kDa zymogen and subject 
to extensive glycosylation. Expression of MMP-2 is constitutive and most pro-




of MMP-9, lacks binding sites for pro-inflammatory transcription factors such as activator 
protein-161.  
The MMP-2 zymogen is activated by the MMP-activation cascade depicted in figure 2. 
Under favourable stoichiometric conditions TIMP-2 complexes with proMMP-2 and this 
complex forms a ligand for the membrane-bound membrane type1-MMP which 
subsequently removes the prodomain of proMMP2 by proteolytic cleavage (aided by free 
active MMP-2) , yielding the truncated 64 kDa active enzyme62. If the concentration of 
TIMP-2 is too high, both MT1-MMP and active MMP-2 will be inhibited, and no further 
activation will ensue. Besides this activation pathway, proMMP2 can also be activated by 
thrombin and activated protein C63. 
MMP-2 differs from other MMPs in the fact that the catalytic domain contains cysteine-rich 
inserts that resemble the collagen binding regions of the type II repeats in fibronectin. 
These inserts are required for binding and cleavage of collagen and elastin64.  
The main function of MMP-2, as with other MMPs, lies in the degradation of extracellular 
matrix proteins. MMP-2 is capable of cleaving gelatine, type I, IV and V collagens, elastin 
and vitronectin65. Through their ability to degrade collagen in the vascular basal membranes 
the gelatinases are involved in neovascularization66 both under physiological conditions and 
in pathologies such as tumour metastasis. MMP-2 can also facilitate migration of cells by 
direct degradation of the basement membrane thus allowing infiltration of for instance 
neutrophils and lymphocytes, or liberation of chemo-attractants67. This latter process, 
named ‘ectodomain shedding’ is one of the important physiological functions of the 
membrane-bound ADAM proteases, but has also been described for many other members 
of the metzincin superfamily. MMP-2 has been known to be involved in both promoting 
and inhibiting inflammation by liberation of pro-inflammatory mediators (for instance the 
active form of interleukin-1β68), proteolytic degradation of chemoattractants (for instance 
transforming monocyte chemoattractant protein-3 into the truncated form with antagonistic 
properties on the CC chemokine receptor69) and a profound role in the chemotactic gradient 
that is necessary in clearance of recruited inflammatory cells from tissue70.  Recent 
evidence from proteomics studies show that the role of MMP-2 in processing of signalling 
proteins may be much greater than originally anticipated which, when confirmed for other 
MMPs could lead to a paradigm shift in the physiological role of these proteases71,72.   
Interestingly, MMP-2 knockout mice exhibit a normal phenotype under physiological 
conditions, although the animals do show different response patterns in allergen challenge 
which may be attributed to disturbance of the important role of clearing immune cells70. 
These findings indicate that MMP-2 function may be interchangeable with other 
metalloproteases, a hypothesis that is supported by the observation that expression of the 
second gelatinase, MMP-9 is greatly increased in MMP-2 null mice73. 
 
MMP-9 
MMP-9 (gelatinase B, 92 kDa type IV collagenase) was first discovered in neutrophils in 
197474. MMP-9 is expressed as a 92 kDa zymogen which can be activated to the 83 kDa 
mature enzyme. The larger size of MMP-9 relative to MMP-2 can be contributed to a 
heavily O-glycosylated collagen V-like insert that links the metalloprotease domain to the 
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hemopexin-like domain75. MMP-9 activation may be mediated by removal of the 
prodomain by serine proteases or other MMPs76, or may be a direct response to oxidative 
stress which disrupts the cysteine switch77. As expected, a considerable overlap exists in the 
substrates degraded by MMP-2 and -9, but MMP-9 is incapable of direct proteolysis of 
collagen I65.  
MMP-9 has been described to release the biologically active form of vascular endothelial 
growth factor (VEGF) which plays an important role in angiogenesis. This process is 
complemented by the direct proteolytic degradation of the vascular basement membrane 
proteins, indicating that MMP-9 (even more than MMP-2) may play a crucial role in the 
formation of new blood vessels78. MMP-9 further has an important role in migration of 
immune cells as demonstrated by the reduced presence of neutrophils, lymphocytes and 
dendritic cells in brochoalveolary lavage fluid (BALF) of MMP-9 knockout mice after 
antigen challenge79. MMP-9 null mice show decreased fertility since MMP-9 is crucial in 
several stages of the female reproductive cycle (implantation of the embryo and the 
remodelling of endometrial tissue that occurs during the menstrual cycle)80. Absence of 
MMP-9 also leads to disorders in bone development, specifically delayed bone ossification 
due to insufficient angiogenesis in growth plates81 and reduced osteoclast recruitment82. 
The biological role of MMP-9 is extensively reviewed in 83.  
As MMP-2, MMP-9 is capable of processing cytokines and chemokines. MMP-9 cleaves 
interleukin-8 to its more potent truncated form,  activates IL-1β and transforming growth 
factor β65. Where MMP-2 is naturally inhibited by TIMP-2, MMP-9 is mostly inhibited by 
TIMP-184. Contrary to MMP-2 which is expressed ubiquitously under physiological 
conditions, MMP-9 is only present constitutively in neutrophils85 where it is stored in 
granules to be rapidly released after stimulation. Expression in many other cell types is 
inducible by (inflammatory) stimuli86, is increased in malignant cell lines and correlates 
with the metastatic potential87. Neutrophil-derived MMP-9 is distinguishable from other 
sources since it forms a covalent complex with neutrophil gelatinase B-associated lipocalin 
(NGAL)88.  
The role of gelatinases in pathology has been studied extensively, especially in lung 
diseases (reviewed in 65) and cancer (reviewed in e.g. 89 and 90). The amount of both 
gelatinases in BALF and sputum of patients suffering from chronic asthma is higher than in 
healthy individuals and this increase is hypothesized to be mainly due to gelatinases 
originating from eosinophils and epithelial cells91,92. This increase may be responsible for 
the characteristic tissue remodelling events observed in chronic asthma such as thickening 
of the basement membrane, smooth muscle tissue hypertrophy and reduced epithelial 
thickness. MMP-2 does not seem to play an important role in the pathophysiology of acute 
asthma, but MMP-9 and MMP-9/TIMP-1 ratio are increased in exacerbations of acute 
asthma79. This phenomenon may be explained by the presence of a pool of MMP-9 inside 
the neutrophils that is released during the asthmatic attack. Since neutrophils do not 
produce TIMP-1, degranulation leads to a strong increase in the local concentration of 
proteolytically active MMP-9 which may cause several of the symptoms observed in acute 
asthma such as airway obstruction due to desquamation of epithelial cells and increased 




The relevance of gelatinases in the pathophysiology of chronic obstructive pulmonary 
disease (COPD) is not clear, but excess protease activity certainly plays an important role in 
development and progression of the disease. Sputum and BALF of patients contain high 
concentration of both MMP-2 and -9, and especially MMP-9 may be an important factor 
since MMP-9 activity not only causes ECM destruction itself, but has also been described 
to degrade α1-antitrypsin leading to increased activity of neutrophil elastase and cathepsin 
G65,93. MMP-9 is further capable of promoting infiltration of neutrophils (loaded with 
MMP-9 containing granules) by production of the biologically more active truncated form 
of IL-8, causing a vicious circle of MMP-9 activity in the diseased lung. Gelatinase 
presence and activity has been described as elevated in many other pulmonary diseases, 
such as cystic fibrosis, bronchiectasis, acute respiratory distress syndrome (ARDS) and 
infectious diseases (reviewed in 65 and 83). 
The obvious relation of gelatinases to tumour metastasis and angiogenesis has lead to a 
plethora of research papers on the role of MMP-2 and -9 in diverse malignant processes. 
This hypothesis was first affirmed by the observation that MMP-2 knockout mice show 
decreased tumour angiogenesis and progression94 and since then MMPs have been 
identified as important players in angiogenesis, growth and metastasis of tumours. 
The development of a new vascular system is necessary for development a tumour, since 
without new blood vessels the size of a tumour will be restricted. Gelatinases are primarily 
involved in this process by enabling proteolytic degradation of the vascular basal 
membrane, opening the way for endothelial migration to the formation of a new vessel95. 
MMP-2 is further capable of cleavage of laminin-5, which after degradation yields a cryptic 
site that increases endothelial cell migration95, and the release of VEGF by MMP-9 
stimulates angiogenesis not only under physiological conditions but also in cancer. Tumour 
growth can be stimulated by gelatinase activity since MMP-2 and -9 have been known to 
release growth factors96. Tumour metastasis is a process that involves release of single 
tumour cells, migration of these single cells to a vessel and penetration into the blood 
stream or lymph system and finally adhesion to vessel endothelium and extravasation into 
the tissue at the metastatic location. The ECM degrading properties of gelatinases are 
crucial in both exit of the metastatic cells from the bulk tumour as well as entrance into the 
new seeding site.   
Increased gelatinase expression and activity has been described in hundreds of publications 
describing malignant diseases ranging from breast cancer97, urogenital cancers98-100, brain 
tumours101, lung cancer102, skin cancer103 and many more. Interestingly many authors have 
found a positive correlation between gelatinase expression or activity and invasive potential 
of the tumour involved, again stressing the crucial role MMP-2 and -9 play in metastasis. A 
comprehensive review of the literature on gelatinase involvement in individual cancers is 
beyond the scope of this thesis, but excellent reviews are available(e.g. 83). 
Besides pulmonology and oncology gelatinase activity is under investigation in several 
other research fields. MMP-2 has been identified as a possible target in cardiovascular 
disease since it was identified as the protease responsible for degradation of the vasodilator 
peptide andrenomedullin, with one of the resulting fragment peptides having 
vasoconstrictive properties, possibly leading to hypertension104. 






MMP-3 or stromelysin-1 was the first described in 1985 as a 51 kDa protein secreted by 
rabbit fibroblasts105 that was able to degrade casein, and could be distinguished from 
collagenase by the inability to degrade type I collagen. More or less simultaneously a 
protease named transin was described in transformed rat cells, which later was identified to 
correspond to stromelysin106,107. Stromelysins have a basic MMP structure, with a 
hemopexin-like domain. The 51 kDa latent zymogen can be activated by proteolytic 
removal of the prodomain by for instance the serine proteases trypsin-2108 and 
matriptase109, yielding a 43 kDa active enzyme in humans. MMP-3 is upregulated by 
exposure to interleukin 1β, and downregulated by retinoic acid and dexamethasone110. 
The substrate specificity is broad and MMP-3 has been described to degrade many ECM 
proteins such as fibronectin, denatured collagens (gelatin), laminin and proteoglycans. 
MMP-3 is incapable of degrading triple helical collagens, but can cleave the globular 
portion of type IV collagen111. Besides degradation of ECM components MMP-3 is also 
involved in the activation cascade of the gelatinases and MMP-13 (see figure 2). The 
physiological function of MMP-3 is, surprisingly, not well described in literature, but is 
assumed to be mainly in turnover of extracellular matrix. MMP-3 is highly upregulated in 
mammary tissue during involution after the lactation period and seems to have a pro-
apoptotic effect112.  
In vitro experiments with cultured cells have identified some membrane-bound signalling 
proteins that may be released by MMP-3 (e.g. E-cadherin113 and Fas ligand114), but the 
physiological relevance of these finding is unclear. One well-described substrate of MMP-3 
is plasminogen activator inhibitor-1 (PAI-1)115, and proMMP-3 can form a complex with 
tissue-type plasminogen activator which increases the activity of t-PA116. These findings 
may be indicative of an important regulatory function of MMP-3 in the fibrinolytic 
pathway.  
MMP-3 has been described as a factor of importance in development of arthritis117,  
asthma118, aneurism119, impaired wound healing120, Alzheimer’s disease121 and various 
cancers122,123. Recent insights and studies demonstrate that association of MMP-3 with 
disease states (especially cancer) is difficult, as many newer studies do not find a positive 
correlation between MMP-3 and the disease. This observation may be (partially) explained 
by the function of MMP-3 as an activator of other MMPs which makes identification of the 




The cloning of rat transin/MMP-3 in 1985 quickly lead to the identification of a second 
stromelysin. This protease, named transin-2124, and later identified in humans as 
stromelysin-2125 or MMP-10 has 82% sequence homology with MMP-3126. MMP-10 is 
secreted as a 53 kDa zymogen, and is activated to a 47 kDa mature protease. Originally, 




cytokines and hormones127, but recent studies have shown results that indicate the 
contrary128. 
The physiological function of MMP-10 is poorly understood, with only a handful of 
publications dealing with characterization of this protease. The in-vitro substrate specificity 
seems similar to that of MMP-3, but catalytic activity towards type III, IV and V collagens 
is weaker129. Contrary to MMP-3, MMP-10 is not produced by fibroblasts, but is expressed 
in keratinocytes which in turn do not produce MMP-3130. MMP-10 seems to have an 
important role in skin wound healing and cellular migration, since it is primarily found at 
the front of the migrating epithelial ‘tongue’131 and has been observed in migrating 
enterocytes in inflammatory bowel disease132,133. MMP-10 is, in vitro, capable of 
processing laminin-5 which may be an additional mechanism in which the enzyme enables 
cellular migration134. 
Stromelysin-2 presence and activity at sites of resorption in developing bone has been 
demonstrated by histochemistry and casein in-situ zymography, and may play a role in the 
remodelling events taking place during ossification135. 
 
MMP-11 
The third human stromelysin is MMP-11, which was first described in 1990 in a breast 
carcinoma cDNA library136. Although MMP-11 is often categorized as a stromelysin, it is 
very different from the other two proteases in this group. Production of MMP-11 is highest 
in fibroblasts, and is particularly observed in remodelling tissues at later stages of the 
process. MMP-11 has been associated with many physiological processes where ECM 
remodelling occurs, such as during embryonic development, female reproductive cycle and 
wound healing. The 56 kDa MMP-11 zymogen is activated intracellularly by furin20 or 
paired basic amino acid cleaving enzyme-4 (PACE-4)137 and is secreted as a 47 kDa active 
protease. The physiological role of MMP-11 is unclear, but differs significantly from other 
MMPs. No major ECM proteins such as collagens, gelatin and fibronectin can be degraded 
by MMP-11, and contrary to many other MMPs, exhibits an anti-apoptotic effect. The 
biological mechanism underlying this effect is not known, but probably involves proteolytic 
cleavage of yet uncharacterized protein substrates that promote cell survival138. Several 
possible substrates of MMP-11 have been identified, mainly being protease inhibitors such 
as α1 proteinase inhibitor and α2 macroglobulin. MMP-11 further has a weak caseinolytic 
activity and has been shown to cleave insulin-like growth factor binding protein-1 (IGF-
BP-1) in a carcinoma cell line139. Recent research has demonstrated that although MMP-11 
does not cleave many ECM proteins, degradation of type VI collagen is one of the 
physiological functions and is related to inhibition of adipogenesis by stromelysin-3140. 
The relatively narrow and aberrant substrate specificity of MMP-11 probably stems from a 
mutation that occurred in the highly conserved methionine-turn. Whereas all other MMPs 
contain an MxP sequence in the met-turn, in MMP-11 the proline is replaced by an alanine. 
This substitution has a profound effect on the structure of the S’1 selectivity pocket leading 
to greatly changed substrate specificity141. 
Although the physiological role of MMP-11 is still poorly understood, the involvement of 
this enzyme in especially the early stages of the process of tumour formation and metastasis 
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has been thoroughly investigated (reviewed in e.g. 142). MMP-11 is rarely present in 
sarcoma tumours, but almost always expressed in carcinomas. An interesting observation is 
that the MMP-11 is produced not by the malignant cells themselves, but by the surrounding 
mesenchymal cells. High levels of MMP-11 have predictive value for tumour 
aggressiveness and low survival rate. MMP-11 plays a role in early invasion of the 
surrounding tissue by the tumour cells, a process which is dependent on the catalytic 
activity of the protease143. This is surprising since MMP-11 is not capable of degradation of 
the major ECM constituents. Cancer cell are able to stimulate nearby fibroblasts to produce 
MMP-11, a process which is associated with modification of the invaded ECM to a stroma 
phenotype by desmoplasia144. The anti-apoptotic effect of MMP-11 may play a role in 
establishment of the tumour, and early survival. MMP-11 deficient tumour exhibit higher 
levels of apoptosis, and implantation of experimental tumours is lower in MMP-11 null 
mice145. Although development of primary tumours is favourably affected by high MMP-11 
levels, the metastatic potential of MMP-11 expressing tumours seems to be lower. In 
experiments with MMP-11 null mice, the number and size of secondary tumours was 
greater than in wild type mice implanted with similar sized tumours, indicating a protective 
effect of MMP-11142. 
 
1.2.4 Membrane-type MMPs 
 
In addition to the soluble matrix metalloproteinases, a small group of membrane anchored 
MMPs has been described. The first member of this subfamily, MMP-14 or membrane 
type-1 MMP (MT1-MMP) was discovered only in 1994146 and cloning experiments have 
since revealed the existence of five additional MT-MMPs. The domain structure of MT1-
MMP is very similar to that of soluble MMPs (see figure 1) with the characteristic zinc 
binding catalytic domain, the prodomain in the inactive zymogen form of the protease, and 
a linked hemopexin-like domain, but most MT-MMPs are membrane-anchored by a single-
pass transmembrane domain, and contain an intracellular cytoplasmic tail that contain three 
putative phosphorylation sites and is presumed to have significance in localization of the 
enzyme on the cell surface147. All MT-MMPs described contain the furin-like recognition 
site in their prodomain, allowing activation of the zymogen by proteolytic removal of this 
domain by furin and other proprotein convertases148.    
 
MMP-14 
MT1-MMP is present at the cell surface as a 55-60 kDa active protease but may be 
processed by autocatalysis into a smaller species of 45 kDa by proteolytic removal of the 
catalytic domain. This truncated form, which still contains the hemopexin-like domain is 
assumed to play a role in autoregulation of MT1-MMP catalytic activity149. The substrate 
specificity of MT1-MMP is well described in literature (reviewed in 150). The enzyme is 
capable of proteolytic degradation of type I, II and II collagens following the characteristic 
cleavage pathway used by collagenases151, a finding that was corroborated by knockout 
experiments that confirmed the role of MT1-MMP as an important interstitial collagenase. 




related to deficiencies in ECM processing, such as dwarfism, skeletal dysplasia and 
defective vasularization152,153. MT1-MMP may be actually regulated by availability of type 
I collagen as a substrate, a hypothesis stating that migrating cells are triggered by clustering 
of cell surface integrins upon encountering a 3-dimensional collagen matrix leading to 
transcriptional activation of the MT1-MMP promotor154. Besides type I collagen, MT1-
MMP is capable of degradation of many other ECM components, such as fibronectin, 
vitronectin, tenascin, nidogen, aggrecan, fibrin, fibrinogen and laminin-5 (leading to a 
possible stimulation of cellular migration as described earlier)150. Although the major 
proteolytic function of MT1-MMP lies in cleavage of extracellular substrates, some studies 
indicate a role in intracellular proteolysis after incorporation and accumulation of active 
MT1-MMP in the centrosomal compartment where it could contribute to development of 
mitotic spindle changes by degradation of pericentrin155,156. This mechanism could give rise 
to a role for MT1-MMP in malignant transformation of cells. MT1-MMP has further been 
identified as a cell-surface sheddase, and is capable of cleavage of many membrane-
anchored proteins such as E- and N cadherin, integrins, hyaluronan receptor CD44, receptor 
activator of NF-κB ligand (RANKL) and several cell-surface proteoglycans and their 
receptors150. 
MT1-MMP was originally identified as the extracellular protease responsible for activation 
of proMMP-2, and this process remains the best described proteolytic function of the 
enzyme. In this process one of the subunits of an MT1-MMP dimer forms a trimeric 
complex with proMMP-2 and TIMP-2 at the cell surface leading to proteolytic removal of 
the propeptide of the MMP-2 zymogen by the ‘free’ MT1-MMP unit. Besides proMMP-2, 
also proMMP-13157 and proMMP-8158 have been identified as possible targets for activation 
by this mechanism, which could be complementary to the intrinsic collagenolytic activity of 
MT1-MMP. 
The role of MT1-MMP in cancer is manifold, but the involvement in angiogenesis is well 
described and demonstrated by the insufficient vascularization in knockout mice. Firstly 
MT1-MMP is capable of degradation of the deposited fibrin matrix after vascular injury, 
effectively disrupting the repair mechanism and allowing endothelial invasion159. MT1-
MMP may also be involved in migration of the endothelial cells into the ECM, by 
proteolytic degradation of the extracellular matrix proteins, and by processing of various 
adhesion molecules160. The formation and stabilization of the newly formed capillary tubes 
may also be dependent on MT1-MMp activity, as demonstrated by impaired capillary 
formation in knockout models and RNA interference experiments161. Finally, MT1-MMP is 




MT2-MMP (MMP-15) was first described in 1995 as the second member of the membrane-
anchored MMP subfamily163. MT2-MMP is an ubiquitously expressed enzyme with largely 
overlapping substrate specificity with MT1-MMP151. Although the physiological function 
of this protease is not as well described as for MT1-MMP, some studies have indicated a 
role in follicle rupture during ovulation164, generation of tubular structures during 
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angiogenesis165 and has anti-apoptotic properties166. MT2-MMP is also capable of 
activating the MMP-2 zymogen, but contrary to MT1-MMP the activation mechanism is 
not dependent on  the presence of TIMP-2, but rather on interaction with the hemopexin-
like domain of MMP-2167. 
Involvement of MT2-MMP in pathology is still unclear, but considering the similarity with 
MT1-MMP a role in cancer is expected. Indeed, MT2-MMP is present in many investigated 
tumours, such as glioblastoma168, non-small cell lung carcinoma169, ovarian170 and breast 
carcinoma171, and seems to correlate to tumour invasiveness168. 
 
MMP-16 and MMP-24 
The two latest additions to the membrane-spanning MMP family are MT3-MMP (MMP-
16), first described in 1997172 and MT5-MMP (MMP-24), first described in 1999173. These 
enzymes are still poorly described in literature. The crystal structure of MT3-MMP has 
been elucidated, and shows extensive homology to MT1-MMP174. MT3-MMP activity is 
regulated by an autoproteolytic shedding process where a soluble form of the enzyme is 
released from the cell surface, and the active enzyme shows a high affinity to TIMP-3, as 
opposed to TIMP-1. Although originally anticipated to be a brain-specific enzyme175, MT5-
MMP is possibly involved in remodelling events in endometrial lesions, and 
endometriosis176. 
Like the other MT-MMPs, both MT3- and MT5-MMP are capable of activating proMMP-
2177,178. 
 
MMP-17 and MMP-25 
The final two MT-MMPs are structurally different from the other four with respect to their 
interaction with the cell membrane. MT4-MMP (MMP-17)179 and MT6-MMP (MMP-25)180 
are linked to the cell membrane via a glycosyl-phosphatidyl-inositol (GPI) anchor, as 
opposed to containing a membrane-spanning domain. This anchor moiety is linked to the 
hemopexin-like domain by a 35-45 amino acid long hydrophilic linker, or stem. After 
production of the enzyme this stem region is linked to a short hydrophobic tail, which is 
exchanged for a GPI anchor in the endoplasmatic reticulum181. The stem region further 
contains 2 or 3 cysteine residues, which probably have a function in formation of 
complexes, as demonstrated by the presence of ~120 kDa and ~180 kDa isoforms of MT6-
MMP that are dissociated in the mature 57 kDa form of the enzyme under reducing 
conditions182. The GPI anchor gives the possibility of interaction of these proteases with 
lipid raft microstructures, and the possibility of internalization and recycling of the 
enzymes181. The TIMP-inhibition profile of the GPI anchored MT-MMPs is different than 
for the membrane-anchored MT-MMPs. While the latter are relatively resistant to 
inhibition by TIMP-1 due to incompatibility of the Thr98 residue with the S’1 selectivity 
pocket, MT4- and MT6-MMP are effectively inhibited by TIMP-1, as well as by TIMP-2 
and TIMP-3183,184. GPI anchored MT-MMPs can be shed from various cells in exosomes,  
possibly leading to paracrine transfer to other cells185.  
Both MT4- and MT6-MMP are capable of degrading ECM protein, albeit MT4-MMP in a 




MMP can cleave a wider range of ECM constituents including fibronectin, type IV collagen 
and proteoglycans186. In vitro experiments have revealed a multitude of possible substrates 
(including TNF alpha, indicating sheddase activity), but the physiological relevance is 
unclear (reviewed in 181). Interestingly, MT4-MMP is not able to activate proMMP-2 even 
in vitro, making this the only MT-MMP that lacks this trait187. MT6-MMP does activate 
proMMP-2, but generates a different form of the active enzyme than the other MT-MMPs, 
indicating that the interaction between MMP-2 and MT6-MMP is unique188. This activation 
mechanism is possibly dependent on the tight junction protein claudin-5, since cells that do 
not produce this protein are incapable of proMMP-2 activation by MT6-MMP189. MT4-
MMP has been described as an activator of the aggrecanase ADAMTS-4190. 
Both GPI-anchored MT-MMPs are  highly expressed in a wide variety of cancer cells 
ranging from breast carcinoma to glioma and colon cancers (reviewed in 181), but the 





MMP-7 (matrilysin) was originally described as PUMP-1 (putatative uterine 
metalloproteinase-1) in 1988, and was long considered a third member of the stromelysin 
family (MMP-11 was not known yet), although it appeared only distantly related to the 
other stromelysins125. The pump-1 gene identified from rat tumour cDNA cloning 
experiments was confirmed to code for a secreted metalloprotease in rat uterus191, and later 
dubbed MMP-7. The mmp-7 gene contains a AP-1 promotor region, leaving it sensitive to 
upregulation by cytokines and growth factors192. MMP-7 is the smallest human MMP (28 
kDa zymogen, 19 kDa mature active form) since it lacks the C-terminal hemopexin-like 
domain. This ‘minimal domain structure’ means the activated enzyme is comprised of only 
the zinc-binding catalytic domain and results in an inability of MMP-7 to degrade intact 
collagens, again demonstating the importance of the hemopexin-like domain in substrate 
recognition193. MMP-7 is however capable of degradation a wide array of other ECM 
components such as gelatin, fibronectin, laminin and elastin. MMP-7 is capable of cleaving 
the prodomain of the gelatinases MMP-2 and -9194, but the relevance under physiological 
conditions seems debatable considering the alternative, well-described activation pathway 
of proMMP-2. Finally, MMP-7 is a possible sheddase, with potential to liberate TNFα, Fas 
ligand, heparin binding epidermal growth factor (HB-EGF), E-cadherin and β4-integrin195. 
The original biological function of MMP-7 was the involvement in involution of the 
endometrium after pregnancy, but as later discovered, an MMP-unique function of MMP-7 
seems to be the role in innate immunity. MMP-7 knockout mice exhibit decreased 
resistance to bacterial gastrointestinal infection, and show decreased clearance of E. coli 
from the small intestine. MMP-7 is constitutively produced in the mucosal epithelium, and 
may exert its function in mice by cleavage of pro-α-defensins yielding peptides with 
antibacterial properties Co-localization of MMP-7 and pro-α-defensins in specialized 
epithelial Paneth cells seems to confirm this function196. The role in mucosal host defense is 
further confirmed by the finding that exposure of cultured mucosal epithelial tissue or cells 
Metzincin proteinases in health and disease: MMPs 
 
25 
to pathogenic bacteria such as E. coli or Pseudomonas aeruginosa causes an increased 
production of MMP-7, and that germ-free bred mice show no expression of MMP-7 in the 
unchallenged gastro-intestinal tract197. The strong induction of MMP-7 by bacterial 
challenge is a epithelium-specialized function, since it does not occur in other cell types 
expressing MMP-7, and is exclusive for MMP-7 since no other MMPs are upregulated198. 
MMP-7 seems to be important in wound repair, since MMP-7 null mice show severe 
defects in epithelial wound healing which is probably due to a disrupted re-
epithelialization199. 
MMP-7 further enables migration of neutrophils through the epithelium during 
inflammation, since in MMP-7 null mice show accumulation of neutrophils in the 
insterstitium without crossing of these cells over the epithelium, resulting in reduced 
mortality200. The mechanism underlying this effect is probably the creation of a chemotactic 
gradient by cleavage of the proteoglycan syndecan-1 at the epithelial cell surface, causing 
liberation of the syndecan-bound chemokine KC that is produced by the epithelial cells 
after injury. 
The role of MMP-7 in cancer is well described in literature. MMP-7 seems to occupy a 
unique place in the MMP-cancer association, since it is one of the few MMPs that is 
actually produced by cancerous cells themselves, as opposed to the stroma under 
stimulation of the malignant cells195. As with other MMPs, MMP-7 has been identified in a 
wide range of tumours, and correlates with the agressiveness of the tumour. In a malignant 
state, the activation of MMP-2 and -9 by MMP-7 may have an important function, and lead 
to increaded invasiveness of the tumour201,202. MMP-7, like MMP-3 may further promote 
tumour invasion by shedding of E-cadherin, leading to decreases cellular adhesion. Tumour 
growth is likely associated with MMP-7 sheddase activity, since the release of soluble HB-
EGF by MMP-7 promotes cellular proliferation203. MMP-7 is further capable of cleaving all 
six members of the insuline-like growth factor binding protein (IGF-BP) family, leading to 
increased availability of free IGF which again promotes cancer cell growth and survival204. 




Recently, a novel matrilysin-like enzyme was identified in an endometrial tumour and 
named MMP-26 (matrilysin-2, endometase)206,207. Like MMP-7, this is a minimal domain 
MMP missing the hemopexin-like C-terminus. This protease seems to have a more limited 
substrate specificity compared to MMP-7, not being able to degrade collagens, laminin and 
elastin208. MMP-26 is unique from other MMPs since it is the only MMP described so far 
that does not have a functional cysteine switch mechanism keeping the pro-enzyme in its 
latent conformation. This functional loss of the cysteine switch is attributed to the presence 
of a histidine residue n-terminal of the cysteine, a feature only observed in MMP-26209 
[marchenko 2001]. Basal expression of MMP-26 is low except in endometrium, but is 
increased in many carcinoma cell lines210. The physiological function of MMP-26 remains 





1.2.6 Macrophage metalloelastase 
 
MMP-12 was first described in 1981211 as murine metalloelastase and later identified as a 
member of the MMP family212. In 1993 an orthologue in human was found213. MMP-12 
was identified as an elastolytic metalloproteinase produced by alveolary macrophages, 
which lead to the trivial name (murine) macrophase metalloelastase (MME) or human 
macrophage elastase (HME). MMP-12 is expressed as a 54 kDa inactive zymogen, and is 
activated to a 45 kDa active enzyme by removal of the propeptide sequence. This mature 
enzyme can be further truncated to a 22 kDa active form involving processing of the C-
terminal sequence mediated by serine protease or autocatalytic cleavage213. This autolytic 
removal of the c-terminal domain is possible in many other MMPs, but occurs very slow in 
contrast to MMP-12 which is readily processed to the smaller form. Expression of MMP-12 
is limited macrophages, and is not observed in blood monocytes. As the name reveals, a 
major substrate for MMP-12 is elastin, but MMP-12 is capable of degrading other ECM 
constituents (but not gelatin)214 and many non-matrix proteins in vitro215. 
MMP-12 null mice show normal development in absence of inflammatory stress, but litter 
size is smaller, presumably due to placenta abnormalities during gestation. Macrophages 
obtained from knockout mice retain only a small fraction of their elastolytic activity, 
indicating that MMP-12 is indeed the most important elastin degrading enzyme (in mice). 
MMP-12 is a vital factor in penetration of macrophages through the basement membrane, 
as demonstrated by a complete inhibition of this migration in macrophages from MMP-12 
null mice both in vitro as in vivo216. 
MMP-12 seems to play an interesting role in cancer which is different from other MMPs. 
MMP-12 is the primary protease responsible for proteolytic liberation of angiostatin from 
plasminogen. Angiostatin is a 38 kDa protein with anti-angiogenic properties by the 
selective inhibition of endothelial proliferation. MMP-2 and -9 are also capable of 
degradation of plasminogen in vitro, but were found to have a minor to non-existing 
contribution in the production of angiostatin in an animal model217,218. This is another 
example of a protective effect of MMP activity in tumourogenesis, and is an indication that 
knowledge of the actual biochemical mechanism of the involvement of the protease is 
indispensible and cannot be replaced by mere association of expression levels in tumours. 
Since human MMP-12 was first cloned from alveolar macrophages it is not surprising that 
the role of MMP-12 in lung diseases has been extensively studied. The hypothetical 
involvement of MMP-12 in fibrotic processes in the lung is obvious, but studies concerning 
the role of MMP-12 in emphysema are diffuse. Some authors find no upregulation of 
MMP-12 in macrophages of patients compared to control groups, but rather of other 
macrophage-derived MMPs219, while others state that macrophage elastase is an absolute 
requirement for the development of  emphysema after cigarete smoke exposure in a 
knockout animal model220-222. The interspecies difference may have caused bias with 
respect to the importance of MMP-12 since, although the failure of MMP-12 null mice to 
develop emphysema makes a more compelling point than determination of expression 
levels, MMP-12 seems to be the major MMP present in murine macrophages, while in 
human several other MMPs are produced198. A polymorphism in the MMP-12 gene has 
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been described to have predictive value in lung function decline in COPD223. Elevated 
MMP-12 has been described in induced sputum of COPD patients224, but a recent studie has 
found a slight increase of MMP-12 only in stage 0 of the disease225, which could imply 
involvement of MMP-12 in the early development of COPD. Proteolytic fragments of 
elastin have been implied as chemotactic factors in macrophage recruitment226, giving a 
possible explanation of an early role of MMP-12, with the severe tissue destruction at later 
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1.3 ADAM proteinases 
 
The “a disintegrin and metalloproteinases” (ADAMs) or MDCs (metalloproteinase-like, 
disintegrin-like, cysteine-rich proteins) are membrane-anchored metzincins of the 
adamalysin subfamily which also contains the interesting biological close relative, the class 
III snake venom metalloproteases1. These proteases have a similar domain structure to the 
membrane-type MMPs (see figure 1), but with two distinct differences. The ADAM 
proteases do not contain the characteristic hemopexin-like domain, but instead have three 
additional domains; the cysteine-rich domain, the EGF-like repeat domain and the 
disintegrin domain from which the family derives its name. While the biological function of 
the EGF-like domain has not yet been fully elucidated, the cysteine-rich and disintegrin 
domains enable the cell surface bound ADAMs to interact with ECM proteins and ligands 
on neighbouring cells. This important function in intercellular interaction was already clear 
from the identification of the first members of the ADAM as key players in the fertilisation 
process, specifically in the binding and fusion between egg and sperm cells. The first 
adamalysins described in mammalia were found on guinea pig sperm and dubbed fertilin α 
and β (or PH-30 α and β)2-4, and were renamed ADAM-1 and -2 after identification of 
several other homologous genes5. 
 
Disintegrin-integrin binding 
The presence of a disintegrin domain in ADAMs is unique among cell-surface proteins, and 
can mediate cell-cell and cell-matrix interaction by binding integrins. The major integrin 
involved in interaction with ADAMs has been identified as integrin α9β1 which can 
interact with a conserved RX6DEVF sequence in the disintegrin domain1, although 
structural modelling of a snake venom disintegrin-metalloprotease has demonstrated that 
this motif is shielded by the cysteine-rich domain and may be inaccessible for integrin 
binding6. 
Many other integrins are capable of binding the disintegrin domain7. The consensus 
recognition site of disintegrins, first identified as integrin antagonists in snake venom, is 
dependent on the presence of Arg-Gly-Asp (RGD) or Lys-Gly-Asp (KGD) sequences, but 
surprisingly only ADAM-15 contains the RGD sequence in its disintegrin domain, and this 
recognition site enables interaction with a broader range of integrins such as αvβ3, αvβ5 
and α5β18,9. Other ADAMs (e.g. ADAM-9 and -23) are capable of binding these integrins 
through interaction with a Glu-Cys-Asp (ECD) sequence in the disintegrin domain, an 
observation that corroborates the pivotal importance of especially the aspartic acid residue 
in disintegrin-integrin interaction site10.  
Although the binding potential of the ADAM proteins to integrins is relatively well 
characterized, the biological relevance and scope is not yet clear10. The only physiological 
process where the functionality is well documented remains the fertilization process, with 
the two fertilin-ADAMs forming a hetero-dimer capable of binding integrin  α6β1 on the 
surface of the egg11, but this model is under debate12. The fact that in human the fertilin 
α/ADAM-1 gene encodes a non-functional protein is a strong indication that this model for 
ADAM involvement in  egg-sperm fusion in mammalia may need to be reconsidered 13. 
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Gene deletion experiments have demonstrated an important role for ADAM-2 in 
fertilization since fertilin β null mice are infertile14, but ADAM-2 is not indispensable in the 
sperm-egg fusion process since sperm from these knockout mice can still fuse with oocytes, 
albeit at a ~50% decreased fusion rate. The observed sterility of fertilin β -/- mice is 
postulated to be due to disruption of transit of the sperm through the female reproductive 
tract15, which may be an indication that ADAM function during fertilization has a hitherto 
unknown mechanism12.  
 
Interaction via the cysteine-rich domain 
Besides the disintegrin-integrin interaction, ADAMs are capable of binding several ECM 
constituents. The cysteine-rich domain may have an important function in binding heparan 
sulfate proteoglycan such as syndecans, a phenomenon described for ADAM-1216. Studies 
involving the Xenopus-specific ADAM-13 have further revealed an important role for the 
cysteine-rich domain in interaction with fibronectin17. An early observation on the structure 
of metalloprotease-disintegrins revealed the presence of a hydrophobic stretch in the 
cysteine-rich domain of several ADAMs which shows high sequence similarity to viral 
fusion peptides18, which may implicate a role for the cysteine-rich domain in membrane 
fusion. This hypothesis has however not been confirmed by experimental data1.  
 
Function of the cytoplasmic domain 
The cytoplasmic domain of the individual ADAM proteases is highly variable in length 
(40-250 amino acids) and sequence, but the majority of ADAMs contain cytoplasmic tails 
with PxxP motifs, which indicates binding sites for SH3 (Src-homology 3) domain 
containing proteins19. This structural feature enables interaction of the cytoplasmic domain 
with a large range of intracellular proteins and may be important in regulation of ADAM 
localization by interaction with cytoskeletal proteins such as α-actinin-220. ADAM function 
may also be regulated by interaction of the cytoplasmic tail with intracellular signalling 
proteins, as demonstrated by the activation of ADAM-9 by phorbol esters via interaction 
with PKC δ21. 
The cytoplasmic domain of some ADAMs further contains putative phosphorylation sites 
for serine-threonine or tyrosine kinases, which may be involved in regulation of ADAM 
function, or supply binding sites for SH2 domain containing proteins1. 
 
ADAM metalloprotease function 
Perhaps the best studied function of the ADAM proteins is the catalytic activity exhibited 
by the metalloprotease domain. The metalloprotease domain is highly homologous with the 
MMP catalytic domain, but interestingly not all ADAMs contain the consensus 
HExxHxxGxxH zinc-binding metalloprotease active site (see table 2), which leads to the 
conclusion that from the 22 human ADAMs only 12 (possibly) may exert endopeptidase 
activity. Interestingly, in mice an additional subfamily of possibly catalytically active 
ADAMs (ADAM-24-26, -34 and 36-40) has been described and named testases, 
referencing the testis-specific expression pattern22. In human no orthologues of the testases 




Table 2: Overview of the 22 identified human ADAM proteases. (t)MDC: (transmembrane) 
metalloprotease-like, disintegrin-like, cysteine-rich protein.  
‡: although full length ADAM-1 contains a metalloprotease domain with active site sequence, this 
domain is removed in the mature processed form4. 
 
ADAM Alternative names MP active site? Remarks 
1 Fertilin α, PH-30 α yes ‡ Non-functional pseudogene  
Testis specific 
2 Fertilin β, PH-30 β 
Cancer/testis antigen 15 
no Testis specific 
3 Cyritestin, tMDC I no Non-functional pseudogene 
Testis specific 
6 tMDC IV no Testis specific 
7 EAP-1, Sperm maturation-related 
glycoprotein GP-83 
no  
8 Cell surface antigen MS2, CD156a yes  
9 MDC9, Meltrin γ 
Myeloma cell metalloproteinase 
yes  
10 Kuzbanian protein homolog, CD156c yes  
11 MDC no Brain specific 
12 Meltrin α yes  
15 Metargidin, MDC-15 yes  
17 TACE,  CD156b  
Snake venom-like protease 
yes  
18 tMDC III, ADAM-27 no Testis specific 
19 Meltrin β, MADDAM 
Metalloprotease and disintegrin 
dendritic antigen marker 
yes  
20 None yes Testis specific 
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21 ADAM-31 no Testis specific 
22 MDC 2 no  
28 MDC-L, ADAM-23 yes  
29 Cancer/testis antigen 73 no Testis specific 
30 None yes Testis specific 
32 None no Testis specific 
33 none yes  
 
The ADAM metalloprotease domain is shielded off by a prodomain in the inactive 
zymogen in a similar structural conformation as in MMPs involving a cysteine switch 
mechanism. The primary activation pathway of the ADAM zymogens involves removal of 
the prodomain by proprotein convertases (PCs) such as furin in the trans-Golgi network as 
demonstrated by strongly diminished activation of ADAM-9 and -15 in the presence of 
early-secretory pathway inhibitors brefeldin A and monensin, increased activation of 
ADAM-10 after overexpression of PC-7 and blocked processing of proADAM-10, -12 and 
-19 after mutational modification of the furin Rx(R/K)R recognition site (discussed in 1). 
Some ADAMs may require autoproteolytic processing for activation, as demonstrated for 
ADAM-823 and -2824. Interestingly, the prodomain may act as a chaperone and is required 
for proper folding of the ADAM protein, and especially the metalloprotease domain. 
Removal of the prodomain prior to folding yields an inactive form of ADAM-1725. For 
ADAM-10 a similar effect has been observed in cells expressing the protease without the 
prodomain, an effect that could be reversed by cotransfection of the prodomain26.  
Although, similar to the MMPs, the catalytically active ADAMs are capable of degradation 
of ECM proteins such as collagens and fibronectin in vitro, the physiological relevance of 
this observation is not clear. The endopeptidase activity for which the ADAMs are best 
known is the so-called shedding; liberation of biologically active proteins from their 
membrane-anchored proforms. This function of the ADAMs was first described 
simultaneously by two groups in 1997, identifying a disintegrin-metalloprotease as an 
important contributor to the production of soluble TNFα from the membrane-bound 
precursor27,28. The responsible protease was named TACE (TNF-alpha converting enzyme) 
and gene-silencing experiments demonstrated a dominant, but not exclusive role for TACE 
since TNFα production was significantly diminished but not completely shut down in the 
knock-out mice. 
Considering the scope of this thesis only the ADAMs containing the metalloprotease active 










ADAM-8 (CD156) was first described in 1990 as antigen MS2 in mice29, and was later 
confirmed as a member of the human ADAM family in 1997 30. ADAM-8 is a 
transmembrane glycoprotein primarily expressed as a 120 kDa zymogen by immune cells, 
but is also found in neurons and oligodendrocytes in the central nervous system. The 
promoter region of the adam-8 gene contains response elements for lipopolysaccharide 
(LPS) and cytokines such as interferon γ, interleukin-6 and TNF α31.  
ProADAM-8 does not contain the furin cleavage recognition site and depends on 
autoproteolytic removal of the prodomain for activation, yielding a 90 kDa mature enzyme. 
The mature cell-surface ADAM-8 may be further processed by autoproteolytic shedding 
yielding a 60 kDa soluble remnant form of the protein missing the metalloprotease 
domain23. ADAM-8 may also exist as a soluble, catalytically active form which is 
presumably released from the cell by autoproteolytic shedding32. Contrary to the MMP and 
MT-MMP families, ADAM-8 catalytic activity is not inhibited by any of the four known 
TIMPs in vitro33.  
The biological function of ADAM-8 is far from clear, but the protein has been associated 
with neuron-glia interactions in the central nervous system34, cell-cell fusion in osteoclast 
differentiation (an effect presumably mediated by the remnant form)32 and recent work has 
shown a possible role in the ovulation process involving hormonal regulation of ADAM-
835. ADAM-8 sheddase activity in vivo is still rather poorly characterized, but in vitro 
experiments involving cleavage assays of 10-mers containing known recognition sites for 
ectodomain shedding have revealed multiple possible substrates such as β-amyloid 
precursor protein (APP), the low affinity IgG (CD16) and IgE (CD23) receptors, L-selectin, 
P-selectin glycoprotein ligand, transforming growth factor α (TGF α) and TNF α36. ADAM-
8 has also been implicated in shedding of the neural adhesion molecule CHL-1 (close 
homologue of L-1), yielding a biologically active fragment that enhances neurite outgrowth 
and suppresses neuronal cell death, indicating an important role in the development of the 
central nervous system37. 
Knock-out experiments in mice have identified ADAM-8 as a non-essential protein during 
development since ADAM-8 null mice show no pathological defects38. This finding may be 
explained by a rather large redundancy with other ADAM proteases or by a specific role for 
ADAM-8 not in development but rather in processes such as inflammation, a hypothesis 
that seems to be substantiated by the responsiveness of ADAM-8 expression to cytokine 
stimulation. 
ADAM-8 has been associated with development of asthma following the observation that 
ADAM-8 is highly upregulated in experimental ovalbumine-induced asthma models in 
mice, showing strong induction in peribronchial and perivascular inflammatory cells and 
bronchiolar epithelial cells39. In an asthma model with transgenic mice producing a soluble 
form of ADAM-8 a protective effect of sADAM-8 was found, presumably related to 
suppressed trafficking of leukocyte migration40, which may be mediated by shedding of 
vascular cell adhesion molecule 1 (VCAM-1) by ADAM-841. The amount of clinical 
evidence linking ADAM-8 to development of pulmonary diseases is limited, but soluble 
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ADAM-8 and VCAM-1 are increased in BAL fluid of patients suffering from eosinophilic 
pneumonia42 and ADAM-8 mRNA is increased in asthma patients with a positive 
correlation with disease severity43. 
ADAM-8 is expressed in human neutrophils where it is stored in granules, and is 
transported to the cell surface upon stimulation. The cell surface exposed ADAM-8 is then 
rapidly released into the extracellular space by a metalloprotease activity dependent 
process. These in vitro findings have been confirmed in neutrophils retrieved from synovial 
fluid from patients suffering from rheumatoid arthritis, again indicating a possible role for 
ADAM-8 activity in inflammatory processes44. 
ADAM-8 expression is increased in neutrophils that are in contact with endothelial cells, 
and since L-selectin is a possible substrate ADAM-8, and ADAM-8 colocalizes with L-
selectin on the neutrophil surface ADAM-8 mediated L-selectin shedding may play an 
important role in regulation of neutrophil rolling and trans-endothelial extravasation44.    
Since ADAM-8 is involved in osteoclast differentiation it is not surprising that several 
studies have focussed on the role of this protease in the development of pathological bone 
destruction. ADAM-8 expression is positively associated with tissue destruction in 
rheumatoid arthritis, and ADAM-8 protein is mainly localized at the edge of the eroded 
cartilage and bone (the so-called pannus)45. A similar induction of ADAM-8 at the edge of 
healthy and eroded tissue is described in loosening hip replacements46.  
ADAM-8 has further, as most metzincins, been associated with various malignant 
processes. In pancreatic duct adenocarcinoma, ADAM-8 expression and protein level is 
correlated with the invasiveness of the tumour and with reduced  survival rate47, a 
phenomenon that may involve tumour hypoxia48. The same correlation has been described 
for primary brain tumours and ADAM-8 activity, as measured by conversion of a peptide 
substrate, is higher in cells obtained from gliomas with higher invasive potential49. 
Overexpression of ADAM-8 has also been associated with poor prognosis in lung cancer, 
with high expression significantly more common in stage IIIb/IV adenocarcinomas 
compared to lower stages. The soluble isoform of the protein has been suggested as a useful 
diagnostic serum marker for lung cancer50. ADAM-8 overexpression has finally been 
described in prostate cancer51 and renal cell carcinoma52,53. 
 
ADAM-9 
ADAM-9 or meltrin γ was first identified in 1996 as MDC-9 from breast carcinoma54 and 
as myeloma cell metalloproteinase in myeloma55. ADAM-9 is ubiquitously produced as a 
110 kDa glycosylated zymogen which can be activated in the medial Golgi apparatus by 
prodomain removal by proprotein convertase activity to the 84 kDa mature form that is 
found on the cell surface. The cell membrane anchored form can be further truncated by 
proteolytic processing to a 47 kDa soluble form which contains the metalloprotease domain 
and retains its catalytic activity as demonstrated by the ability to cleave insulin B-chain in 
vitro. Purified soluble ADAM-9 is further capable of cleaving peptides containing the 
membrane-proximal cleavage region of β-APP, proTNFα, the p75 TNF receptor and c-kit 
ligand-1 (KL-1), but not IL-6 receptor, the p55 TNF receptor, transforming growth factor α 




but the physiological relevance is not proven57. Like ADAM-8, ADAM-9 activity is not 
inhibited by any of the four TIMPs33. 
As with ADAM-8, knockout models have demonstrated that ADAM-9 is not vital for 
development and survival since ADAM-9 null mice show no major abnormalities58. 
ADAM-9 is capable of processing β-APP, and is widely considered to be one of the three 
alpha-secretases from the ADAM family (next to ADAM-10 and -17)59. The ADAM-9 
knockout mice do however show no aberrant APP processing, indicating functional 
compensation by or redundancy with other ADAMs. Similarly, shedding of HB-EGF which 
is known to be decreased in cells overexpressing a mutant form of ADAM-921 is unaffected 
by ADAM-9 knock-out.  
In rat kidney, ADAM-9 is mainly found in the basolateral surface of the tubular cells. The 
expression in glomerular epithelia is restricted to areas in contact with the underlying 
basement membrane indicating an important role in cell-cell and cell-matrix interaction60 
which may be mediated by binding of the disintegrin domain to beta-1 integrins which co-
localize with the renal ADAM-9 distribution61. 
The soluble isoform of ADAM-9 has been reported as an important player in tumour 
metastasis in the liver. After shedding from the cell surface of activated hepatic stellate 
cells, sADAM-9 is hypothesized to bind to α6β4 and α2β1 integrins on the surface of 
carcinoma cells and promote stroma-tumour interaction. Addition of the soluble ADAM-9 
to Matrigel invasion assays showed an increased invasive potential in several cancer cell 
lines. This effect is blocked by the broad-range metalloprotease inhibitor 1,10-
phenantroline, indicating a possible role for an active metalloprotease, although it remains 
unclear whether this is activity of ADAM-9 itself. Histological examination of tumour 
sections obtained from liver metastases revealed that ADAM-9 expression was highest at 
the invasive front, and in regions of tumour-stroma contact while the tumour cells and 
hepatocytes themselves were negative for ADAM-962.  
ADAM-9 expression is higher in malignant prostate tumours, and expression in carcinoma 
cell culture is increased in response to oxidative stress. This effect is likely mediated by an 
androgen receptor (AR) involving mechanism, since AR-negative prostate cancer cells do 
not exhibit increased expression after exposure to radical oxygen species (ROS), and 
preincubation of the cells with the anti-androgen bicalutamide abrogates the higher 
expression of ADAM-963. By blocking ADAM-9 production apoptotic cell death could be 
induced in the cultured prostate cancer cells, indicating a role for ADAM-9 in tumour 
survival64. Concurrently, high tumour ADAM-9 expression has been identified as a 
significant prognostic marker for relapse in prostate cancer65. 
Since ADAM-9 is a putative α-secretase of β-APP this protease has gained some interest 
from the Alzheimer’s disease research field (although less than the two other α-secretases 
in the ADAM family). Alpha secretases supposedly have a protective effect in the 
development of Alzheimer’s disease, which is amongst others characterized by 
accumulation of neurotoxic amyloid-beta peptides (Aβ) and plaque formation in the brain. 
These peptide fragments are the result of sequential β- and γ-secretase processing of APP, 
while α-secretases have a cleavage site within Aβ leading to degradation of the neurotoxic 
peptides. Decreased sheddase activity of the ADAM α-secretases may therefore play an 
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important role in the development of the disease66. The physiological relevance of ADAM-
9 as an α-secretase has however been debated in recent years, especially after findings that 
APP cleavage is unaltered in ADAM-9 knockout models, and the consensus seems to point 
to a minor role of ADAM-9 in APP processing in vivo67,68.  
 
ADAM-10 
ADAM-10 was first isolated in 1995 as a membrane-bound metalloproteinase capable of 
cleaving myelin basic protein69, later found to be expressed by various cell types and named 
MADM (mammalian disintegrin-metalloproteinase), and have significant sequence 
homology with several other earlier discovered mammalian disintegrin-metalloproteinases 
such as meltrin-α (ADAM-12) and MS2 (ADAM-8) in 199670. MADM/ADAM-10 was 
discovered to be a mammalian counterpart of the Drosophila protein Kuzbanian which 
plays an important role in neurological development by proteolytic activation of the Notch-
receptor and shedding of the Notch receptor ligand delta71. 
ADAM-10 is produced as an inactive zymogen which is activated by proprotein 
convertases in the trans-Golgi network to its 56-58 kDa glycosylated mature form72. 
Contrary to most other metzincins, the cysteine switch mechanism which normally links the 
prodomain to the catalytic centre keeping the enzyme inactive seems to be non-functional 
in ADAM-1073. ADAM-10 catalytic activity is inhibited by TIMP-1 and -374. 
ADAM-10 is one of the better characterized ADAMs to date, with many studies focussing 
on the proteolytic function of this enzyme. ADAM-10 is capable of degradation of type IV 
collagen in vitro75 and has been identified as a possible sheddase of cell-surface bound 
proteins such as epidermal growth factor receptor ligands EGF and betacellulin76, ephrin-
A277, cellular prion precursor protein78, chemokines CX3CL1 and CXCL1679,80 adhesion 
molecule L181 and many others, although some caution has to be taken in interpreting these 
results since most target substrates have been identified in vitro, an many ADAM-10 
mediated shedding events in cell lines are validated by incubation with supposedly ADAM-
10/ADAM-17 selective hydroxamate-based inhibitors (like TAPI, TNF alpha protease 
inhibitor) that were later shown to actually be broad-range metzincin inhibitors. ADAM-10 
is believed to be primarily involved in the constitutive shedding of cytokines, chemokines 
and their receptors, while ADAM-17 mediated shedding is more responsive to stimuli82. 
The release of TNFα from cells was thought to be (partially) mediated by ADAM-10 but 
recent insights have demonstrated that ADAM-10 probably plays a minor role83.  
The best studied shedding activity mediated by ADAM-10 lies within the Notch signalling 
pathway. Notch signalling is a highly conserved, ancient pathway that is essential in 
intercellular contact and cell fate determination in all stages of neural development. The 
membrane-bound Notch receptor is activated by either membrane-bound ligands delta or 
serrate/jagged on adjacent cells leading to an intracellular signalling cascade involving a 
series of proteolytic cleavages (S1-3), internalization of the processed Notch receptor, 
transport to the nucleus and finally activation of gene transcription. The precise outcome of 
Notch receptor activation is highly dependent on other extra- and intracellular signals and 
can lead to inhibition of neuronal cell and oligodendrocyte differentiation, or promotion of 




Although the role of the invertebrate ADAM-10 homologues Kuzbanian (Drosophila) and 
Sup-17 (C. elegans) in Notch signalling is clear85,86, involving proteolytic activation of the 
Notch receptor-ligand complex (stage S2), attempts to identify ADAM-10 as a key player 
in mammalian Notch signalling have yielded variable results. Some studies point to 
ADAM-17 as the essential protease for Notch processing, at least by proteolytic cleavage 
assays using ADAM-17 in vitro87 and cotransfection of DTACE  (the Drosophila ADAM-
17 homologue) in delta-expressing Drosophila S2 cells, but ADAM-17 knockout models 
show little similarity to Notch knockouts while ADAM-10 deficient mice die early in 
embryogenesis showing major defects in development of the central nervous system and 
the vascular system with similar histological abnormalities observed in complex Notch 
deficiency induced in mice88,89. 
This apparent discrepancy between in vitro substrate specificity and biological relevance is 
also apparent from the unclear role of ADAM-10 as an APP α-secretase. ADAM-10 is 
widely expressed in neuron in the CNS90, is capable of cleaving APP-derived peptides in 
vitro and overexpression of ADAM-10 increases the release of cleaved APP from HEK 293 
cells, while transfection with a non-functional ADAM-10 mutant inhibited APP 
processing91. On the other hand most preserved embryonic fibroblast cell lines obtained 
from ADAM-10 knockout mice show no decreased or altered APP processing compared to 
control, although two out of 17 lines do have severe APP processing defiencies88. 
Several shedding events possibly mediated by ADAM-10 have been associated with cancer 
pathology. Proteolytic removal  of the extracellular domain neuronal cell adhesion receptor 
L1-CAM by ADAM-10 promotes metastasis in colon cancer92, ADAM10 may be involved 
in metastasis by shedding of CD44 promoting migration of cancer cells through the ECM 
by interaction with hyaluronic acid93 and ADAM-10 mediated shedding of EGF receptor 
ligands may promote tumour growth. ADAM-10 activity may be associated with poor 
prognosis in breast cancer by shedding of membrane-anchored HER2 receptor leaving a 
fragment with constitutive kinase activity leading to ligand independent cell growth and 
resistance to apoptotic signals94. 
ADAM-10 proteolytic activity has been associated with a protective effect in inflammatory 
processes by shedding of the receptor for advance glycation products (RAGE), yielding a 
soluble form which acts as a decoy receptor for RAGE ligands95. ADAM-10 may on the 
other hand stimulate inflammatory processes in allergic response by shedding of the low 
affinity IgE receptor CD23 yielding the soluble form that is described to stimulate 
differentiation of germinal B-cells into plasma cells, cytokine release by monocytes and IgE 
production by B-cells96. ADAM-10 is involved in shedding of FAS ligand resulting in a 
soluble form which can have both pro- and anti-apoptotic effects, depending on the 
microenvironment. sFAS-L concentration in serum correlates with progression of 
inflammatory diseases such as arthritis and colitis indicating a possible role for ADAM-10 
activity in these diseases 97,98. 
 
ADAM-12 
ADAM-12 was first described in mouse in 1995 as meltrin α as a disintegrin-
metalloproteinase involved in myoblast fusion99. The human homologue was cloned 3 years 
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later and experiments revealed a peculiarity of this ADAM compared to most other 
members of the family with respect to the existence of an alternative splicing variant 
yielding a soluble form of the enzyme (ADAM12-S)100. For most other ADAMs soluble 
forms have been described that are the result of autoproteolytic ectodomain shedding, but 
for most of these proteins the biological relevance is unclear since many experiments 
demonstrating these soluble forms have been performed with cell lines expressing 
recombinant ADAMs. Soluble ADAM-12 has a very similar ectodomain structure 
compared to the membrane-anchored form but lacks the transmembrane and cytoplasmic 
domains, but instead possesses a unique 33 amino acid C-terminus. Both the membrane-
anchored and the soluble ADAM-12 are expressed a inactive zymogens that are activated 
by proprotein convertase cleavage of the prodomain101. Interestingly, the prodomain 
remains attached to the activated enzyme after PC activation, giving sADAM-12 a four-leaf 
clover like structure102. ADAM-12 expression is relatively resistant to transcriptional 
upregulation, only TGFβ has been reported as an inducer in hepatic stellate cells103,104. 
Interaction of the disintegrin domain of ADAM-12 and integrins α9β1 and α7β1 may be 
involved in cell differentiation during muscle development105. ADAM-12 has been 
suggested to be involved in modulation of the cytoskeleton by altering β1 integrins on the 
ECM, which causes reorganisation of the actin-integrin binding between cytoskeleton and 
ECM106.  A second mechanism by which ADAM-12 can reorganize the cytoskeleton is 
mediated by interaction with actinin-1 and -220. ADAM-12 knockout mice show only 
limited abnormal muscular development, which could be an indication that ADAM-12 
function overlaps with and can be compensated by other (ADAM) proteins107. 
Overexpression of ADAM-12 improves muscle regeneration after injury108, and induces 
adipogenesis due to enhanced adipocyte proliferation. ADAM-12 efficient mice are 
resistant against high-fat diet-induced obesity109. 
ADAM-12 is capable of degrading several ECM proteins such as fibronectin, type IV 
collagen and gelatin in vitro110, but the physiological relevance is probably minor111. The 
membrane-bound isoform of ADAM-12 is reported in ectodomain shedding of several 
substrates. ADAM-12 is capable of cleaving insulin-like growth factor binding proteins 
(IGFBP) 3 and 5 in vitro112, HB-EGF113, the oxytocinase placental leucine 
aminopeptidase114, EGF and betacellulin115 and notch ligand delta-like 1116. 
ADAM-12 is highly expressed in placenta, and sADAM-12 levels in serum are markedly 
increased during pregnancy. Interestingly, this rise in serum sADAM-12 is not observed in 
women carrying trisomy-18 and -21 foetuses, making ADAM-12 a possible prenatal 
marker for Down syndrome117. 
ADAM-12 has been associated with various pathological states. As expected from the 
postulated biological function, ADAM-12 is implicated in development of musculoskeletal 
disorders. Polymorphisms in ADAM-12 have been associated with osteoarthritis 
susceptibility118, and although ADAM-12 seems to play a role in muscle regeneration, 
prolonged high expression of ADAM-12 is associated with muscular dystrophy119. In heart 
muscle tissue ADAM-12 is increased in patients with hypertrophic cardiomyopathy, and 





The role of ADAM-12 in cancer has been extensively reviewed121 and ADAM-12 
overexpression is observed in many tumours, ranging from breast and lung cancer to 
glioblastoma and osteoclastoma. An interesting difference with the majority of MMPs and 
ADAMs is that in most tumours, the cancerous cells themselves and not the stroma are the 
main source of ADAM-12 in the tumour122. ADAM-12 is often hypothesized to stimulate 
tumour growth, as demonstrated by a strongly reduced tumour progression in ADAM-12 
deficient mice with experimental prostate cancer123, but anti-ADAM-12 antibodies have a 
stimulating effect on breast and gastric carcinoma proliferation in vitro124,125.The latter 
effect may be effectuated by ADAM-12 induced apoptosis-resistance in tumour cells126. 
Adam-12 is a candidate breast cancer gene, with two possibly functional polymorphisms in 
the metalloprotease and disintegrin domains showing strong association with development 
of breast cancer127. 
The existence of a soluble variant makes ADAM-12 a possibly interesting biomarker 
compared to the membrane-bound ADAMs since sADAM-12 can be found in a functional 
form in biofluids such as serum and urine. A positive correlation has already been 
demonstrated between breast cancer progression and urinary level of sADAM-12110, and 
urine levels of patients with bladder cancer are higher than in healthy individuals128. 
ADAM-12 has recently been comprehensively reviewed129. 
 
ADAM-15 
ADAM-15 was first described in 1996 as metargidin, referring to its RGD-motif in the 
disintegrin domain unique within the ADAM proteases130. ADAM-15 is produced by many 
cell types as an inactive glycosylated zymogen with the prodomain linked to the catalytic 
domain via a cysteine switch. The prodomain contains a proprotein convertase recognition 
site, so the activation process is presumed to involve PC mediated removal of the 
prodomain, yielding the 85 kDa mature protease. 
ADAM-15 deficient mice are viable and fertile, but show reduced neovascularization after 
hypoxia-induced retinopathy, and growth of implanted melanoma is reduced in null mice 
compared to wild type, which could indicate inhibited tumour angiogenesis, but histological 
examination of the tumours revealed no difference in vascularization131. 
The consensus integrin binding site RGD in disintegrins was first found in snake venom 
derived disintegrin, but until the discovery of ADAM-15 no similar site was found in the 
mammalian ADAMs. Since ADAM-15 does contain this sequence it is expected to have a 
much broader binding selectivity towards integrins, and therefore more possibilities for 
cellular adhesion to neighbouring cells and the ECM than the other ADAMs, where the 
interaction is preferentially mediated through RGD independent interaction with integrin 
α9β1132. The ADAM-15 disintegrin domain containing the RGD sequence is found to have 
a strong affinity towards integrin  αvβ3 after expression as a recombinant fusion protein 
with glutathione S-transferase8. Recombinant ADAM-15 is capable of binding αvβ3 on a 
monocytic cell line, and α5β1 on a T-cell line133. The putative role in intercellular adhesion 
is confirmed by the observation that overexpression of ADAM-15 leads to increased 
adhesion in cultured NIH3T3 cells134. In concurrence with this result is the observation that 
overexpression of ADAM-15 inhibits wound healing in monolayers of intestinal epithelial 
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cells by increasing cellular adhesion and inhibition of migration135. RGD-mediated integrin 
αvβ3 binding has been postulated to inhibit cellular adhesion and motility by blocking 
integrin αvβ3 so contact with ECM proteins such as vitronectin, as demonstrated by 
reduced migration of ovarian cancer cells when overexpressing ADAM-15136. This anti-
invasive function of ADAM-15 was also found in melanoma cells, and is possibly linked to 
p38 kinase activation137. 
The pro-adhesive properties of ADAM-15 may provide the protein with a protective or 
homeostatic function in degenerative diseases such as osteoarthritis. ADAM-15 deficiency 
accelerates cartilage destruction, while overexpression has a protective effect138. The 
disintegrin domain of ADAM-15 has further been demonstrated to inhibit migration of 
airway smooth muscle cells through binding to β1-integrins139. 
Integrin binding mediated by ADAM-15 is a possible player in inflammatory processes 
such as inflammatory bowel disorder. ADAM-15 expression is higher in diseased area, and 
histological examination shows binding of ADAM-15 expressing endothelia and crypt 
epithelia to leukocytes. Interestingly, immunochemistry shows mainly the active, mature 
form to be present in these cells. In regenerating tissue, ADAM-15 positive epithelia cells 
are in close contact with integrin-positive myofibroblasts140. 
ADAM-15 may play a role in cardiovascular disease. ADAM-15 is expressed in 
endothelium, and is capable of binding of platelets by interaction with platelet integrin 
α(IIb)β3. Platelets are further activated by adhesion to ADAM-15 and thrombus formation, 
leading to a possible role in thrombotic diseases141. ADAM-15 expression in arterial cells is 
markedly higher in atherosclerotic tissue than in healthy control. ADAM-15-integrin 
binding may play a modulating role in formation of neo-initima142.  
Although most interest in biological function of ADAM-15 has been directed towards the 
integrin binding capacity, the metalloprotease domain does contain the consensus zinc-
binding sequence, and is thus expected to be proteolytically active. Purified ADAM-15 is 
capable of proteolytic degradation of type IV collagen and gelatin143. Experiments with 
recombinant ADAM-15 and a peptide library have demonstrated broad substrate specificity 
in vitro, with a pattern similar to that of ADAM-8. Transfection experiments in HEK 293 
cells exposed to recombinant ADAM-15 did reveal cleavage of the low affinity IgE 
receptor CD23 144. Only recently the first report of a possible biologically relevant substrate 
was published. ADAM-15 was found to be the sheddase responsible for E-cadherin, 
yielding a soluble form that interacts with, and stabilizes HER2 and HER3 receptors. This 
finding may be a first clue of a role for ADAM-15 in the development of breast cancer145. 
 
ADAM-17 
ADAM-17 or TNF alpha converting enzyme (TACE) is undoubtedly the ADAM that has 
attracted the most interest in research right from its discovery as the protease responsible 
for the release of soluble TNFα from cells in 199727,28. The shedding of TNFα had already 
been described earlier, and was reported to be inhibited by metalloprotease inhibitors146,147, 
but with the identification of ADAM-17 as the principle TNF sheddase the first 




TACE is constitutatively produced by many cell types as an inactive zymogen with a 
cysteine switch motif, and is activated by prodomain removal by proprotein convertase 
proteolysis. The prodomain of ADAM-17 appears to be essential for correct folding of the 
metalloprotease domain in proADAM-17 and may have a chaperone function in transport 
through the subcellular structures25. After activation in the late Golgi apparatus, active 
ADAM-17 may be sequestered in lipid rafts, an observation supported by the increased 
processing of TNF after cholesterol depletion and after incubation of ADAM-17 expressing 
cells with high-density lipoproteins148,149.   
One interesting observation is that recombinant soluble ADAM-17 is highly sensitive to 
salt (NaCl), with complete inhibition observed at concentration where no structural or 
conformational changes in the protein occur. This effect has been attributed to disturbance 
of the electrostatic interaction between protease and substrate, but the physiological 
relevance is puzzling. Perhaps this effect is a safety precaution regulating the proteolytic 
activity of TACE after its shedding from the cell surface, but experimental proof is not 
available25. ADAM-17 activity is inhibited by the endogenous metalloprotease inhibitor 
TIMP-3, but not by TIMP-1, -2 and -4150.  
ADAM-17 proteolytic activity is essential during embryonic development. Mice with a 
targeted deletion lacking the zinc-binding region in the catalytic domain generally die 
perinatally, an effect that seems independent on decreased TNF processing. The mice 
exhibit anatomical abnormalities like open eyelids, missing conjuctival sac and attenuated 
corneas. Surviving mice display lower body weight, epithelial dysgenesis in may tissues, 
perturbed hair coats caused by disorganization of the hair follicles, and irregular 
pigmentation151. 
ADAM-17 (together with the closely related ADAM-10) is not a typical member of the 
ADAM family when examining the catalytic domain: the catalytic domain is much longer 
than in most adamalysins, leading to two unique protuberances in the structure of the 
catalytic pocket. The S’3 pocket is very deep and merges with the S’1 pocket, and the 
characteristic Ca2+ binding motif is not found in TACE152.  
ADAM-17 sheddase activity is a well-studied phenomenon, with the liberation of soluble 
TNFα being the first substrate. ADAM-17 (as ADAM-10) cleaves proTNF at Ala76-Val77 
and is the dominant TNF sheddase, since genetic deletion of the zinc-binding sequence in 
mice results in monocytes that are incapable of releasing soluble TNFα27. Other ADAMs 
may compensate for decreased ADAM-17 activity as ADAM-9, -10 and -19 are capable of 
processing of proTNF in vitro, but the physiological relevance of this redundancy seems 
limited, especially under stimulating conditions83. ADAM-10 has been postulated to be 
responsible for the constitutive release of TNFα, while after stimulation ADAM-17 takes 
over the shedding from the cell surface82.  
ProTNFα de novo production in monocytes can be induced with LPS but for TNF release (a 
measure for enhanced ADAM-17 activity) stimulation by phorbol esters is necessary, 
indicating a PKCδ mediated mechanism involving phosphorylation of the cytoplasmic tail 
of TACE leading to activation or translocation of the enzyme25. Other studies have found 
that the cytoplasmic tail is not necessary for phorbol ester induced shedding153, again 
contradicting a possible role for intracellular phosphorylation. The effect of phorbol ester 
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stimulation on ADAM-17 mediated shedding is intriguing: shedding is induced within 
minutes after exposure, but prolonged stimulation results in downregulation of ADAM-17 
involving internalization of the cell surface bound TACE, a process which appears to be 
dependent of metalloprotease activity154.  
Besides TNFα, ADAM-17 is also capable of shedding of soluble TNF receptors p55 and 
p75 TNF-R151. Shedding of p55 TNF-R is inducible by hydrogen peroxide155. ADAM-17 is 
implicated in shedding of L-selectin151, and ADAM-17 relocalizes to L-selectin on the 
neutrophil cell surface after interaction with endothelial E-selectin156.  
ADAM-17 may function as an α secretase157, but as with ADAM-9 and -10 the 
physiological relevance and role in development of Alzheimer’s disease is under debate. 
There is some additional evidence identifying ADAM-17 as a relevant α secretase, since 
ADAM-17 activation downstream of muscarinic receptor 1 stimulation has been described 
to decrease the accumulation of neurotoxic Aβ peptides, a hallmark of α secretase 
activity158. The activation pathway of ADAM-17 via muscarinic receptor activation is also 
implicated in processing of cellular prion protein159.  
The adam17 ΔZn/ΔZn mouse model bears striking similarity with transforming growth factor 
α (TGFα) deficient phenotype. The role of ADAM-17 in TGFα shedding was confirmed by 
a strong decrease in soluble TGFα production in the ADAM-17 mutant mice151. The 
anatomical abnormalities in heart valves observed in ADAM-17 deficient mice may also 
arise from decreased shedding of another EGFR ligand, HB-EGF which is also a possible 
substrate for ADAM-17160,161. 
Since TNFα is an important proinflammatory mediator, ADAM-17 activity has been 
implicated in many diseases involving inflammation such as rheumatoid arthritis, Crohn’s 
disease and inflammatory bowel disorder. An interesting finding is that inhibition of 
ADAM-17 by conditional knockout has a strong protective effect in endotoxin shock in 
mice, and significantly reduces mortality. This observation may find use in the clinic where 
septic shock is still a condition with high mortality162. 
ADAM-17 mediated TNF processing may be important in atherosclerosis, since 
atherosclerotic plaques express both ADAM-17 and substrates TNFα and p55 TNF-R. 
Shedding is stimulated by microparticles, small vesicles that are present in atherosclerotic 
lesions as a result of cellular apoptosis163. 
ADAM-17 expression is upregulated in many tumours164. ADAM-17 mediated shedding of 
EGFR ligand TGFα and amphiregulin may be involved in invasion of breast cancer cells, 
and high expression of both ADAM-17 and TGF α correlates with poor prognosis165. 
Experiments with renal carcinoma cells have demonstrated ADAM-17 may be an essential 
factor in tumour formation since cells are unable to form solid tumours and loose their 
invasive potential after ADAM-17 silencing166. ADAM-17 (and -10) may be involved in 
early steps in the malignant transformation and tumour growth. ADAM-17 is shown to be a 
major sheddase of the natural killer cell receptor ligand MICA, thereby inhibiting the 








ADAM-19 or meltrin β was first cloned in human in 2000 as a disintegrin-metalloprotease 
involved in 1α,25-dihydroxy vitamin D3 induced differentiation in primary monocytes and 
named MADDAM (metalloprotease and disintegrin dendritic antigen marker). Expression 
was found to be maintained in monocytes differentiating to dendritic cells, while 
macrophages do not produce MADDAM168. The authors also identified the novel protein as 
a human homologue of the earlier discovered murine meltrin β (ADAM-19)99,169. ADAM-
19 is closely related to ADAM-12 (meltrin α) and both proteins appear to be involved 
during development in mesenchymal cells, with ADAM-19 expression observed mainly in 
areas where peripheral neural cell lineages are formed. ADAM-19 expression is also found 
in the developing lung, intestine, heart and skeletal muscle, while ADAM-12 gene activity 
is found mainly in mesenchymal cells giving rise to bone, visceral organs and skeletal 
muscle170. Knockout experiments revealed ADAM-19 to be essential for heart development 
with ADAM-19 null mice dying perinatally with severe cardial abnormalities, mainly in the 
ventricular septum and the heart valves171. ADAM-19 may exist as an alternative splice 
variant missing the disintegrin and metalloprotease domain, dubbed meltrin β mini. This 
isoform is capable of initiating neural outgrowth in mouse neuronal cells, implicating a 
possible role for this alternative form in the development of the nervous system172. 
ADAM-19 is widely expressed in adult mammals, with high expression in bone, lung and 
heart. ADAM-19 is expressed as an inactive zymogen which is activated by cleavage of 
either one of two furin-recognition sites locate between the pro- and metalloprotease 
domain173. Indications exist that autoproteolytic truncation of ADAM-19 by cleavage 
within the cysteine-rich domain is necessary for proteolytic activity174. 
ADAM-19 is catalytically active and is capable of cleaving α2 macroglobulin in vitro, but 
was not able to cleave proteins such as type I and IV collagen, gelatin, casein and laminin, 
nor was cleavage of tested synthetic fluorogenic MMP and TACE substrates observed175. 
Later studies using a soluble recombinant ADAM-19 revealed a wide substrate specificity, 
with potential targets for proteolysis including myelin basic protein, insulin B-chain TNFα, 
TRANCE (TNF related activation induced cytokine) and kit ligand-1, but not TNF 
receptor-55 and -75 and IL6-receptor. The proteolytic activity of recombinant ADAM-19 is 
not inhibited by TIMP-1, -2 and -3. Cell-based shedding assays show increased release of 
TRANCE (TNF related activation induced cytokine) in COS-7 cells overexpressing 
ADAM-19, and kit ligand-1 shedding seems to be negatively regulated by ADAM-19176. 
The proteolytic activity towards TRANCE, a member of the TNF family is interesting since 
TRANCE signalling is associated with dendritic cell survival by inhibiting apoptosis177.    
ADAM-19 has been implicated in shedding of neuregulin (NRG), with a preference for the 
beta-isoform, with observed shedding of NRG β1 and β4, but not α2. Overexpression of 
ADAM-19 increases shedding, while shedding is markedly decreased in ADAM-19 
deficient mutants. The shedding of NRGs seems in line with the essential role of ADAM-19 
in the development of heart and central nervous system178. The sheddase activity of 
ADAM-19 towards NRG has been attributed to presence of the protease in lipid rafts within 
the neurons, an localization which is not common in the ADAMs which are mostly 
membrane-anchored179. Recently the NRG-processing activity of ADAM-19 has been 
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demonstrated to occur within the Golgi apparatus, and not the cell surface, again hinting at 
a unique localization of ADAM-19 mediated proteolysis180. The role of ADAM-19 in the 
developing heart and the shedding of NRG β is not exclusive, and may be compensated by 
other members of the ADAM family, as demonstrated in a study investigating the role of 
individual ADAM proteases. Apparently there is significant redundancy between the 
individual family members, which may complicate interpretation of results of individual 
knockout models181. ADAM-19 has recently been described having α-secretase activity 
towards APP, since overexpression increased release of the cleaved APP fragment 
increased while RNA interference decreased shedding. This may implicate a (partial) role 
for ADAM-19 in the processing of APP182. 
High ADAM-19 expression has been associated with invasive potential of primary brain 
tumours, with detectable proteolytic activity present on tumours with the highest 
expression49. ADAM-19 expression is high in renal cell carcinoma52 and ADAM-19 
expression is significantly higher in patients with chronic allograft nephropathy compared 
to healthy graft recipients, but is also increased in acute rejection and in non-allograft 
related diseases. Interestingly, ADAM-19 colocalizes with CD4+ T-cells (T-helper cells) 
indicating a role in the allograft rejection process183. ADAM-19 may be involved in 
development of fibrotic lesions in kidney disease. Expression is markedly higher in many 
renal structures in patients compared to healthy adults, and may be related to infiltration of 
macrophages184. 
 
ADAM-20 and -30 
These two proteins are interesting with respect to being the only human testis-specific 
ADAMs with the metalloprotease active site sequence. Unfortunately, almost no research 
has been aimed at elucidating the biological roles of these proteases. ADAM-20 was first 
described in 1998, and has high sequence similarity to the fertilins (ADAM-1 and -2) and 
surprisingly, ADAM-9185. Since mature ADAM-1 loses its metalloprotease domain during 
processing and is considered non-functional in human, ADAM-20 was hypothesized to be 
the functional equivalent of ADAM-1. ADAM-30 was cloned in 1999186, but the 
publication describing the cDNA sequence remains the only study published to date. 
Considering the expression pattern these two ADAMs may be functional homologues of the 
murine testases, although no evidence for this is published. 
 
ADAM-28 
ADAM-28 was first described in 1999 as eMDC II187 in human and macaque epididymis, 
and as MDC-L in human lymphocytes188. There is some confusion about the identity of 
ADAM-23 and ADAM-28, there is some consensus that they correspond to the same 
protein, but why the annotation ADAM-28 is preferred is unclear. ADAM-23 was 
described as a disintegrin-metalloprotease (MDC-3) without the zinc-binding catalytic site 
sequence, and thus probably does not have proteolytic activity189, while ADAM-28 does 
contain the zinc-binding site. 
ADAM-28 is expressed as a 115 kDa zymogen that is activated to an 88 kDa mature form 




observed. Interestingly, ADAM-28 lacks the furin recognition site, and may depend on 
autolytic activation, or activity of other metalloproteases (MMP-7) for prodomain 
removal24,190. 
Purified ADAM-28 has proteolytic activity in vitro, and is able to cleave myelin basic 
protein, but not ECM constituents like collagen I-IV,  fibronectin, and laminin. The 
substrate specificity in vitro seems to overlap largely with ADAM-8 and ADAM-15, as 
demonstrated by screening against a library of synthetic peptides, and ADAM-28 is capable 
of cleavage of the low affinity IgE receptor CD23144. The soluble form of ADAM-28 is 
capable of in vitro cleavage of insulin-like growth factor binding protein-3190. ADAM-28 
catalytic activity is not inhibited by TIMP-1, and only weakly inhibited by TIMP-2191. 
ADAM-28 can bind integrin α4β1 by interaction with its disintegrin domain192,193. 
The expression of ADAM-28 in the epididymis suggests a role in reproduction. The soluble 
splice variant was found in mouse epididymus, but no functional role could be attributed to 
this protein in sperm194. ADAM-28 may have a function in development of dental tissue, 
since expression in the developing tooth, and appears to be associated with tooth root 
hypoplasia in patients195. The mechanism behind this biological effect is postulated to be a 
survival promotion mediated through ADAM-28 induced proliferation of dental papilla 
mesenchymal cells, while silencing of ADAM-28 results in apoptosis of the dentals 
mesenchymal cells196. Some studies have included ADAM-28 in screening for 
overexpressed protein in cancer. Expression of ADAM-28 was found to be high in non-
small cell lung carcinoma, and correlated with proliferation and metastasis197. ADAM-28 
expression in breast cancer is also high, and proteolytic activity of ADAM-28 in shedding 
of IGFBP-3 may contribute to cell proliferation in breast cancer198. 
 
ADAM-33 
ADAM-33 was first described in 2002 as a novel disintegrin-metalloprotease in mouse and 
human199. ADAM-33 in quite unique within the metzincin family in the fact that within 6 
months after its discovery, even before ADAM-33 was well characterized at the protein 
level, it was already associated with a disease state200. ADAM-33 is now widely regarded as 
an asthma susceptibility gene and many studies have tried to find associations of ADAM33 
polymorphisms with asthma and bronchial hyperresponsiveness. 
ADAM-33 is widely expressed, except in liver. An interesting structural peculiarity is that 
ADAM-33 lacks SH3 binding sites in its cytoplasmic domain, which may indicate that the 
role in intracellular signalling is different than for other ADAMs199. ADAM-33 is produced 
as a  123 kDa glycosylated zymogen, and may be activated by cleavage of one of three 
putative furin recognition site between the pro- and metalloprotease domain resulting in a 
100 kDa mature enzyme that can be detected at the cell surface. ADAM-33 contains the 
zinc-binding metalloprotease active site, and recombinant ADAM-33 has been 
demonstrated to possess proteolytic activity and soluble ADAM-33 is capable of cleaving 
α2-macroglobuline201. The disintegrin domain of recombinant ADAM-33 has affinity 
towards integrin α9β1, but not α4β1 and α4β7 (implicated in ADAM-28 mediated 
interaction with lymphocytes)202, but later studies have revealed a possible mechanism for 
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inhibition of cell migration by ADAM-33 mediated interaction with integrins α4β1 and 
α5β1203. 
An in vitro cleavage specificity screening of recombinant ADAM-33 has revealed limited 
substrate specificity compared to other ADAMs. Only four peptides, based on the putative 
cleavage sites of kit ligand-1, APP, TRANCE and insulin B-chain were cleaved while 
broadly recognized sheddase cleavage sites such as in EGF, HB-EGF, proTNFα, p55 and 
p75 TNF receptors and TGFα were not hydrolyzed by ADAM-33204. The cleavage sites of 
the four recognized peptides are similar to those observed in ADAM-19, an observation 
already expected from the phylogenic tree identifying this ADAM and Xenopus ADAM-13 
as having the highest sequence homology199. The catalytic activity is quite different from 
ADAM-17, and can be explained by marked differences in the catalytic pocket as 
demonstrated by crystallographic resolution of the structure of both proteins205. Cellular 
shedding of KL-1 was evaluated by cotransfection of full length ADAM-33 into COS-7 
cells. After transfection KL-1 shedding was slightly higher, and transfection of a non-
functional ADAM-33 mutant slightly decreased KL-1 release. A similar experiment with 
APP shedding resulted in no increase in soluble αAPP release from the cells, leading to the 
conclusion that ADAM-33 is not a relevant α secretase in vivo. ADAM-33 activity is 
inhibited in vitro by TIMP-3 albeit at much higher concentration than ADAM-17204. 
As expected from the genetic association with asthma, most research efforts involving 
ADAM-33 have been focussed on the biological and pathophysiological function in the 
lung. Pulmonary ADAM-33 expression has been found in cells of mesenchymal origin like 
smooth muscle cells and fibroblasts, but expression in epithelia has been subject to debate. 
Early reports show no expression in airway epithelia, while the consensus now seems to be 
that epithelia does indeed produce ADAM-3343,206, but expression in epithelia is sensitive to 
gene silencing by hypermethylation of the promoter region206. ADAM-33 is found in 
smooth muscle tissue and airway epithelia while its presence is limited in the immune 
system, which may be an indication that the role of ADAM-33 lies more in tissue 
remodelling than in the allergic component  of asthma207. ADAM-33 may be expressed as a 
number of isoforms as the result of alternative splicing. Originally ADAM-33 was already 
described as having a β-isoform as result of a 26 amino acid deletion in the region linking 
the cysteine-rich region to the EGF-like domain199, but a study investigating the production 
of ADAM-33 isoforms by fibroblasts from a healthy volunteer has revealed a large number 
of isoforms may be expressed in fibroblasts, with 6 forms missing the metalloprotease 
domain. The alternative mRNA sequences are partially translated into protein as 
demonstrated by Western blot with at least 5 specific bands corresponding to protein of 
smaller molecular size are visualized. Several of these bands in the 50-60 kDa region are 
hypothesized to correspond to the isoform lacking the metalloprotease domain, although no 
validation for this hypothesis is supplied208. Later investigation of the different splice 
variant expressed in biopsies of asthmatic lung revealed a similar result showing transcripts 
corresponding to many isoforms being present, with a minority actually containing the 
metalloprotease domain region209. These findings, combined with the observation that the 
alternatively spliced ADAM-33β appears to be insensitive to proteolytic activation of the 




The 55 kDa isoform of ADAM-33 has been detected in BAL fluid of patients, and levels 
were higher in patients with moderate and severe asthma. The level of ADAM-33 
correlated inversely with the measured FEV1 % predicted, which associates ADAM-33 
production in the lung with airway obstruction211. Expression of ADAM-33 in airway 
smooth muscle cells obtained from asthma patients was found to be higher than in healthy 
control, and the overexpression could be reversed by incubation of the cells with interferon 
γ212. Expression of ADAM-33, like ADAM-8 was found to increase with disease severity in 
asthma patients43. 
Knockout experiments in mice have demonstrated that ADAM-33 is not essential for 
development and survival, ADAM-33 null mice show no morphological abnormalities and 
are fertile. Interestingly, the knockout mice response in allergen sensitization/challenge 
experiments is normal compared to wild type and pharmacological bronchoconstriction 
gives a normal response. These results have demonstrated that, at least in mouse, the role of 
ADAM-33 in allergic airway disease may be limited, although the model may not 
correspond perfectly to asthma in human213. 
The genetic association of ADAM-33 with asthma and bronchial hyperresponsiveness has 
been extensively studied, with group worldwide attempting to reproduce the association 
found in 2002 in other populations. Many groups do find polymorphisms that are 
associated214-216, while others fail217,218, and there seems to be a rather high heterogeneity in 
SNPs that appear to be responsible for the association, a trait that is observed more often in 
population-wide genetic screening.  In recent years, several reviews have been published 
summarizing the state of events219,220. 
Since the physiological function of ADAM-33 in not clear to date, interpretation of the 
effect of individual SNPs on protein function are complicated. In theory both dysfunction 
of the metalloprotease domain (shedding of EGFR ligand and inflammatory cytokines) and 
the disintegrin domain (cellular adhesion and migration) are possible causes of smooth 
muscle remodelling observed in asthma. Much evidence points to a minor role of the 
metalloprotease domain, but most studies have found expression of metalloprotease domain 
containing ADAM-33 low, while on the protein level no distinction is made. More research 
on the biological role of ADAM-33 and elucidation of its endogenous substrate (if any) are 
necessary to explain the genetic association found in many studies. 
Although almost all research on ADAM-33 has been focussed on asthma, there appears to 
be an association of an ADAM-33 polymorphism in the cytoplasmic and development of 
chromic obstructive pulmonary disease (COPD), with increased airway 
hyperresponsiveness and higher infiltration of inflammatory cells221.  
Two recent studies have found an association of ADAM-33 with psoriasis susceptibility, 
with the second study reproducing two out of three SNPs identified in the first, making a 
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1.4 ADAMs with a thrombospondin type I-like motif (ADAMTS)  
 
The latest discovered subfamily of the metzincins are the ADAMTS proteases whose first 
members were cloned in mouse in 1997, and were immediately associated with 
inflammation1. The human ADAMTS family comprises 19 secreted disintegrin-
metalloproteases (ADAMTS-1 to -20, with -11 being identified as a literature alias of 
ADAMTS-5) with a similar domain structure to the membrane-anchored ADAMs but with 
some marked structural differences in the C-terminal region. ADAMTS proteins lack the 
EGF-like domain (and naturally the transmembrane and cytoplasmic regions), but contain a 
central thrombospondin type I-like repeat (TSR) between the disintegrin domain and the 
cysteine-rich domain. The cysteine-rich domain is followed by a spacer region of unknown 
function, and (with the exception of ADAMTS-4) a variable number of additional TSR’s 
(see figure 1)2. The TSR motifs have a putative function in protease-substrate interaction 
and association with the extracellular matrix, as demonstrated for the interaction of 
ADAMTS-1 with sulphated glycosaminoglycans like heparan3. 
ADAMTS’s are expressed as inactive zymogens that can be activated intracellularly, a 
process that is likely dependent on proprotein convertase activity in the late-Golgi network 
since all ADAMTS’s contain the furin recognition site within their prodomain4. 
Autocatalytic processing has been described in the C-terminal domain, effectively releasing 
several of the TSR’s from the protein5. 
The ADAMTS’s can be roughly divided into four functional groups: the hyalectanases or 
aggrecanases (ADAMTS-1, -4, -5, -8, -9 and -20), the pro-collagen N-endopeptidases 
(ADAMTS-2, -3 and -14), ADAMTS-13 as a unique member and a heterogeneous group of 
proteases with unknown function. The biochemical and biological characterization is 
limited for the majority of ADAMTS’s especially when looking at the most recently 
decribed members. Although several studies were published on the biological and 
pathological role of the pro-collagen peptidases, which are implied in processing of pro-
collagens prior to fibril formation and therefore have an important role in formation of 
connective tissue6,7, most research effort so far has been directed to only a few 
submembers: the aggrecanases ADAMTS-1, -4 and -5 and the putative von Willebrand-
factor cleaving protein ADAMTS-13. 
 
1.4.1 Aggrecanases 
ADAMTS-1 or METH-1 was the first identified human ADAMTS in 19988. ADAMTS-1 is 
a proteolytically active enzyme as demonstrated by the α2-macroglobuline trapping assay9, 
and is capable of degradation of aggrecan by cleavage in the chondroitin sulphate 
attachment domain10. ADAMTS-1 knock-out mice are viable, but are considerably smaller 
than wildtype, with growth retardation continuing after birth. The smaller size of the null 
mice is contributed mainly to disfunction in fat metabolism, since the knockouts are 
extremely lean, although no histological abnormaliteis are visible in adipocytes (besides the 
smaller size). ADAMTS-1 knockout mice show abnormalities in the structure of the adrenal 
medulla, but no functional deficiency is observed. The mice further exhibit abnormal 
development of the kidney, with enlarged calices and fibrotic interstitial lesions, indicating 
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a role for ADAMTS-1 in ECM turnover during development11,12. This role in ECM 
homeostasis is confirmed by the observation that ADAMTS-1 is markedly downregulated 
in the liver of chirrotic rats13. ADAMTS-1 has been implicated in ECM turnover during 
bone formation14,15, and may play a role during follicular development and ovulation16,17, a 
function that is corroberated by the observed sub-fertility in ADAMTS-1 null mice. 
ADAMTS-1 inhibits fibroblast-growth factor-2 VEGF mediated vascularization, an effect 
presumably mediated by autocatalytically processed fragments, while full-length 
ADAMTS-1 has sheddase activity towards HB-EGF and amphiregullin and may promote 
angiogenesis in tumours18. ADAMTS-1 expression is lower in patients suffering from 
asthma 19 and non-small-cell lung carcinoma20. 
Although ADAMTS-1 is capable of aggrecan processing, this process is attributed more to 
ADAMTS-4 (aggrecanase-1) and -5 (aggrecanase-2) activity, with ADAMTS-1 only 
fulfilling a minor role in vivo21. ADAMTS-4 was first described in 199922, as was 
ADAMTS-5/ADAMTS-1123,24. Since the specific Glu373-Ala374 cleavage of aggrecan 
mediated by the ADAMTS’s is observed in cultured explants undergoing cartilage 
destruction25,26 and the resulting aggrecan fragments are detectable in synovial fluid of 
patients with arthritis27 the role of ADAMTS-4 and -5 in arthritic diseases is well 
investigated. ADAMTS-4 expression is sensitive to pro-inflammatory factors such as IL-1, 
TGFβ and TNFα, but ADAMTS-5 is not, or to a much lesser extent (28 and references 
therein), which is indicative that ADAMTS-5 functions as a constitutative aggrecanase 
while ADAMTS-4 functions more under inflammation. IL-1 stimulation may induce 
production of a 37 kDa variant form of ADAMTS-4 in chondrocytes which is capable of 
aggrecan degradation29, while a truncated form resulting from C-terminal processing yields 
an inactive form, presumably due to disrupted substrate binding30. Another interesting 
alternative processing pathway has been described in in situ, extracellular activation by the 
proprotein convertase PACE4 in cultured cartilage explants31.  
Findings in knockout experiments investigating the major aggrecanase in murine 
osteoarthritis however contradicted the role of ADAMTS-4 under inflammatory stimuli as 
observed during arthritis, with knockout yielding no protective effect32, while the 
ADAMTS-5 null mice exhibited a decreased cartrilage destruction33,34. The relevance of 
these observations in human arthritic diseases is not entirely clear, since indications exist 
that the cytokine-sensitivity of ADAMTS-4 is not present in murine cells, making the 
translation of the knockout results difficult35, but recent characterization of the proteolytic 
profile of both aggrecanases have provided indication that ADAMTS-5 is indeed the major 
aggrecanase in arthritis, since the aggrecanolytic activity is around a 1000-fold higher than 
of ADAMTS-4 under physiological conditions36, but this may not be true under 
inflammatory conditions observed in arthritis. The consensus seems to be that both 
aggrecanases have a significant effect in the pathological cartilage destruction observed in 
human osteo- and rheumatoid arthritis28,37, but recent evidence from double-knockout mice 
has shown that aggrecanase activity from ADAMTS-4 and -5 may have redundance with 
another, yet unidentified protease which has a different substrate specificity under 




development and cartilage turnover, indicating that the role of these aggrecanases may be 
more limited than found in earlier studies38. 
 
1.4.2 ADAMTS-13 
The most studied ADAMTS to date is perhaps ADAMTS-13 or the van Willebrand factor 
cleaving protease. This protein was first identified in 2001, and immediately associated 
with processing of ultralarge multimeric form of von Willebrand factor (vWF)39,40.  
In the phylogenic tree ADAMTS-13 stand apart from the other family members, mainly 
due to the presence of C-terminal CUB (Complement C1r/C1s, Uegf (EGF-related sea 
urchin protein) and BMP-1 (bone morphogenic protein-1)) domains which are presumed to 
play a role in protein-protein interaction with other CUB-containing proteins2. The 
prodomain of ADAMTS-13 is unusually short and, contrary to other ADAMs is not 
necessary for accurate folding of the metalloprotease domain. Removal of the prodomain 
by proprotein convertases is furthermore not required for proteolytic activity, since 
proADAMTS-13 is well capable of processing of vWF41.  
Defects in vWF processing are the underlying pathology in thrombotic thrombocytopenic 
purpura (TTP), a rare syndrome involving microangiopathic haemolytic anaemia and 
thrombocytopenia, and may lead to neurological dysfunction, tissue infarction and renal 
failure. The mortality is high (90%) when untreated, but the reduced processing of the ultra-
large vWF multimers can be compensated by plasma exchange essentially supplementing 
the patient with active vWF cleaving protease (ADAMTS-13)42,43. The inactivity of 
ADAMTS-13 in TTP may be congenital, or the result of an acquired auto-immune response 
targeting ADAMTS-13. The pathophysiology of TTP and the role of ADAMTS-13 has 
recently been extensively reviewed44. 
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1.5 Scope of the thesis 
 
This thesis describes the development of novel methods for activity-based proteomics based 
on the selective interaction of active metalloproteinases such as matrix metalloproteinases 
(MMPs) and a disintegrin and metalloproteinases (ADAMs) with newly synthesized 
inhibitor molecules. 
The general introduction (chapter 1) gives an overview of the current literature on the 
biological and pathophysiological role of the MMPs, the ADAMs and the recently 
discovered subfamily of ADAMs with a thrombospondin repeat (ADAMTSs).  
Excessive metalloproteinase activity is a possible underlying cause for the development of 
many diseases ranging from inflammatory conditions to pathological tissue remodelling 
and cancer the profiling of metalloproteinase activity could provide a valuable diagnostic 
tool and shed light on the complicated role of the MMPs and ADAMs in health and disease. 
As metalloproteinase activity is highly regulated in vivo, determination or profiling of the 
actual active isoforms that are present could provide a better picture of the (patho)-
physiological situation. Several analytical techniques for distinguishing active from non-
active, either in pro-protease, or zymogen form or inactivated by endogenous inhibitors, 
have been described in literature. Chapter 2 gives an overview of the traditional methods 
for activity determination based on monitoring of substrate conversion and expands to the 
recently developed field of activity-based proteomics (ABP). 
ABP methodology uses small molecular weight inhibitors as ligands and roughly can be 
divided into two approaches; using inhibitor probes labelled with either biotin or a 
fluorophore for tagging and visualisation of active proteinases or by using immobilized 
reversible inhibitors for activity-based solid phase extraction. 
In chapter 3 we describe the first approach where the base structure of a successful 
reversible hydroxamate-based inhibitor was modified to include a photoreactive moiety for 
crosslinking of the probe to the active metalloproteinase and a biotin group for visualisation 
and pulldown using biotin-streptavidin interaction. A similar probe with an incorporated 
fluorescent moiety was tested alongside the biotinylated probe and the probe is optimized 
by transfer of the photocrosslinking group from the P’2 to the P’1 position in the molecule. 
In chapter 4 we test a library of reversible peptide-based hydroxamates as inhibitors 
against three model metalloproteinases, MMP-9, MMP-12 and ADAM-17. The best 
performing inhibitors are immobilized on Sepharose beads and used for activity-based 
enrichment of metalloproteinases. This approach is used to enrich active endogenous 
ADAM-17 from a complex proteome (a total cell lysate of A549 lung carcinoma cells).  
Solid phase extraction has the advantage of being susceptible to automation, and this 
approach is described in chapter 5. By packing the immobilized inhibitor beads into a 
cartridge suitable for the PROSPEKT automated solid phase extraction module, and 
coupling the automated extraction to inline tryptic digestion and LC-MS analysis we show 
a system for fully automated activity-based analysis of metalloproteinases. The enrichment 
platform is coupled to a chip-based LC interface for improved robustness and the system is 




In chapter 6 we summarize the results and give future perspectives. A preliminary 
approach for the use of the inhibitor probes for in-vivo imaging using a 99m-technetium 
label is discussed and the challenging task of proper pre-analytical sample handling to 
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Metzincins are a family of Zn2+ dependent metalloproteinases, with well known members 
such as the MMPs and the ADAMs. Metzincin function is mainly geared towards 
modulation and regulation of the extracellular matrix by proteolytic degradation of  ECM 
proteins, and by liberation or production of biologically active proteins from their pro-
forms. Since metzincin activity is strictly regulated in vivo novel analysis methods are 
necessary to elucidate the role of the active enzymes in health and disease. This concept 
gives an overview of available methods, and describes an approach to use synthetic 
metzincin inhibitors as affinity-probes for selective determination of active metzincins in  






Metzincins are multidomain proteins with endopeptidase activity that are dependent on a 
Zn2+ ion in their catalytic pocket for proteolysis. The two best-described members of this 
superfamily are the Matrix Metalloproteinases (MMPs) and A Disintegrin And 
Metalloproteinases (ADAMs) 
The main physiological role of MMPs lies in the regulation of extracellular matrix (ECM) 
by promoting turnover through direct proteolytic degradation of ECM proteins such as 
collagens, or by the production of bioactive signalling proteins through proteolytic 
activation (MMP biological function has been extensively reviewed in the literature, for 
instance in 1).  ADAM proteinases have a bimodal function: They mediate cell-cell and 
cell-matrix interaction through integrin binding to their disintegrin domain, and more than 
half the known human ADAMs contain a catalytic domain that enables modulation of the 
cellular environment by activation of signalling pathways through proteolytic release of 
bioactive proteins from their membrane anchored proform. This ectodomain shedding is 
well described for many ADAM proteinases and their natural substrates such as cytokines 
(soluble TNF release by ADAM-17 or TNF alpha converting enzyme, TACE) and growth 
factors such as TGFα (ADAM-9). For a review on ADAM proteinases see 2. 
Metzincins are expressed as inactive zymogens, where the catalytic pocket is shielded by a 
prodomain that interacts with the zinc ion in the catalytic centre via a highly conserved 
cysteine residue (the so-called cysteine switch). Through proteolytic removal of the 
propeptide by furin proprotein convertases or other MMPs the catalytic site becomes 
accessible to substrates. MMP activity is controlled by a small family of endogenous 
specific inhibitors, the Tissue Inhibitor of Metalloproteinases (TIMP 1-4) or the generic 
proteinase inhibitor α2-macroglobulin. 
Endopeptidase activity is mediated by a Zn2+ ion coordinated between three histidine 
residues in the consensus zinc-binding HExGHxxGxxHD motif that is present in the 
catalytic centre of all known proteolytically active MMPs and ADAMs. The exact 
mechanism of proteolysis is under debate, but probably involves polarization of an active-
site-bound water molecule to function as a nucleophile that attacks the polarized carbonyl-
group of the scissile peptide bond. Proton transfer to the peptidic nitrogen atom, which may 
be facilitated by the adjacent glutamate residue in the catalytic pocket acting as a base, 
leads to cleavage of the peptide bond. 
Disregulation of MMPs can lead to a wide range of disease states, mainly correlated to 
proteolytic destruction, aberrant development or repair of tissue. MMPs are implicated in 
cardiovascular disease such as atherosclerosis and aneurism, rheumatoid and osteo-arthritis 
and cancer progression by promoting metastasis and angiogenesis. The 
(patho)physiological roles of MMPs have been reviewed by Malemud 3 
ADAM proteinases have been implicated in many of the same pathologies as MMPs due to 
their similar proteolytic function, but are also linked to development of Alzheimer’s disease 
(ADAM-10 functions as an α-secretase for amyloid precursor peptide), tissue remodelling 
in heart failure and gastro-intestinal diseases linked to TNF (such as inflammatory bowel 
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syndrome). ADAM-33 has been implicated in airway diseases e.g. asthma and emphysema, 
although it is not yet known if this is due to an altered proteolytic activity.  
 
Activity-based metalloproteinase analysis 
 
The majority of hypotheses associating metzincins to disease states have been focussed on 
disregulation of the catalytic activity in vivo. This poses a challenge to the analysis of these 
enzymes, since the strict regulation of proteolytic activity means that traditional protein 
analysis techniques may not provide the required information.   
Since any given sample can contain three different forms of the metalloproteinase, the 
inactive zymogen, the inactivated TIMP-proteinase complex and the activated mature 
enzyme, a mere determination of gene expression by quantitative PCR or protein amount 
by immunochemical techniques or conventional proteomics may be of limited diagnostic 
value. 
To overcome this limitation several analytical techniques, that determine actual 
metalloproteinase activity, have been under development since the late 1980’s. Table 1 
gives an overview of available ‘traditional’ methods for measuring metalloproteinase 
activity. The earliest methods (preceding the identification and nomenclature of the MMPs) 
were already described in the 1950’s and 1960’s and are based quite simply on conversion 
of a known (protein) substrate of the metalloproteinase. Substrate degradation may be 
monitored by techniques such as liquid chromatography, radioactivity measurement in the 
supernatant after incubation of the proteinase with a radiolabeled substrate, gel 
electrophoresis or even weight loss of a solid piece of collagen over time. Variations on this 
theme include zymography, where the substrate is incorporated in an SDS-PAGE gel, 
which after visualisation yields not only a measure for the activity, but also the apparent 
molecular size of the proteinase, which in turn gives an indication of its identity.  
For improved quantification several reporter molecules have been incorporated into 
substrates, being either whole protein (e.g. biotinylated gelatine, which yields singly 
biotinylated fragments after proteolytic degradation that can be distinguished from the 
multiply biotinylated original substrate in a rather elegant two-step capture-labelling 
procedure)4 or small synthetic peptide sequences with internally quenched fluorophores. 
These substrates are readily available for most MMPs and give the opportunity for 
relatively precise measurement of total activity of metalloproteinase subfamilies with 
similar substrate specificity, but unfortunately give no information about the identity and 
relative abundance of individual MMPs. 
Finally activity-based analysis of metalloproteinases may be based on the hypothesis that 
MMP-related diseases are caused by an imbalance between proteolytic activity and the 
TIMP-based inhibition system. An excess of activated proteinase may over time deplete the 
pool of available TIMP and cause unwanted degradation of tissue since the proteinase is no 
longer controlled. Although elegant, this technique may yield results of limited value since 
it depends on accurate quantification of the amount of active, mature proteinase that is 
present in a complex biological sample. A second difficulty is that the enzyme activities 




measured in the soluble biological sample will reflect the situation in the tissue. Therefore, 
often parallel studies are performed using tissue samples and histological staining 
techniques. This problem is particularly important in case of ADAMs, since many of the 
ADAMs are strong cell surface bound molecules that are not easily released into biological 
fluids. Another problem is the lack of specificity of TIMPs for individual MMPs, which 
may lead to incorrect conclusions when only one pair (such as MMP-9 / TIMP-1) is 
determined. 
 
MMP inhibitor design and evaluation 
 
Since MMPs and ADAMs are potentially highly interesting targets for therapeutic 
intervention, attempts at producing synthetic MMP inhibitors with therapeutic value have 
been made, especially in the field of oncology. Several chemical entities have entered 
clinical trials, but finally failed due to undesirable side-effects or lack of efficacy during 
phase II/III clinical trials. One major factor determining the failure of MMP inhibitors so 
far seems to be the strong homology between catalytic sites within the MMP and ADAM 
families which meant that the majority of the first generation inhibitors lacked selectivity. 
This lack of selectivity was likely responsible for the observed side-effects and the lack in 
clinical benefit, since it has become clear that some metalloproteinases, for instance MMP-
8, exert a protective effect against development and metastasis of tumours5. 
Most MMP inhibitors synthesized to date are based on a Zn2+-chelating group fitted onto a 
peptide (like) backbone mimicking the endogenous protein substrate of the proteinase. 
Following the Schechter and Berger nomenclature6 three distinct inhibitor types can be 
distinguished: inhibitors with a peptide sequence N-terminal (P1-P3) or C-terminal (P’1-P’3) 
of the scissile peptide bond (i.e. the Zn2+ ion in the catalytic site) and compounds 
with a zinc binding group (ZBG) located in the middle of the inhibitor with a backbone 
protruding on either side. 
The “N-terminal” approach has proved little successful, although one well-known inhibitor 
(Pro-Leu-Gly-NHOH) is characterized in the literature and is capable of inhibiting MMP 
activity with low µM Ki values. Although inhibitors with a ZBG in the centre of the 
molecule are being investigated14 the most popular approach has been the synthesis of 
inhibitors, which interact at the “C-terminal” side of the catalytic zinc ion.  
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Several functionalities can be used as effective ZBGs (for instance carboxylic acid 
derivatives, thiol groups, phosphinates) and can also be used to modulate selectivity15, but 
the most effective ZBG for producing high-affinity inhibitors has been the hydroxamate 
moiety. Hydroxamates are capable of strong bidentate ligation of the Zn2+ ion, effectively 
replacing the water molecule and inhibiting the catalytic mechanism. The binding is further 
strengthened by a hydrogen bond that is formed between the hydroxamate NH-group and 
the carbonyl oxygen of the highly conserved alanine (Ala-182 in MMP-1)16.  
The strong interaction of the hydroxamate group with the catalytic zinc ion combined with 
the homology of the catalytic centre in MMPs has led to the development of a large number 
of highly efficient broad spectrum inhibitors with low-to-sub nanomolar affinity (reviewed 
in 17). Although variation in other positions can also lead to differences in inhibition 
pattern18, the major determinant of affinity has proven to be the substituent at the P’1 
position which enters the hydrophobic pocket at the S’1 position in the catalytic site. The 
depth of this pocket (also named the specificity pocket) varies considerably across the 
MMP family, from being very shallow in MMP-1 to forming an open ‘pore’ through the 
entire catalytic domain in, for instance, MMP-319. This variation opens the possibility of 
modulating selectivity when using P’1 substituents that are larger than an iso-butyl group, 
which can still be comfortably accommodated by all MMPs. 
In order to tailor novel metalloproteinase inhibitors to a given set of enzymes, it is pivotal 
to develop analytical methods to profile the activity of MMPs and ADAMs on a family-
wide scale in clinical samples to assess their respective roles in disease and to follow the 
activity of individual members during therapy.  
  
Activity-based probes (ABPPs) to profile metalloproteinases 
 
Since the analytical methods described above each have their shortcomings when 
applied to the family-wide profiling of metalloproteinase activity, investigators have 
searched for alternatives. Most presently available MMP inhibitors have broad spectrum 
affinity for MMPs. Although this may be less suitable for therapeutic intervention, broad-
spectrum inhibition allows the profiling of proteinase activity on a family-wide scale. When 
an inhibitor has affinity for (almost) all metzincin proteinases in the human body one can 
imagine using such an inhibitor as a ligand for selective analysis of active metzincin 
proteinases. This approach, termed activity-based or chemical proteomics was pioneered by 
Bogyo and Ploegh, and Cravatt, developing probes respectively for serine hydrolases 20, the 
proteasome 21 and cysteine proteinases 22 where active site directed molecules were fitted 
with a reactive group or ‘warhead’ to enable covalent tagging of the active site of the 
proteinase. Incorporating a suitable reporter molecule such as a fluorophore or biotin 
enabled visualisation and enrichment of labelled, active proteinases from complex 
proteomes (see Figure 1). 
Taking into account that the catalytic mechanism of metalloproteinases is somewhat 
different than that of the above mentioned proteinases, since the nucleophile is not part of 
the protein itself but rather an active-site bound water molecule, the development of 




probes for MMPs 14,23,24 and for ADAM proteinases 25 all rely on inhibitor probes that have 
an interaction with the catalytic zinc ion (usually a hydroxamate zinc-chelating group) 
combined with a reactive photocrosslinking group that forms a covalent bond with the 
enzyme after UV irradiation. The reporter molecule can be biotin, a fluorophore, or a 




Figure 1: Schematic representation of labelling of active proteinases in a complex proteome by 
activity-based probes. The probe selectively recognizes the active site of the proteinase and forms a 
covalent bond with the active enzyme. By incorporation of a reporter molecule such as a fluorescent 
dye or biotin the labelled proteinases can be visualised after gel electrophoresis, or enriched on 
affinity beads for further analysis. 
 
Sieber and Cravatt recently succeeded in coupling this approach to mass spectrometric 
identification of the labelled proteinase by enriching ABPP-labelled proteomes on 
immobilized avidin beads followed by tryptic digestion and identification after 2D-LC-
MS/MS 26. Using a cocktail of metalloproteinase-selective probes they were able to identify 
endogenous active members from several subfamilies in human cancer cell lines. 
This approach provides investigators with a tool for profiling metalloproteinases in 
biological samples, but is still far from trivial. Although it gives superior enrichment 
possibilities, using a naturally occurring molecule like biotin as a reporter molecule gives 
rise to interference from endogenously biotinylated proteins. Preclearing of the sample by 
pull-down of biotinylated proteins with immobilized streptavidin is an option to overcome 
this problem, but the carrier material (usually crosslinked agarose beads) can give rise to 
loss of proteins due to non-specific interaction (unpublished observations). An additional 
problem with photocrosslinking probes is the fact that the crosslinking step is not a 
quantitative process, and may be influenced by many experimental factors. This limits the 









Activity-based solid-phase extraction (SPE) 
 
Although the ABPP methodology provides an elegant platform for the family-wide activity-
based analysis of metalloproteinases, it is advantageous to use immobilized synthetic 
inhibitors for the enrichment of active enzymes that are present at very low concentrations 
in large volumes of biofluids such as urine. When considering that the highly effective 
reversible inhibitors have Ki values in the low nanomolar range one can envision using 
them to create a platform to enrich active metalloproteinases. This approach was first 
described in 1986 by Moore to purify human collagenase from fibroblasts and synovial 
fluid using the low-affinity inhibitor PLG-NHOH as affinity ligand 27. More recently, Freije 
et al. demonstrated the activity-based enrichment of MMP-12 using Sepharose beads with 
this immobilized inhibitor 28. This lead to the analysis of active gelatinases in synovial fluid 
of a rheumatoid arthritis patient 29 and the finding that membrane-type 1 MMP (or MMP-
14) was present in its active form only in breast carcinoma tissue but not in tissue from 
benign breast tumours 30. Figure 2 shows a schematic representation of the process of 
activity-dependant enrichment using immobilized reversible inhibitors. 
Since this technique is basically a solid-phase extraction (SPE) method, it is very suitable 
for development of an automated analysis platform. Freije et al. have demonstrated this 
potential by using the commercially available high affinity inhibitor TAPI-2 as an affinity 
ligand for the online analysis of active MMP-12 31. 
By using combinatorial synthesis for introducing variation in the peptide backbone, a wider 
range of reversible inhibitors has become available, which allows optimization of the ligand 
prior to immobilisation. The inhibitors can be screened for their inhibitory potential in a 
standard high-throughput enzyme inhibition assay and promising candidates selected for 
immobilization. Since immobilization may change the affinity of the inhibitor for the 
enzyme, the SPE material should be tested with a standard sample, for instance containing 
one or more recombinant active metalloproteinases prior to application to complex 
biological samples. Using this approach activity based analysis of ADAM-17 in an extract 


















Figure 2: Schematic representation of activity-based solid phase extraction using immobilized 
inhibitors as affinity ligands. A suitable inhibitor is immobilized on a solid support (e.g. Sepharose) 
and packed into a column. Aqueous samples containing active metalloproteinases are pumped over 
the column, where selective interaction between the catalytic site of active metalloproteinases and the 
immobilized inhibitor causes retention. Elution by either a zinc-chelating compound (e.g. EDTA) or a 
competitive inhibitor removes the bound metalloproteinase from the column. The activity-enriched 
fraction can be further analysed by immunological techniques (Western blot; WB), or processed for 




The analytical use of small molecule inhibitors of metalloproteinases has the potential to 
greatly improve our understanding of the roles of these proteinases in health and disease. 
By using these functional proteomics techniques, as described in Figure 3, the analysis may 
move from correlating known and well-described MMPs to disease towards profiling of all 
active metalloproteinases. This may lead to new insights, and potentially to new targets for 
pharmaceutical intervention and the opportunity for a better follow-up of therapy. On the 
other hand, this methodology may also be used to identify unknown protein targets that 
interact with newly developed inhibitors thus allowing better optimization of inhibitors 
prior to entering clinical trials.   
 
Affinity screening using immobilized inhibitors may also be used for determination of 
selectivity profiles of inhibitor libraries towards individual MMPs as recently demonstrated. 
[32] By using chip-based arrays of immobilized inhibitors the binding- or affinity profile of 
fluorescently labeled MMPs was evaluted leading to better optimalisation of inhibitor 
selectivity. By evaluating the binding profiles of catalytically active MMPs and inactivated 
enzymes the specific interaction of the inhibitor to the enzyme can be determined and 















Figure 3 (previous page):  
Schematic protocol for functional proteomics of metalloproteinases using inhibitor probes. 
 
 1: Selection of a suitable available inhibitor, or synthesis of novel inhibitors 
2: Screening of the inhibitory profile using a panel of recombinant metalloproteinases 
3: Selection of best-suited inhibitor (e.g. for profiling or selective tagging / enrichment) 
4: Conversion of inhibitor into suitable structure for activity-based proteomics 
a: Synthesis of activity-based probe based on the selected inhibitor by introducing 
photocrosslinker and a reporter molecule 
b: Immobilisation of the selected inhibitor(s) on a solid support after introducing a primary 
amine and a spacer arm 
5: In-vitro testing of newly synthesized probes for activity-based proteomics with recombinant 
proteases 
a: Labelling of samples of interest with the activity based probe and visualisation of active 
metalloproteinases after gel electrophoresis  
b: Extraction of samples of interest with the immobilized inhibitor and visualisation of 
enriched active metalloproteinases by Western blot 
6: Isolation and enrichment of active proteases from biological samples 
a: Enrichment of photolabelled proteins with immobilized streptavidin 
b: Extraction of active proteases from a biological sample by activity-based solid phase 
extraction 
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Matrix metalloproteases (MMPs) and A Disintegrin And Metalloproteinases (ADAMs) are 
catalytically active Zn2+-dependant proteins that belong to the metallo-endopeptidase 
superfamily.  
MMPs are soluble proteins that have an important physiological function in degradation, 
and turnover of extracellular matrix components, such as collagens and fibronectin. MMPs 
are subdivided according to their substrate preference in gelatinases (MMP-2 and -9), 
collagenases (MMP-1, -8 and -13), stromelysins (MMP-3, -10 and -11) and a number of 
MMPs with other natural substrates such as MMP-12 (macrophage metallo-elastase). 
Besides this substrate proteolysis some MMPs are capable of activation of other 
metalloproteases by proteolytic removal of the activity-inhibiting prodomain, allowing 
substrate access into the catalytic pocket. A well-known example of this is the TIMP-
dependent activation of MMP-2 by membrane-bound MMP-14 1. 
Disregulation of MMPs can lead to a wide range of disease states, mainly correlated to 
proteolytic destruction or aberrant development and repair of tissue. MMPs are implicated 
in cardiovascular disease such as atherosclerosis 2 and aneurism 3, rheumatoid 4  and osteo-
arthritis 5 and cancer progression by promoting metastasis and angiogenesis 6.  
ADAMs are membrane-anchored metalloproteases members of the metzincin superfamily. 
These multidomain proteins display adhesive properties through their integrin-binding 
disintegrin domain and interaction of the cysteine-rich region with glycoproteins 7 and 
extracellular matrix proteins (e.g. fibronectin) 8. Many members of the ADAM family 
contain the consensus zinc-binding catalytic sequence HEXGHXXGXXHD in their 
metalloprotease domain 9. The catalytic activity enables these enzymes to process 
extracellular matrix components and plays an important role in proteolytic activation of 
membrane-anchored precursors of, for instance, growth factors and cytokines. This so-
called ‘ectodomain shedding’ is exemplified by the release of soluble TNFα from the cell 
membrane through proteolysis by ADAM-17 or TACE (TNF-alpha converting enzyme) 10, 
the release of heparin-binding epidermal growth factor by ADAM-9 11 and the α-secretase 
function of ADAM-10 in amyloid precursor protein APP processing 12 as well as the 
convertase activity of the same protein in the Notch/delta signalling pathway 13. 
Disregulation of metalloprotease catalytic activity has been linked to inflammatory 
processes such as arthritis 14 and inflammatory bowel disease 8, Alzheimer’s disease 15, 
cancer 16 and cardiac hypertrophy 17. 
Conventional proteomic and genomic approaches to determine the relation of 
metalloproteases to disease states are limited by the fact that they only take the total amount 
of protein or mRNA into account, while in many cases the functionality, i.e. the catalytic 
activity, is more relevant. Several elegant options to determine proteolytic activity in 
biological samples have been developed, such as zymography and activity-linked ELISA 
techniques 18. Although these techniques are able to visualize and quantify active protein, 
application to a family-wide proteomic approach is difficult since the techniques are 
inherently limited to sub-classes of enzymes due to substrate specificity (e.g. gelatinases in 
gelatine zymography) and antibody specificity in immunoassays. 
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Due to these problems the interest in family-wide, functional proteomic probes has greatly 
increased in recent years. Probes that selectively target active enzymes have been 
developed for a great number of protein classes, such as cysteine proteases 19, serine 
hydrolases 20, proteasome subunits 21, metalloproteases in yeast 22 and matrix 
metalloproteases in human samples 23-25. In this chapter novel, photoactivatable inhibitor 
probes for activity-based MMP and ADAM labelling will be described. 
 
Materials and methods 
 
Recombinant ADAM-8, -9, -10 and -17 (ectodomain) and recombinant human TIMP-3 
(Tissue Inhibitor of Metalloproteases-3) were purchased from R&D Systems (Minneapolis, 
MN, USA). ADAM-8 was autocatalytically activated by incubation at 37°C for 5 days 
according to the manufacturer’s instructions. 
Recombinant catalytic domains (CD) of human MMP-1, MMP-2, MMP-3, MMP-7, MMP-
8, MMP-10, MMP-11, MMP-13 were from Biomol International (Butler Pike, PA, USA). 
Recombinant human MMP-12 CD and recombinant human MMP-9 CD without fibronectin 
type II inserts (expressed in E. Coli as described 26,27 were a kind gift from AstraZeneca 
R&D (Lund & Moelndal, Sweden). TIMP-1 from human neutrophil granulocytes was from 
Calbiochem (La Jolla, CA, USA)   
Alkaline phosphatase conjugated streptavidin was from Sigma-Aldrich (Zwijndrecht, The 
Netherlands). 5-bromo-4-chloro-3-indoyl phosphate (BCIP) and nitro blue tetrazolium 
(NBT) were from Duchefa (Haarlem, The Netherlands). 




The photoactivatable inhibitor-probes ML22 (HAPhe(Tmd)AhxLys(Bio)NH2) and ML28 
(Hydroxamic acid-Phe(Tmd)-Ahx-Lys(Bodipy-Tmr)-peptide) were synthesized as 
described by Leeuwenburgh 28. A non-biotinylated control probe ML29, lacking the biotin 
or fluorescent moiety, was synthesized in the same manner (see Fig. 1).  
Second generation probes PPG1 and PPG3 were synthesized according to the schemes 
depicted in figure 2. In these probes the trifluoroazirine photocrosslinker moiety is 








                                                 
1 Details of the synthesis will be reported in the thesis of Paul Geurink (Leiden University) 





































































































































Figure 1:  
Chemical structures of biotinylated, photoactivatable inhibitors (ML22) and (PPG3), 
BODIPY-TMR conjugated fluorescent, photoactivatable inhibitor (ML28) and the non-
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a Reagents and conditions: a) TEMPO, BAIB, DCM/H2O, 96%; b) i. (ClCO)2, DMF, DCM, 
0oC to RT; ii. Evans template, nBuLi, THF, 0oC, 82%; c) LiHMDS, tBuBrAc, THF, -78oC 
to -10oC; d) AllylOH, nBuLi, THF, 0oC to RT, 65%; e) TFA, DCM, 97%; f) (ClCO)2, 
DMF, DCM; g) TBSO-NHBoc, nBuLi, THF, 0oC, 77%; h) (PPh3)4Pd, N,N’-




a Reagents and conditions: a) TFA, DCM; b) compound 8, DiPEA, DCM; c) TFA:H2O:TIS 


























a Reagents and conditions: a) i. 20% piperidine/DMF, ii. Fmoc-Lys(Mtt)-OH, HCTU, 
DiPEA, NMP; b) i. 1% TFA/DCM, ii. Biotin-OH, HCTU, DiPEA, NMP; c) i. 20% 
piperidine/DMF, ii. Fmoc-Ahx-OH, HCTU, DiPEA, NMP; d) i. 20% piperidine/DMF, ii. 
Fmoc-Phe-OH, HCTU, DiPEA, NMP; e) i. 20% piperidine/DMF, ii. compound 8, DiPEA, 
NMP; f) TFA:H2O:TIS 95:2.5:2.5, HPLC purification, 2.3%. 
 
Figure 2:  
Top panel: synthesis route of the protected, pentafluorophenol-activated intermediate (8)  
Middle panel: conversion to the photoactivatable building block for solid-phase synthesis of the PPG 
series (equivalent to PPG1) (10) 
Lower panel: solid-phase synthesis of biotinylated inhibitor probe PPG3 (16) 
 
Determination of IC50 values 
 
The affinity of the photoactivatable probes for ADAM and MMP proteases was determined 
in a competitive enzyme activity assay monitoring conversion of the fluorogenic substrate 
Mca-PLAQAV-Dpa-RSSSR-NH2 (R&D systems) by recombinant ADAM-9, -10 and -17 
in presence of increasing concentrations photoactivatable probe. For MMP-9 and MMP-12 
inhibition of the conversion of fluorogenic substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-
NH2 (Bachem, Bubendorf, Switzerland) was determined. Measurements were performed in 
Costar White 96-well plates (Corning, Schiphol-Rijk, The Netherlands), where each well 
contained either 10 ng ADAM-17, 100 ng ADAM-10 or 200 ng ADAM-9 and a final 
concentration of 10 μM substrate in a final volume of 100 μL ADAM assay buffer (25 mM 
Tris pH 9.0, 2.5 µM ZnCl2, 0.005% w/v Brij-35). Inhibition of MMP proteolytic activity 
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μM substrate in 100 μL MMP assay buffer (50 mM Tris pH 7.4, 0.2 M NaCl, 10 mM 
CaCl2, 2.5 μM ZnCl2, 0.05 % (v/v) Brij-35). Proteolysis rates were followed by measuring 
fluorescence (λex,em = 320, 440 nm) increase using a Fluostar Optima plate reader (BMG 
Labtech, Offenburg, Germany) at 37°C. Six-point inhibition curves (0-10 μM) were plotted 
in Origin 7.0 (Micronal) and IC50 values were determined by sigmoidal fitting. 
 
Labelling of active recombinant metalloproteases by biotinylated, photoactivatable 
inhibitors ML22 and PPG3  
 
Recombinant MMP catalytic domains and recombinant ADAM ectodomains were 
incubated with photoactivatable biotinylated inhibitor probe ML22 or PPG3 in 96-well 
plates (Costar White). Each well (final volume 30 μL) contained 4 pmol enzyme and a final 
concentration of 250 nM (unless indicated otherwise) inhibitor probe in MMP or ADAM 
assay buffer. The plate was irradiated by UV light under a CAMAG universal UV lamp 
(20W, distance to plate 4 cm) with a 366 nm filter for 30 minutes. The reaction was stopped 




Samples were analyzed by SDS-PAGE on 0.75 mm thick 12.5% polyacrylamide gels. 
Electrophoresis was carried out at 20 mA per gel using a mini-Protean III electrophoresis 
system (Bio-Rad, Veenendal, The Netherlands). The proteins were transferred to an 
Immun-Blot PVDF membrane by wet Western blotting in a mini Trans-blot cell at 350 mA 
for 60 minutes in 25 mM Tris, 190 mM glycine with 20% v/v methanol. Membranes were 
blocked overnight at 4°C in TBST (25 mM Tris buffer pH 7.5 containing 150 mM NaCl, 
0.05% v/v Tween-20) supplemented with 5% w/v non-fat dried milk (Protifar Plus, 
Nutricia, Zoetermeer, The Netherlands) and incubated for 1 hour in a 1:1500 dilution of 
streptavidin-alkaline phosphatase (0.67 μg/ml) in TBST supplemented with 1% non-fat 
dried milk. Biotinylated proteins were visualized by staining with an NBT/BCIP substrate 
solution (0.1 M Tris buffer, pH 9.5 containing 5 mM MgCl2, 0.15 mg/ml BCIP and 0.30 
mg/ml NBT). 
 
Effect of TIMPs on labelling 
 
Aliquots of 4 pmol ADAM-10 and ADAM-17 were incubated overnight at 4°C with 
different molar equivalents of recombinant TIMP-3 in assay buffer, and 4 pmol aliquots of 
MMP-9 and MMP-12 were incubated overnight with an equimolar concentration of 
recombinant TIMP-1. Control aliquots were also kept at 4°C overnight. Photoactivatable 
inhibitor ML22 was added to TIMP-incubated and control ADAM-10 and -17 aliquots to a 
final concentration of 250 nM. Photoactivatable inhibitor PPG3 was added to TIMP-
incubated and control aliquots of MMP-9 and MMP-12 to a final concentration of 200 nM. 





Competition with non-biotinylated photoactivatable inhibitors 
 
The control photoactivatable probes ML29 and PPG1 were structurally similar to inhibitor 
probes ML22 and PPG3, respectively, the main difference being the absence of the biotin 
moiety (see Figure 1). Aliquots of 4 pmol ADAM-9 and -10 in assay buffer were 
preincubated for 15 minutes with 2.5 μM of the control inhibitor under UV irradiation. 
Positive controls were treated the same, but without control inhibitor added to the solution. 
Next, photoactivatable probe ML22 was added to a final concentration of 250 nM. 
Labelling and analysis were performed as above. This procedure was repeated for MMP-9 
and MMP-12, were the enzyme solutions were preincubated with 400 nM control probe 
PPG1 and subsequently labelled with inhibitor probe PPG3 at 200 nM. 
 
Preparation and labelling of lung carcinoma cellular proteomes 
 
Lung carcinoma cell line A549 (ATCC, Manassas, VA, USA) was cultured in 75 cm2 
culture flasks (Corning Costar, Cambridge, MA, USA) in RPMI 1640 culture medium with 
l-glutamine (Cambrex, Vervier, Belgium) with addition of 10% Fetal Calf Serum (FCS; 
Cambrex), penicillin (10,000 U/mL) and streptomycin (10,000 μg/mL). Cells were grown 
(37°C, 5% CO2) to 80-90% confluence (determined by light microscopy) and then split or 
used for analysis.  
Cells were serum starved for 24 hours and subsequently either stimulated with phorbol 12-
myristate 13-acetate (PMA) at 50 ng/mL for 2 hours or left for 2 hours without stimulation.  
Cells were harvested in ice-cold lysis buffer (50 mM Tris pH 7.4, 200 mM NaCl, 10 mM 
CaCl2, 2.5 μM ZnCl2, 2% (w/v) CHAPS) and incubated on ice for 1 hour with regular 
vortex mixing. Insoluble material was removed by centrifugation at 20.000 x g and the 
supernatant was used for the experiments. 
Stimulated cell lysate supernatants were incubated with 1 μM photoactivatable probe 
ML22 and irradiated as described above. A control lysate was treated identically but 
without addition of probe.  Protein labelling was analyzed by Western blotting as described 
above. 
The same lysates were also incubated with BODIPY-TMR conjugated probe ML28.  
Lysates of basal and PMA-stimulated cells were incubated with 1 µM of probe PPG3 and 
analyzed as above. 
 
Labeling of cell lysate samples with ML28 and fluorescence scanning detection 
 
Cell total proteome samples prepared as described above were incubated with 1 µM of 
photoactivatable probe ML28 and labeled by UV irradation at 366 nm for 30 minutes as 
described earlier for labeling with ML22. The reaction was stopped by adding non-reducing 
SDS-PAGE sample buffer and the samples were analyzed by gel electrophoresis as 
described above (10% polyacrylamide gel). The gels were scanned using a Biorad FX pro 
fluorescence imager with λex at 532 nm and λem filtered through a 555 nm long pass filter.  
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Pull-down of labelled, biotinylated proteins 
 
Cell lysate labelled with probe ML22 and control lysate (40 μL each) were incubated with 
20 μL streptavidin-agarose beads (ImmunoPure Immobilized Streptavidin, PIERCE) for 30 
minutes in a cooled shaking incubator (Eppendorf Thermomixer, 4ºC, 1200 rpm). 
Supernatants were collected and beads were washed once with 1 mL lysis buffer, 2-times 1 
mL washing buffer with Tween (50 mM Tris pH 7.4, 200 mM NaCl, 10 mM CaCl2, 2.5 μM 
ZnCl2, 0.05 % v/v Tween-20) and 5-times 1 mL washing buffer without Tween. All 
washing steps were performed in an Eppendorf thermomixer for 10 minutes at 1200 rpm 
and 15ºC. Beads were sedimented by centrifugation (3 minutes at 3000 x g). Wash fractions 
were collected. Beads were boiled for 15 minutes with 30 μL of non-reducing sample 
buffer for SDS-PAGE and sedimented by centrifugation. The supernatants were collected. 
Original samples, supernatants formed after incubation of lysates with beads, second wash 
fractions and the fractions obtained after boiling were analyzed by SDS-PAGE on 10% 
polyacrylamide gels followed by Western blotting as described above. Immunodetection 
was performed by incubation with a monoclonal anti-ADAM 10 antibody (clone 163003, 
R&D systems) at 1 μg/mL in TBST with 1% Protifar for 2 h, and alkaline phosphatase 
conjugated goat-anti-mouse IgG (Sigma-Aldrich) at 0.67 µg/mL in TBST with 1% Protifar. 
ADAM 10 bands were visualized with NBT/BCIP.  
 
 
Labelling of urine from a kidney-graft recipient 
 
An aliquot of fresh urine from a transplant patient that visited the clinic for a check-up was 
obtained with informed consent of the patient, kindly provided by Wynand Meelenhorst, 
Dept. of Pathology, University Medical Center Groningen. 
The urine was centrifuged at 20,000 xg for 5 minutes to remove debris, and subsequently 
labelled with 1 µM probe PPG3. A control aliquot was treated the same with omission of 
PPG3. Both samples were analysed by SDS-PAGE and biotin Western blot as described 
above. 
 
Results and discussion 
 
Characterization of first generation probe ML22 
 
The design of first-generation probe ML22 was a result of earlier successful experiments 
with the novel reversible hydroxamate-based probes, which yielded a highly effective 
broad-spectrum inhibitor with IC50 values comparable to, or even below those of 
commercially available inhibitors like TAPI-228,29. Incorporation of a UV-reactive 
trifluoroazirine moiety on the P’2 position was hypothesized to enable photocrosslinking 
and thus covalent, irreversible labelling of active metalloproteases. 
Both probe and control compound retain their high inhibition efficacy compared to the 




trifluoroazirine group increased IC50 values for all three tested ADAMs. The IC50 values are 




Table 1: IC50 values (nM) of photoactivatable inhibitor probe ML22 and control probe ML29 (see 
figure 1). For comparison the values of the non-functionalized inhibitor ML5 are included. Values 
were determined in a standard enzyme inhibition assays with recombinant enzymes. nd: not 
determined. 
 
 MMP-9 MMP-12 ADAM-9 ADAM-10 ADAM-17 
ML5 nd 5.27 nd nd 10.7 
ML22 25.1 3.60 148 114 20.6 
ML29 nd nd 22.2 48.8 4.32 
 
To test whether photocrosslinking is effective and to determine the conditions necessary for 
optimal covalent tagging some preliminary experiments were carried out. From the first 
tests with recombinant ADAM proteases it was apparent that labelling of ADAM10 was 
most efficient (see figure 3b). Figure 3a shows that the labelling process is dependent on 
UV irradiation, as expected. Figure 3 further shows that labelling was dependent on 
irradiation time, and that maximum crosslinking is reached after 30 minutes. This finding 
was confirmed by mass spectrometric analysis of a solution of ML22 after different 
incubation times, which showed that after 30 minutes only photolyzed probe remained in 
the sample (data not shown). A third observation was that the required concentration of 
probe to achieve maximum labeling is actually much lower than the 2.5 µM that was 
originally used, as a labeling concentration of 0.5 µM already yields the same band 
intensity. Additional experiments show that even lower concentrations are still tolerated, 
with even 100 nM still giving a good signal (data not shown). For further experiments a 
concentration of 250 nM was chosen as a compromise. For later labeling of biological 
samples the concentration of probe was increased to 1 µM since the total concentration of  
protein is expected to be much higher.  
Figure 3a shows the effect of denaturing the enzyme prior to incubation with the 
photocrosslinker probe. In lane 8 (after denaturation) the intensity of the biotinylated, and 
thus labelled ADAM10 was strongly decreased. A more detailed study (figure 3b) 
cvonfirmed that all three tested ADAM proteases showed clearly decreased labelling after 
the enzymes had lost their tertiary structure due to denaturation. This is an indication that 
the labelling is indeed dependant on strong interaction with the catalytic pocket of the 
enzyme, since the crosslinking process itself is non-selective, and could also occur by 
nucleophilic attack of the carbene moiety to amino acids in the denatured enzyme. 
 
 




Figure 3:  
a) Biotin blot of recombinant ADAM-10 ectodomain labelled with 2.5 µM photoactivatable inhibitor 
probe ML22. The effect of UV irradiation time at 366 nm is shown (lanes 1-5 resp. 0; 5; 15; 30; 60 
minutes) as well as the effect of competition with 100 µM reversible MMP inhibitor TAPI-2 (lane 6). 
Lane 7 shows labelling at 0.5 µM ML22 for 30 minutes. Lane 8 shows decreased labelling of ADAM-
10 after denaturing by preboiling the sample in a 2% SDS solution. 
b) Effect of denaturation on labelling of ADAM proteases with inhibitor probe ML22. Aliquots of 4 
pmol ADAM-9, -10 and 17 were labelled with 0.25 µM ML22 in either native form, or after 
denaturation by boiling in 2% SDS for 5 minutes (D). 
 
Competition with a known reversible inhibitor with high affinity towards metalloproteases 
did however not yield the anticipated result (Fig. 3A, lane 6). Since one of the competing 
inhibitors in this experiment is actually covalent while the other is reversible, this may 
indicate favourable kinetics (Kon/Koff) for ML22 (no off rate once it is covalently bound) 




















A) Biotin blot of recombinant ADAM-17 and -10 incubated with increasing molar equivalents of 
TIMP-3 overnight prior to photoaffinity labelling with probe ML22.  
B) Biotin blot of recombinant ADAM-9 and -10 labelled with 250 nM photoactivatable probe ML22, 
with (+) and without (-) preincubation with 2.5 µM non-biotinylated, photoactivatable control probe 
ML29. 
 
To further substantiate that labelling is not only dependant on an intact three-dimensional 
protein structure but in particular on a functional active site, aliquots of ADAM-10 and 
ADAM-17 were incubated with their endogenous inhibitor TIMP-3 prior to photoaffinity 
labeling. Figure 4a shows a concentration-dependant decrease of labelling in the presence 
of TIMP-3, which is indicative of competition between TIMP-3 and the photoactivatable 
probe. At a two-fold molar excess neither ADAM-10 nor ADAM-17 are detectably 
labelled. The ability of the endogenous inhibitor to decrease the labelling of ADAMs 
demonstrates the specificity of the probe for the active enzyme.  
TIMP-3 is a rather bulky protein compared to the small size of the inhibitor probe, which 
could imply that most binding sites for the probe are simply shielded off and the probe 
cannot access these sites. To prove that labelling is indeed active site-specific, a non-
biotinylated control of the photoactivatable probe was synthesized (see figure 1). Pre-
incubation with an excess of this inhibitor should occupy the available binding sites and 
thus preclude labelling with the biotinylated probe. Since detection by Western blotting is 
based on the biotin-streptavidin interaction, enzyme labelled with only control inhibitor will 
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not be visible. Figure 4b shows a clear decrease of labelling of both ADAM-9 and ADAM-
10 after preincubation with a 10-fold molar excess of control probe, further indicating that 
labelling of these ADAMs with the biotinylated probe is indeed active site-specific. These 
results show also that the lack of competition with a high-affinity, reversible inhibitor were 
most likely due to the fact that the photoactivatable probe binds irreversibly to the active 
site. Taken together, these experimental results demonstrate that the photoactivatable probe 




Figure 5:  
Biotin blot of 10 recombinant MMP proteases (4 pmol each; numbers above the lanes correspond to 
the respective MMP), and 4 recombinant ADAM proteases (ditto) labelled with 250 nM of 
biotinylated, photoactivatable inhibitor ML22.  
 
By testing a wider range of metalloproteases, we subsequently wanted to investigate 
whether ML22 is a truly family-wide, activity-dependent photoaffinity label. Activity-
dependent photoaffinity labelling of metalloproteases on a family-wide scale requires a 
probe that interacts with the active site of any MMP or ADAM. So far such a probe has not 
been described in the literature. The results shown in figure 5 demonstrate that ML22 labels 
several active ADAM proteases resulting in the covalent incorporation of biotin, but as 
shown in figure 5, this does not hold true for all MMPs nor for ADAM-8. Interestingly, 
efficiency of photolabelling does not correlate with the measured IC50 values (see Table 1) 
indicating that there are additional structural factors involved in arriving at an efficient 




proteases. To investigate this further, a new synthetic approach was developed to produce 
the PPG series of inhibitors.  
 
Characterization of second generation probe PPG3 
 
To facilitate family-wide labelling a new probe (PPG3; see Figures 1 and 2 for details) was 
designed by placing the photoactivatable trifluoroazirine group in the P’1 rather than in the 
P’2 position. Based on the 3-dimensional structures of metalloprotease inhibitor complexes, 
it is hypothesized that the photocrosslinker on this position enters the hydrophobic S’1 
pocket in the catalytic site of MMPs 30. This should bring the photoactivatable group into 
more intimate contact with the enzymes. Since the labelling mechanism, a nucleophilic 
attack after activation of the photolabile group by UV irradiation to generate a carbine, is 
by nature not selective, close proximity to amino acids in the active site is critical for 
efficient labelling to avoid inactivation of the reactive carbene through reaction with water. 
Transfer of the photocrosslinker moiety to the P’1 position resulted indeed in improved 
labelling efficiency for most MMPs although there were still gradual differences (Figure 6). 
The labelling of ADAM-10 increased further, while labelling of ADAM-9 and -17 was 
comparable. ADAM-8 was also labelled, albeit at a lower yield. The efficient labelling of 
all tested MMPs (10 types) and ADAMs (4 types) makes PPG3 an excellent candidate for 
family-wide labelling of these classes of enzymes. It is noteworthy that most labelled 
MMPs resulted in multiple bands upon SDS-PAGE analysis. This is likely due to 
degradation (auto-proteolysis) prior to or during photoaffinity labelling. Further 
experiments are planned to investigate this. 
 
 
Table 2: IC50 values (nM) of photoactivatable inhibitor probe PPG3 and control probe PPG1. 
Values were determined in a standard enzyme inhibition assays with recombinant enzyme ND: not 
determined. 
 
 MMP-9 MMP-12 ADAM-10 ADAM-17 
PPG3 24.2 12.5 54.1 490 















Biotin blot of 10 recombinant MMP proteases (4 pmol each; numbers above the lanes correspond to 
the respective MMP), and 4 recombinant ADAM proteases (pmol each; numbers above the lanes 
correspond to the respective MMP) labelled with biotinylated, photoactivatable inhibitor PPG3.  
 
Inhibition data show again a rather poor correlation between inhibitor affinity as expressed 
in IC50 values (Table 2) and photolabelling efficacy. IC50 values determined for MMP-9 
and -12 and for ADAM-10 and -17 show that PPG3 is more potent against MMP-12 than 
against ADAM-10 while ADAM-10 is more strongly labelled. Comparison of the IC50 
values between ML22 (Table 1) and PPG3 shows furthermore that the lower IC50 value for 
ML22 does not translate into more efficient photolabelling rather the contrary. While 
ML22 is a better inhibitor of MMP-12 and ADAM-17 activity than PPG3, labelling of 
MMP-12 with PPG3 is stronger and labelling of ADAM-17 is not decreased. The inhibition 
constant of PPG3 for MMP-9 is similar to that of ML22 but labelling is more efficient with 
PPG3. Another interesting observation when comparing labelling of MMP-9 in figures 5 
and 6 is the decreased autocatalytic degradation of MMP-9, indicating that PPG3 is in fact 
an inhibitor with strong binding properties., or that one of the autolytic fragments is 
preferentially labeled by PPG-3. 
This lack of a clear correlation of IC50 values and labelling yield confirms the greater 
importance of placing the photoactivatable trifluoroazirine in close proximity to amino 
acids in the enzymes’ active sites rather than trying to increasing inhibitor affinity. More 
work is ongoing to probe this structure-labelling efficiency relationship further to arrive of 








Activity-dependence of photoaffinity labelling with PPG3 
 
To prove that labelling with of MMPs with PPG3 is activity-dependent, we followed a 
similar strategy as for ML22. MMP-9 and -12 were incubated with a twofold molar excess 
of TIMP-1 prior to labelling with the probe. Figure 7a  shows that pre-incubation with 
TIMP-1 completely inhibited the labelling of both MMP-9 and MMP-12, indicating that 
labelling by PPG3 was selective for the catalytically active isoform of the enzyme and that 
it is possible to distinguish free active enzyme from TIMP-complexed, inactive MMP. 
The effect of competition with a non-biotinylated control probe (PPG1) was also 
investigated. As shown in figure 7b, preincubation with a 2-fold molar excess of competing 
probe is capable of preventing labelling with PPG3 almost completely, as compared to the 
10-fold excess that was necessary in the case of ML22 and its control ML29. This is a 
further indication that the PPG probes have higher crosslinking efficiency and that less of 
the probe is lost due to non-productive photolysis of the inhibitor. The fact that a 2-fold 
excess completely inhibits binding of PPG3 to the recombinant enzymes makes also a 
strong point for the site-specificity of the probes, since many places for non-selective 




A) Biotin blot of recombinant MMP-9 and -12 incubated with a two-fold molar excess of TIMP-1 
overnight prior to photoaffinity labelling with 200 nM probe PPG3.  
B) Biotin blot of recombinant MMP-9 and -12 labelled with 200 nM photoactivatable probe PPG3, 
with (+) and without (-) preincubation with 400 nM non-biotinylated, photoactivatable control probe 
PPG1. 
 




Labelling of proteins in complex proteomes with probe ML22 
 
To test the applicability of the probes, functional proteomics labelling experiments were 
performed in detergent-based total cell lysates of a human lung carcinoma cell line (A549 
cells) stimulated with phorbol 12-myristate 13-acetate (PMA). This matrix was chosen as a 
“model sample” since previous experiment had already demonstrated the presence of 
several (catalytically active) metzincins, such as ADAM-10 and ADAM-17. 
Early experiments using the non-denaturing surfactant Triton X-100 for solubilisation of 
membrane-anchored proteins (such as ADAMs) yielded disappointing results, which was 
explained by an unknown interference of Triton with the photocrosslinking process (as 
demonstrated by labelling of recombinant ADAM-10 in increasing concentrations of Triton 
X-100, data not shown). After switiching to CHAPS for solubilisation of membrane 
proteins several bands were visualized on a biotin blot as shown in figure 8a. One 
interesting observation is the presence of three intense bands in both the labelled and the 
unlabeled sample, which correspond to endogenously biotinylated proteins. Since the 
staining method is based on streptavidin-biotin binding it is unable to discriminate between 
naturally biotinylated proteins and proteins that are biotin conjugated due to the inhibitor 
probe. 
Mass spectrometric analysis of a pull-down experiment with immobilized streptavidin 
revealed that the endogenously biotinylated proteins were mainly CoA carboxylases 
involved in the cellular energy metabolism. The presence of these highly abundant 
biotinylated proteins interfered with the mass spectrometric identification of photolabelled 
proteins, since the chromatograms were ‘flooded’ with tryptic peptides resulting from the 
naturally biotinylated proteins. 
To demonstrate that labelling of endogenous ADAM proteases is in fact possible in a 
complex proteome with these probes (as was already shown by the group of Cravatt using 
different probes 24), a similar pull-down experiment was performed on labelled and 
unlabeled A549 lysate. The bound and unbound fractions were subsequently analysed by 
ADAM-10 Western blot as shown in figure 8b. ADAM-10 is only recovered in the bead 
fraction after labelling with ML22 and no unlabeled ADAM-10 binds to the streptavidin 
beads. The amount of recovered ADAM-10 was very low, when compared to alternative 
analysis methods where more than half the ADAM-10 is actually in the catalytically active 
isoform (As determined by activity-based enrichment, see chapter 4). This may be an 
indication that the crosslinking yield is relatively low, leaving most active ADAM-10 













Figure 8:  
A) A lysate of A549 cells stimulated with phorbol 12-myristate 13-acetate (PMA) was labelled with 
(+) and without (-) the photoactivatable probe ML22. Biotinylated bands were visualized by Western 
blotting with alkaline phosphatase conjugated streptavidin staining. Labelled bands are marked with 
an asterisk. 
B) Lysates of PMA stimulated A549 cells were labelled with (left lanes) and without (right lanes) the 
photoactivatable probe ML22 and a pull-down was performed with streptavidin-conjugated 
Sepharose beads. Proteins were eluted from the beads by boiling in non-reducing SDS sample buffer. 
1: original lysate; 2: supernatant after incubation with streptavidin beads; 3: final wash fraction; 4: 
supernatant obtained after boiling of the beads. ADAM-10 was visualized by immunoblotting with a 
monoclonal anti-ADAM10 antibody and alkaline phosphatase staining only after labelling with 
ML22 (see arrow). 
C) Fluorescence scan of an SDS-PAGE gel of a lysate of PMA stimulated A549 cells after 
photolabelling with and without 1 µM of the BODIPY-TMR conjugated inhibitor probe ML28. The 
gel was scanned using a fluorescence imager (λex 532, λem 555 nm long pass). 




The labelling of several proteins by ML22 was confirmed by the results from an 
experiment where an A549 lysate was labelled with 1 µM ML28, a structurally identical 
counterpart of ML22, except for the conjugated fluorescent dye BODIPY-TMR as reporter 
molecule instead of biotin (see figure 1 for structure). Figure 8c shows four distinct 
fluorescent bands in the sample incubated with ML28. The very prominent band around 70 
kDa was not visible in the anti-Biotin Western blot (figure 8a) most likely since it was 
shielded by the presence of intense bands from endogenously biotinylated proteins. This 70 
kDa band is selectively labelled since the binding can be outcompeted with both EDTA 
(indicating the process is metal-dependent) as well as by an excess of control probe ML29 
(data not shown).  
The labelling pattern obtained with ML28 is somewhat different than with ML22. two 
higher molecular weight bands are visible, one of which may correspond to the upper band 
in Fig. 8A at about 125 kDa, while the lower band at 50-60 kDa seems to have disappeared. 
This effect may be due to a subtle difference in selectivity due to the presence of the rather 
bulky fluorophore in the molecule, although it is not possible to compare the two results 
exactly due to the use of different molecular weight markers. 
 
Labelling of proteins in complex proteomes with probe PPG3. 
 
To investigate if the improved labelling yield of the PPG series of probes towards MMPs 
could also be demonstrated in a complex biological sample, CHAPS-based lysates of basal 
and PMA stimulated A549 cells were incubated with 1 µM of PPG3 and subsequently 
analysed by SDS-PAGE and biotin Western blot. 
 
One interesting observation from figure 9 is the presence of many more naturally 
biotinylated proteins, but absence of the differentially detected, labelled bands in the higher 
MW region that were labelled with ML22. The band around 37 kDa that was also observed 
in the ML22 labelled lysate was most prominent in this case. When increasing the contrast 
of the lower molecular weight region several less intense bands became visible in the 
sample treated with PPG3. An interesting fact about this experiment is the stronger 
labelling of the 37 kDa protein by treatment of the cells with PMA indicating upregulation 
or activation. Phorbol esters are known to activate PKCδ, and experiments in another type 
of epithelial cells (16HBE) have shown that this activation leads to an increased release of 
TNF-α from the cell membrane (a process that was not observed in A549 cells under 
identical conditions). Since this process is strongly dependent on ADAM-17 (and to a lesser 
extent ADAM-10) it was hypothesized that PMA treatment could lead to an activation of 
metalloproteases in the cell, but this was not observed on the protein level in either cell line. 
Our result based on activity-dependent photoaffinity labelling may shed more light on the 










Biotin blot of total cell lysates of basal (BAS) and PMA stimulated A549 cells after incubation with 
(+) and without (-) 1 µM photoactivatable inhibitor probe PPG3. The higher contrast zoom of the 
lower molecular weight region shows several bands visible in the labelled lysate. 
 
The task of identifying the 37 kDa protein has so far not been completed and is again 
complicated by the presence of large amounts of naturally biotinylated proteins. Several 
experiments were carried out to remove naturally biotinylated proteins from the cell lysates 
prior to analysis, but for unknown reasons complete depletion of biotinylated protein using 
immobilized streptavidin was impossible (as judged from anti-biotin staining of Western 
blotted samples prior to and after preclearing). 
 
To investigate if the novel probe PPG3 could be useful in clinical samples, a preliminary 
experiment was carried out using fresh urine of proteinuria patients with various diseases 
where metalloprotease activity could be implicated (with patient consent, kindly provided 
by Wynand Melenhorst, Dept. of Pathology, University Medical Center Groningen). Figure 
10 shows the labelling obtained in the urine of a patient visiting the clinic for a check-up 
after kidney transplantation. The blot shows labelling of 2 distinct bands around 70 kDa, 
the anticipated molecular size of most active full length ADAM proteases. Identification of 
the labelled protein was in this case not complicated by interference of naturally 
biotinylated protein, but the total amount of the protease in the sample was probably too 
low since no  database identification was achieved. This experiment showed, however, that 
labelling of protein in clinical samples is possible, and may be a good starting point for 
further studies. 





Biotin blot showing labelling of proteins in urine of a kidney-transplant patient with 1 μM PPG3. 






Functional proteomic tools can provide valuable additional information that complements 
results obtained with generic proteomics techniques. In this chapter two novel activity-
based, photoactivatable inhibitor probes that label MMP and ADAM proteases were 
characterised.  
Placing the photoactivatable trifluoroazirine group in the P’1 position of the inhibitor PPG3 
proved to enhance labelling efficiency significantly relative to the first generation inhibitor 
ML22 (trifluoroazirine group in the P’2 position), especially with respect to the labelling of 
MMPs. This second generation probe selectively labels catalytically active members of 
both enzyme families and may therefore provide a valuable tool for development of 
activity-based methods for the analysis of these enzymes in biological samples.  
The results obtained with both probes show that there is little correlation between measured 
IC50 values and the suitability of a given probe to be an effective photoaffinity label. 
Further experiments to study the actual kinetics of enzyme-inhibitor interactions may prove 
useful to optimize probes, since it likely that a slow off-rate is beneficial to efficient 
photoaffinity labelling. This in combination with the developed library synthesis approach 




The biotin moiety incorporated in the probe provides not only the possibility for 
visualization but also for enrichment of labelled ADAMs through pull-down with 
immobilized streptavidin or avidin beads. Although far from trivial, this opens the way to 
the identification of labelled proteins by proteolytic digestion and mass spectrometry. The 
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A compound library of 96 enantiopure N-terminal succinyl hydroxamate functionalized 
peptides was synthesized on solid phase. All compounds were tested for their inhibitory 
potential towards MMP-9, MMP-12 and ADAM-17 which led to the identification of both 
broad spectrum inhibitors and metalloproteinase selective ones. Eight potent and less potent 
inhibitors were immobilized on Sepharose beads and evaluated in solid-phase enrichment 
of active MMP-9, MMP-12 and ADAM-17. In addition, one of these inhibitors was used 
for solid-phase enrichment of endogenous ADAM-17 from a complex proteome (a lysate  






Matrix metalloproteinases (MMPs) are involved in numerous biological processes such as 
cell migration, wound repair and tissue remodeling. MMPs exert their role in these 
processes by the processing of extracellular matrix proteins including gelatin, elastin, and 
collagen and the release of growth factors. ADAMs (a disintegrin and metalloproteinase) 
are metalloproteinases that contain a membrane-spanning and a disintegrin (integrin-
binding) domain. These membrane-bound enzymes are involved in membrane fusion, 
cytokine and growth factor shedding, cell migration, muscle development, fertilization, 
cellular differentiation, cell-cell interactions and cell-matrix interactions.[1-3] The best 
known ADAM is ADAM-17, also known as TACE or tumor necrosis factor α (TNFα) 
converting enzyme, which was discovered based on its sheddase activity with respect to 
membrane-bound TNFα.[4,5] 
The expression of MMPs and ADAMs is regulated by transcription factors and activity is 
controlled by natural inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). 
Disturbances in these regulatory mechanisms are believed to cause, or be involved in, a 
wide range of pathological states. These include cancer metastasis, rheumatoid arthritis and 
autoimmune diseases.[6,7] Deregulation of ADAM expression or activity has also been 
linked to asthma, Alzheimer’s disease, bacterial lung infections and allergies of the 
airways.[1,8] Both academic and industrial research groups are therefore actively involved in 
the study of MMP and ADAM inhibitors to modulate activity in an effort to develop novel 
therapeutic agents based on a better insight into the role of MMPs and ADAMs in disease 
etiology and progression. As a result a large number of MMP and ADAM inhibitors have 
been described in the literature,[7] some of which have been evaluated in clinical trials.[9-11]  
MMPs and ADAMs contain a Zn2+ ion in their active site, which forms a complex with the 
carbonyl group of the scissile amide bond, thereby enhancing its reactivity towards 
nucleophilic attack of the water molecule that is present in the active site.[7,12] As a result, a 
requirement for potent MMP or ADAM inhibitors is that they contain a good zinc binding 
group (ZBG). A large number of MMP and ADAM inhibitors that have appeared in the 
literature consist of an oligopeptide sequence that is equipped with a hydroxamate moiety at 
either the C- or the N-terminus. In these structures the oligopeptide portion ensures 
recognition by the metalloproteases, whereas the hydroxamate acts as zinc chelator. Indeed, 
of the different zinc binding moieties known, hydroxamates have proven to be the most 
versatile. 
C-terminal peptide hydroxamic acids are readily available through modified solid phase 
peptide synthesis (SPPS) protocols.[13-18] In contrast, there are very few synthetic 
procedures towards N-terminal peptide hydroxamates,[19-21] which obviate a non-SPPS step 
during synthesis.[22-26] The preparation of compound libraries containing N-terminal peptide 
hydroxamates would be greatly facilitated by the existence of suitable, complete SPPS 
methods. With this aim in mind, we recently reported[27] the synthesis of an 
enantiomerically pure N,O-diprotected succinyl hydroxamate building block 1 (Figure 1) 
and demonstrated that N-terminal peptide hydroxamates can be prepared by SPPS using 
compound 1 in the penultimate step, prior to acid cleavage and deprotection. Here we 
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report the application of building block 1 in the preparation of a library containing 96 
enantiopure peptide hydroxamates 2 (Figure 1).  
 
The compound library consists of various amino acid residues at positions R1 and R2, and a 
lysine residue at the C-terminus, enabling future modifications with for instance biotin, 
fluorophores or for coupling to a matrix for solid phase extraction (SPE) procedures.[28,29] 
The synthesis and characterization of the compound library as well as the inhibitory 
potential against recombinant MMP-9, MMP-12 and ADAM-17 are reported. A selected 




Figure 1:  Structure of the chiral succinylhydroxamate building block 1 for SPPS of a library of 96 
compounds with the general structure 2. P1’, P2’ and P3’ refer to the binding pockets in the 
metalloproteinase. Boc: tert-butyloxycarbonyl, TBS: tert-butyldimethylsilyl, PFP: pentafluorophenyl. 
R1 and R2 represent amino acid side chains. 
Results and discussion 
 
The preparation of the target compound library (see Scheme 1) commenced with 
α-NHFmoc-, ε-NHBoc-protected lysine on Rink amide resin 3. After removal of the Fmoc 
protecting group the first set of amino acids (Aa1) was coupled in a parallel fashion under 
standard SPPS coupling conditions giving 12 different peptides. These resin bound peptides 
were divided into 8 equal portions. Removal of the Fmoc group and coupling of the second 
amino acid (Aa2) gave 96 immobilized peptides with the general structure 4. Final Fmoc 
deprotection and condensation with building block 1 (see Figure 1) in the presence of 2 
equivalents of DIPEA resulted in the immobilized and fully protected peptide 
hydroxamates 5.[27] Acidic cleavage from the resin and concomitant deprotection of the 
TBS and Boc protecting groups resulted in a 96-membered library of crude compounds 2, 




determined by LC-MS analysis) varied between 3% and 40%. The amount of side products 
formed differed considerably between the compounds. Hydrolysis of the hydroxamic acid 
to the carboxylic acid in the final step appeared in most cases to be the major side reaction. 
The formation of this side product was apparent from the LC-MS analyses of the crude 
mixtures by a 15 Da decrease in molecular weight. In some cases condensation with the 
activated hydroxamate ester was incomplete. In general, the best results in terms of yield 
and side product formation were obtained for compounds containing an amino acid with an 
aliphatic side chain at the Aa2 position. Representative LC-MS analyses of crude peptides 
with and without high levels of side products together with their HPLC-purified 





Scheme 1. Solid phase synthesis of a succinylhydroxamate library containing 96 compounds: a) 
20% piperidine/DMF, 15 min.; b) Fmoc-Aa1-OH (5 equiv.), HCTU (5 equiv.), DIPEA (10 equiv.), 
NMP, 1h; c) 20% piperidine/DMF, 15 min.; d) Fmoc-Aa2-OH (5 equiv.), HCTU (5 equiv.), DIPEA 
(10 equiv.), NMP, 1h; e) 20% piperidine/DMF, 15 min.; f) compound 1 (5 equiv.), DIPEA (2 equiv.), 
NMP, 2h; g) 95% TFA/H2O, 1h (2.5h for Aa1 = Arg(Pmc)). Aa1 = D, E, F, H, L, P, Q, R, S, T, W or 
Y; Aa2 = A, D, F, H, L, V, W or Y. 
 
The results of the inhibitory potential of the 96 compounds against MMP-9, MMP-12 and 
ADAM-17 are depicted in Figure 2 (heat map representation, the compounds were screened 
at 100 nM). We performed this initial screen to obtain qualitative insight in the difference 
in inhibitory potential of the 96 peptide hydroxamates. It is apparent that the efficacy of the 
inhibitors towards MMP-12 is generally higher than for the other two enzymes. 
Introduction of a proline residue at the Aa1-position greatly decreases the activity of the 
inhibitor with respect to both MMPs. This effect appears to be strongest for MMP-12 but 







































































the fact that MMPs contain a straight horizontal cleft and therefore a proline would result in 
a large steric hindrance within the active site. ADAMs, however, do not contain such a 
rigid cleft and the inhibitor activity is thus less affected by proline.30,31 It is also obvious 
that the presence of acidic residues (D and E) in either position greatly reduces the efficacy 
of the inhibitors for MMP-9 and ADAM-17 and to a somewhat lesser extend for MMP-12. 
The inhibitors with the highest efficacy towards MMP-12 are those with the aromatic 
amino acids phenylalanine, tryptophan or tyrosine in either position. These results are in 
line with earlier observations by Lang and co-workers.31 
 
Figure 2  
Remaining enzymatic activity of three recombinant metalloproteinases (5 ng) at 100 nM of inhibitor 
(black: no inhibition; white: complete inhibition). Each value is the average of three individual 
experiments: a) MMP-12 (0.25 pmol); b) MMP-9 (0.25 pmol); c) ADAM-17 (66 fmol). 
 
The beneficial effect of incorporating aromatic moieties also holds true for MMP-9, 
especially if both positions are occupied by phenylalanine, tryptophan or tyrosine. 
Interestingly, a serine residue in the Aa1 position yields very active MMP-9 inhibitors, 
whereas threonine at Aa1 has a much less beneficial effect.  MMP-12 and ADAM-17 show 
a similar, albeit not so strong tendency. The presence of an aliphatic amino acid (A, L or V) 




for the other two enzymes. Netzel-Arnett and co-workers reported an extensive study on the 
substrate preference of MMP-9 towards a set of oligopeptides.[32] Their findings corroborate 
our results with respect to a positive effect of aromatic moieties in both positions (Aa1 and 
Aa2) or a serine residue at Aa1 on inhibitory potential towards MMP-9.  
 
Table 1. IC50 values (nM) of eight selected inhibitors for MMP-9, MMP-12 and ADAM-17. Each 
value represents the mean of three independent inhibition curves (standard deviation in brackets). [a] 
Activity of enzyme greater than 50% at 10 µM inhibitor. 
 
 
 MMP-9 MMP-12 ADAM-17 
DV 905 (221) 10.5 (4.0) 2241 (250) 
FF 23.2 (3.9) 0.92 (0.22) 16.0 (6.4) 
FW 6.69 (0.66) 2.57 (0.80) 29.6 (9.1) 
PD >10,000[a] 2788 (392) 5998 (2555) 
PL 3624 (328) 147 (12) 92.1 (28) 
QY 9.92 (0.79) 0.85 (0.020) 18.9 (2.0) 
SF 9.93 (1.3) 7.70 (1.3) 11.1 (2.3) 
YW 6.71 (0.96) 4.03 (0.95) 36.0 (3.4) 
 
 
Interestingly, our results are in disagreement with their findings that leucine, and to a lesser 
extent alanine, at Aa2 has a beneficial effect on inhibitory potential, since we observe a 
detrimental effect for both residues at this position. Incorporation of arginine in position 
Aa1 improves efficacy towards MMP-12 and ADAM-17 but highly reduces the efficacy 
towards MMP-9, as was also shown by Netzel-Arnett and co-workers.[32] The positive 
effect of aromatic amino acids also holds true for ADAM-17 but to a lesser extent than for 
the tested MMPs. In addition it is found that heteroaryl moieties (His and Trp) or a serine at 
the Aa1 position improves the potency towards ADAM-17. These observations are 
consistent to what is reported in literature.[7, 33] 
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To assess the applicability of the novel inhibitors for activity-based extraction[34] eight 
inhibitors were selected for further experiments. The IC50 values (see Table 1) of these 
inhibitors for the target enzymes span the entire range from sub-nanomolar to over 10 µM 
(see for instance FF with PD) and some of them show considerable selectivity towards one 
or two of the three tested enzymes (for example YW towards both MMPs and PL towards 
ADAM-17). Activity-based extraction of the three metalloproteases was performed at both 
5 and 0.5 nM enzyme concentrations.[39] Especially at lower concentrations of active 
enzyme, highly efficient interaction of the immobilized ligand with metalloproteases in the 
sample is likely critical for efficient extraction. Next to achieving high affinity, it is 
important to minimize non-specific binding to the carrier material, especially at low 
enzyme concentrations. Since finding a carrier material that exhibits no non-specific 
interaction with proteins in the sample is practically impossible, good controls are required. 
For these experiments two control materials were used: a) NHS-Sepharose that was reacted 
with ethanolamine instead of the inhibitors to study non-specific interaction with the 
Sepharose itself, and b) a low-affinity inhibitor (PD) was immobilized to assess the 
importance of a good fit with the enzyme’s active site. 
Table 2 shows the results of extraction studies with the eight selected inhibitors. 
Quantitative extraction of ADAM-17 proves much more challenging than extraction of the 
MMPs. MMP-9 and MMP-12 can be extracted by a number of inhibitors with yields above 
99% at both 5 and 0.5 nM, but only inhibitors QY, SF and FF show enrichment of ADAM-
17 at 5 nM enzyme concentration (extraction yields of 70% or higher). The efficiency drops 
significantly at 0.5 nM for inhibitors QY and SF. The negative control with immobilized 
ethanolamine shows no detectable non-specific binding at both concentrations which is also 
the case for the low-affinity inhibitor PD. 
The results (summarized in Table 2) show that it is difficult to classify immobilized 
inhibitors according to their inhibition efficacy by affinity-SPE and that it may be 
misleading to assess inhibitor selectivity in this manner.[28] One interesting inhibitor in this 
respect is DV, which gives extraction yields of >99% for MMP-12 at both concentrations 
while its IC50 value is 10.5 nM. This is higher than, for example, inhibitor YW, which 
extracts between 96% and 99%. Inhibitor DV also looses its selectivity towards MMP-12 
after immobilization, since both MMP-12 and MMP-9 were almost completely extracted 
even at low concentration. In contrast ADAM-17 is not extracted at all although the IC50 









Table 2. Extraction yield (%) of three recombinant active metalloproteases at two 
concentrations of enzyme by using the immobilized inhibitors as affinity ligand (standard 
deviation in brackets). EA: ethanolamine. 
MMP-9 MMP-12 ADAM-17 
 
5 nM 0,5 nM 5 nM 0,5 nM 5 nM 0,5 nM 
DV 98.7 (1.2) >99 >99 >99 <1 <1 
FF 98.9 (0.85) 98.8 (0.99) 98.9 (0.92) >99 72.9 (1.8) 73.7 (9.8) 
FW 99.0 (0.78) >99 95.1 (0.14) >99 35.7 (24) 43.3 (10) 
PD 7.2 (9.4) 31.7 (24) 96.6 (0.071) 75.7 (11) <1 <1 
PL 98.8 (1.1) 96.9 (0.92) 97.8 (0.49) 80.8 (20) 65.8 (0.85) <1 
QY 98.4 (0.57) 98.6 (1.3) >99 >99 88.2 (12) 4.60 (5.8) 
SF >99 98.5 (0.21) 98.9 (0.92) >99 85.7 (1.3) 49.6 (22) 
YW >99 >99 97.1 (1.3) 96.0 (5.0) 70.0 (6.4) 2.15 (2.3) 
EA <1 <1 <1 <1 <1 <1 
 
Figure 3 shows activity-dependent enrichment of ADAM-17 from a complex proteome (a 
lysate prepared from cultured A549 cells) using immobilized inhibitor FF (see Scheme 1). 
The extraction was almost complete, with no loss of mature 70 kDa ADAM-17 in the flow-
through fraction (FT) and minor loss in the wash fractions. Active ADAM-17 could be 
eluted with a competitive inhibitor (SF; see Scheme 1) further confirming that the 
interaction was inhibitor-mediated. We have shown in previous work that inhibitor-
metalloprotease interactions are strictly dependent on a functional active site and that 
enzyme-inhibitor complexes or pro-enzymes are not bound.[29] The minimal losses in the 
flow-through and washing fractions indicate that there is little inactive ADAM-17 in non-
stimulated A549 cells and that the interaction is relatively tight. We anticipate that 
enrichment of active ADAM-17 from larger sample volumes is possible allowing detection 
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of low levels active ADAM-17. Extraction of the same sample on a control material that 
was derivatized with ethanolamine (EA cartridge) did not result in any enriched ADAM-17. 
 
Figure 3. Activity-dependent enrichment of ADAM-17 from a cell lysate of non-stimulated cultured 
A549 cells using immobilized inhibitor (FF) and control ethanolamine-Sepharose (EA) cartridges. S: 
original lysate, FT: flow-through, W: wash fractions, E: elution with 100 µM competitive inhibitor 
SF, SDS: final elution with 1% sodium dodecyl sulfate. Fractions were analyzed by electrophoresis 
on 8% polyacrylamide gels and transferred to PVDF membranes. ADAM-17 was detected by Western 
blotting. 
Phorbol esters have been described to enhance ADAM-mediated shedding of membrane 
anchored compounds.[37] It is therefore assumed that ADAM-17 becomes activated upon 
PMA (phorbol-12-myristate-13-acetate) stimulation. Figure 4 shows the effect of PMA on 
A549 cells with respect to extraction of active ADAM-17. Interestingly, short-term 
exposure (30min) to PMA results in appearance of a non-active form of ADAM-17 with an 
apparent molecular weight corresponding to the 93 kDa pro-ADAM-17 zymogen (marked 
with *). Extraction efficiency decreases as shown by the recovery of a substantial fraction 
of ADAM-17 in the flow-through and wash fractions, although the major portion still binds 




endogenous inhibitors or by inactivation of ADAM-17 by another, unknown mechanism. 
After two hours of exposure the expression level of ADAM-17 has decreased significantly 
(Figure 4, lower panel). Down-regulation of ADAM-17 after cell stimulation has been 
described.[38] Our results show that this down-regulation does not cause complete 
disappearance of active ADAM-17 from the proteome.  
 
Figure 4. Western blots of extracted cell lysate of PMA-stimulated cultured A549 lung carcinoma 
cell line on immobilized inhibitor FF beads. S: original lysate, FT: cartridge flowthrough, W: wash 
fraction, E: elution with 100 µM competative inhibitor SF, SDS: final elution step with 1% sodium 
dodecyl sulfate. Fractions were analyzed by electrophoresis on 8% polyacrylamide gels and 
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In summary we prepared a library of 96 enantiopure peptide hydroxamates which were 
tested on their inhibitory efficacy towards three metalloproteases.[40] Our results show that 
different amino acids at both positions (Aa1 and Aa2) have a great influence on the 
inhibitory capacity towards MMPs. This is in contrast to what Whittaker et al. report by 
stating that an amino acid at the Aa2 position sticks out of the enzyme and therefore has ‘a 
modest effect’ on the potency.[7]  
Several potent inhibitors were immobilized on Sepharose beads and evaluated for use in 
solid phase enrichment of active metalloproteases. Experiments showed complete 
enrichment of recombinant MMP-9 and MMP-12 even with lower-affinity inhibitors. 
Enrichment of active ADAM-17 proved more challenging, but two of the tested inhibitors 
were successful. Our results may be the first step towards an MMP-selective enrichment 
material, and furthermore shows that the correlation between affinity (i.e. IC50 value or Ki) 
of free inhibitor and suitability for activity-based enrichment may be less clear than could 
be expected. One of the inhibitors was used for enrichment from a complex biological 


































1. D. F. Seals, S. A. Courtneidge, Genes Dev. 2003, 17, 7-30. 
2. R. A. Black, J. White, Curr. Opin. Cell Biol. 1998, 10, 654-659. 
3. M.L. Marcia, J. W. Bartsch Biochem. 2004, 43, 7227-7235. 
4. P. J. Huovila, A. J. Turner, M. Pelto-Huikko, I. Kärkkäinen, R. M. Ortiz, Trends Biochem. Sci. 2005, 30, 
413-422. 
5. R. A. Black et al., Nature 1997, 385, 729. 
6. L. L. Johnson, R. Dyer, D. J. Hupe, Curr. Opin. Chem. Biol. 1998, 2; 466-471. 
7. M. Whittaker, C. D. Floyd, P. Brown, J. H. Gearing, Chem. Rev. 1999, 99, 2735-2776. 
8. H. F. Kauffman, J. F. Tomee, M. A. van de Riet, A. J. Timmerman, P. Borger, J. All. Clin. Imm. 2000, 105, 
1185-1193. 
9. E. Breuer, J. Frant, R. Reich, Expert Opin. Ther. Pat. 2005, 15, 253-269. 
10. M. Hidalgo, S. G. Eckhardt, J. Natl. Cancer Inst. 2001, 93, 178-193. 
11. W. P. Steward, A. L. Thomas, Expert Opin. Invest. Drugs 2000, 9, 2913-2922. 
12. F. Grams, P. Reinemer, J. C. Powers, T. Kleine, M. Pieper, H. Tschesche, R. Huber, W. Bode, Eur. J. 
Biochem. 1995, 228; 830-841. 
13. E. W. S. Chan, S. Chattopadhaya, R. C. Panicker, X. Huang, S. Q. Yao, J. Am. Chem. Soc. 2004, 126, 
14435-14446. 
14. K. Ngu, D. V. Patel, J. Org. Chem. 1997, 62, 7088-7089. 
15. S. L. Mellor, C. McGuire, W. C. Chan, Tetrahedron Lett. 1997, 38, 3311-3314. 
16. R. Sasubilli, W. G. Gutheil, J. Comb. Chem. 2004, 6, 911-915. 
17. S. Gazal, L. R. Masterson, G. Barany, J. Pept. Res. 2005, 66, 324-332. 
18. Z. Yin, K. S. Low, P. L. Lye, Synth. Commun. 2005, 35, 2945-2950. 
19. B. BarlAam, P. Koza, J. Berriot, Tetrahedron 1999, 55, 7221-7232. 
20. K. Jenssen, K. Sewald, N. Sewald, Bioconjugate Chem. 2004, 15, 594-600. 
21. J. Wang, M. Uttamchandani, L. Ping Sun, S. Q. Yao, Chem. Comm. 2006, 717-719. 
22. S. Reddy, M. S. Kumar, G. R. Reddy, Tetrahedron Lett. 2000, 41, 6285-6288. 
23. G. Giacomelli, A. Porcheddu, M. Salaris, Org. Lett. 2003, 5, 2715-2717.  
24. D. E. Levy et al., J. Med. Chem. 1998, 41, 199-223. 
25. C. Y. Ho, E. Strobel, J. Ralbovsky, R. A. Jr. Galemmo, J. Org. Chem. 2005, 70, 4873-4875. 
26. J. Wang, M. Uttamchandani, J. Li, M. Hu, S. Q. Yao, Org. Lett. 2006, 8, 3821-3824. 
27. M. A. Leeuwenburgh, P. P. Geurink, T. Klein, H. F. Kauffman, G. A. van der Marel, R. Bischoff, H. S. 
Overkleeft, Org. Lett. 2006, 8, 1705-1708. 
28. J. R. Freije, T. Klein, J. A. Ooms, J. P. Franke, R. Bischoff, Prot. Res. 2006, 5, 1186-1194. 
29. J. R. Freije, R. Bischoff, J. Chrom. A 2003, 1009, 155-169. 
30. W. Bode, C. Fernandez-Catalan, H. Tschesche, F. Grams, H. Nagase, K. Maskos, K. Cell. Mol. Life Sci. 
1999, 55, 639-652. 
31. R. Lang, A. Kocourek, M. Braun, H. Tschesche, R. Huber, W. Bode, K. Maskos, J. Mol. Biol. 2001, 312, 
731-742. 
32. S. Netzel-Arnett, Q. X. Sang, W. G. I. Moore, M. Navre, H. Birkedal-Hansen, H E. van Wart, Biochem. 
1993, 32, 6427-6432. 
33. K. Maskos et al., Proc. Natl. Ac. Sc. U. S. A. 1998, 95, 3408-3412. 
34. An interesting application of high-affinity reversible metalloprotease inhibitors is their use as immobilized 
ligands for activity-dependent enzyme enrichment. For examples see references [28] and [29] and: D. 
Activity-based enrichment using immobilized inhibitor probes 
 
127 
Hesek, M. Toth, S. E. Meroueh, S. Brown, H. Zhoa, W. Sakr, R. Fridman, S. Mobashery, Chem. Biol. 
2006, 13, 379-386. 
35. J. M. White, Curr. Opin. Cell Biol. 2003, 15, 598-606. 
36. J. Schlödorff, J. D. Becherer, C. P. Blobel, Biochem. J. 2000, 347, 131-138. 
37. N. L. Tsakadze, S. D. Sithu, U. Sen, W. R. English, G. Murphy, S. E. D'Souza, J. Biol. Chem. 2006, 281, 
3157-3164. 
38. J. R. Doedens, R. A. Black, J. Biol. Chem. 2000, 275, 14598-14607. 
39. In order to relate the extraction yields of active metalloproteases to the measured IC50 values, it is important 
to know the ligand densities of the immobilized inhibitors. The determined ligand densities of the eight 
selected inhibitors (see Table 1) are shown in the supporting information. 
40. For the combinatorial synthesis and application of a similar compound library containing enantiomeric 
mixtures see: M. Uttamchandani, J. Wang, J. Li, M. Hu, H. Sun, K. Y. –T. Chen, K. Liu, S. Q. Yao, J. Am. 

























An improved integrated analysis system for online  


















The previous chapter described the use of small synthetic metalloprotease inhibitors as 
affinity ligands for activity-dependent solid phase extraction (SPE). Although the technique 
seems to be robust and applicable to the analysis of both MMPs and ADAMs in biological 
and clinical samples it suffers from being rather labour-intensive, especially when dealing 
with larger numbers of samples. 
To overcome this problem attempts have been made to incorporate this activity-based 
enrichment step into a platform for on-line SPE, which enables automated extraction of 
analytes from aqueous samples and in-line coupling to analysis techniques such as liquid 
chromatography1. 
A prototype of an integrated analysis system (figure 1) was described recently2 and 
consisted of a PROSPEKT-2 automated SPE module fitted with an in-house prepared 
cartridge packed with Sepharose conjugated with the commercially available inhibitor 
TAPI-2 and an in-line trypsin reactor packed with modified immobilized trypsin beads 
(Porozyme)3 coupled to an LC-(nano)ESI platform with an ion trap for mass spectrometric 
detection of the extracted and digested proteases. 
Although this is a working system, it required high femtomol levels of the model enzyme 
MMP-12 and lacked in robustness due to instability of the nano-LC-ESI interface. The 
analytical column was a prototype 50 µm ID capillary filled with a C18 reversed phase 
monolith (Merck), production of which was discontinued, and the ESI interface was 
basically a gold-coated nano-emitter that was sleeve connected to the capillary HPLC 
column and fitted in a casing for electrical contact. Although this setup did work relatively 
well, it was prone to analytical variation due to the limited lifetime of the emitter tips, and 
the fact that the tips have to be cut manually to the correct size, which was a rather difficult 
procedure in itself. Introducing a new tip after a previous one had “run out” led to different 
electrospray conditions, and possibly changes in peak shape due to variation in post-column 
dead volume. 






Schematic representation of the first online platform for activity-dependent analysis of MMPs. The 
system consists of a PROSPEKT-2 module with a Triathlon autosampler for automated introduction 
of sample, a µ-high pressure dispenser, which is capable of delivering four individual solvents (ExB: 
extraction buffer; TEB1-2: trypsin equilibration buffer 1-2; EDB: elution-digestion buffer) at µL/min 
flow rates, and an automated cartridge exchange system (ACE) with three 6-port switching valves. 
The first valve is fitted with a 2 mm ID SPE cartridge filled with TAPI-2 conjugated Sepharose, the 
second valve is fitted with an immobilized trypsin reactor and the third valve is fitted with a collection 
loop for transfer of the digested proteins to the nano-LC system. 
 
 
To improve the robustness of the system, alongside with the ease of use, a new version of 
the analysis platform, where the nano-LC-ESI interface is replaced by a chip-based 












Recombinant human MMP-12 catalytic domain (18.8 kDa 4), stable isotope labelled 15N-
MMP-12 catalytic domain and recombinant human MMP-9 catalytic domain (without 
fibronectin type II inserts, 18.4 kDa 5) were a kind gift from AstraZeneca R&D (Lund & 
Moelndal, Sweden).  
MMP inhibitor ML5 was synthesized as described earlier6. 
N-hydroxy succinimide (NHS)-activated Sepharose was from Amersham Bioscience 
(Uppsala, Sweden), TAPI-2 (N-(R)-(2-(Hydroxyaminocarbonyl)Methyl)-4-
Methylpentanoyl-l-t-Butyl-Glycine-L-Alanine 2-Aminoethyl Amide) was from Calbiochem 
(La Jolla, CA, USA). Calcium chloride (>99% pure), ethanolamine (>98% pure) and 
Tris(hydroxymethyl)aminomethane (Tris, >99.5% pure) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Sodium chloride (>99.5% pure) and EDTA 
(Ethylenediaminetetraacetic acid, >99% pure) were from Fluka (Seelze, Germany). Brij-35 
was from ICN Biomedicals (Zoetermeer, The Netherlands), Polyethyleneglycol-400-
monooctylether (C8-PEG) was from Acros Organics (Geel, Belgium), and dodecyl-β-D-
maltoside was from MP Biomedicals (Solon OH, USA). 
Acetic acid N-hydroxysuccinimide (NHS) ester (AANHS) was from ICN Biomedicals 
(Zoetermeer, The Netherlands); Poroszyme® immobilized-trypsin beads were from Applied 
Biosystems (Foster city CA, USA). 
Acetonitrile (Supragradient grade) was from Biosolve (Valkenswaard, The Netherlands); 
formic acid (Suprapure grade) was obtained from Merck (Darmstadt, Germany). Ultra-pure 
water, produced in-house by an Elga purification system, was used for all buffer and mobile 
phase preparations, which were filtered (0.22 μm pore size) before use.  
The term combi surfactant is used for a mixture of equal concentrations of C8-PEG and 
dodecyl-β-D-maltoside. 
 
Preparation of cartridges 
 
The immobilized inhibitor cartridge was prepared as described before 7 by incubating NHS-
activated Sepharose with an equal volume of 2 mM MMP inhibitor (either TAPI-2 or ML5) 
in phosphate buffer pH 7.5 for 2 hours at room temperature. The remaining activated ester 
groups were reacted by incubation with 0.5 M ethanolamine for 1 hour. Control beads were 
prepared by immediately incubating the NHS-activated Sepharose with ethanolamine. The 
beads were stored in 20% ethanol at 4ºC until use. Before extraction the beads were slurry 
packed in empty 2 mm ID x 10 mm PROSPEKT cartridges fitted with a stainless steel filter 
on one side.  
The immobilized inhibitor cartridges were tested for efficacy in an extraction protocol of 10 
ng MMP-12 catalytic domain with detection of active enzyme in the flowthrough and 
washing fractions using an enzyme assay (as described in chapter 4). 
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The modified trypsin reactor was prepared as described before3 by packing Poroszyme 
immobilized trypsin beads in a clean 2 mm ID x 10 mm PROSPEKT cartridge fitted on one 
side with a stainless steel frit. The cartridge was fitted in a stainless steel clamp (Spark 
Holland, Emmen, the Netherlands) for further use. The trypsin cartridge was acetylated by 
pumping 25 mM AANHS in phosphate buffer pH 8.0 over the cartridge using a syringe 
pump and incubating at stopped flow for 20 minutes. The clamp with the modified trypsin 




Agilent Technologies (Palo Alto, CA, USA) has developed a commercially available 
microfluidics device specifically geared towards peptide analysis in proteomics8. This 
Chipcube (figure 2) combines an analytical C18 microbore column (75 µm ID) with an ESI 
emitter and a 40 nL C18 trapping column in one device, eliminating dead volumes 
introduced by nut-connections and theoretically reducing the analytical variation. The flow 
paths on the chip are regulated by an external six-port rotor and stator that are pressed onto 





Comparison of the Agilent HPLC Chip to conventional nano-LC-ESI components. 
 
Early experiments with this interface showed sub-femtomol sensitivity for a standard 
bovine albumin digest sample, indicating that this system is well suited for the (anticipated) 










One problem that arose during the incorporation of the chip interface into the integrated 
system was the small dimensions of the enrichment column and flow paths on the chip. The 
earlier version described by Freije et al contained an external 400 nL trapping column 
allowing loading of the digested proteins from the trapping loop on the right-most valve on 
the ACE (see figure 1)  at a flow rate of 20 µL/min, while the chip only tolerates a flow rate 
of 2-3 µL/min without exceeding the pressure limits of the (relatively) pressure sensitive 
polyimide chip (maximum pressure 150 bar).  
To overcome this problem a third enrichment column was introduced into the system 
design by replacing the trapping loop on valve 3 of the ACE with a cartridge packed with 
strong anion exchange (SAX) material (trimethylaminopropyl modified HySphere silica, 
40-70 µm particles, Spark Holland) 
 
Instrumental setup with a chipLC-MS interface 
 
Figure 3 shows a schematic representation of the integrated analysis system with the chip 
interface. The system consists of a PROSPEKT II module with a Triathlon autosampler, a 
µHPD pump for delivering solvents and an automated cartridge exchange module with 
three 6-port switching valves (all Spark Holland). The autosampler is fitted with a 1 mL 
syringe to accommodate introduction of larger sample volumes. 
 
The µHPD is connected to four solvents (all prepared with UP water and passed through a 
0.22 µm filter before use): Extraction buffer (ExB: 25 mM Tris pH 7.4, 0.2 M NaCl, 5 mM 
CaCl2 and 0,01% combi surfactant); Trypsin equilibration buffer (TEB: 25 mM Tris pH 
8.5, 1 mM CaCl2, 3% ACN); Elution digestion buffer (EDB: 25 mM Tris pH 8.7, 1 mM 
EDTA, 3% ACN, 0.005% combi surfactant (w/v); Trypsin wash buffer (TWB: 25 mM Tris 
pH 8.2, 1 mM CaCl2, 45 % v/v ACN). 
The PROSPEKT II platform is connected with a 75 µm ID PEEK coated fused silica capillary to an 
Agilent 1100 series HPLC-MS system with a nano HPLC pump, a capillary HPLC pump, a Chipcube 



















Instrumental setup of an integrated system for the activity-based analysis of MMPs. The trapping 
loop on valve 3 of the ACE has been exchanged for a 1 mm ID x 10mm strong anion exchange (SAX) 
cartridge that can be eluted using the capillary LC pump of the LC-Chip-MS system (loading pump). 
After elution to the C18 enrichment column on the chip the peptides can be resolved and identified by 
LC-MS(/MS)  using the separating column. 
 
PROSPEKT II method 
 
Table 1 gives an overview of a programme used in the automated extraction method for an 

































































































































































































































































































































































































   








































































































































































































































































































































































































































































































































































































































































































































































The LC-MS acquisition method is started by an auxiliary signal from the PROSPEKT 
workstation. The mobile phases connected to the HPLC are as follows:  
Nano LC solvent A: water, formic acid 0.1% (v/v); solvent B: acetonitril/water 90/10, 
formic acid 0.1% (v/v). 
Capillary (loading) pump solvent A: water/acetonitril 97/3, formic acid 0.1 % (v/v); solvent 
B: ammonium acetate 200 mM pH 5.0/acetonitrile 97/3. 
 
Table 2: gradient for nano-LC pump (flow rate 300 nL/min) 







Table 3: gradient for capillary LC pump (flow rate 3 µL/min) 











 Tables 2 and 3 show the gradients used during elution of the bound peptides from the SAX 
cartridge on valve 3 of the ACE to the chip, and chromatographic separation of the 
peptides. The method is further explained in the results section. 
The electrospray conditions were as follows: capillary voltage 1800-2000V (adjusted for 
spray stability, the lowest value where a stable spray current of 50-100 nA was obtained at 
97% phase A was used), drying gas (N2) flow 4 L/min, drying gas temperature 300ºC. 
Mass spectrometric data was acquired in profile mode using MS2 with data-dependent 
precursor selection with an absolute minimal threshold for precursor ions of 5000. 
Monoisotopic m/z values for ubiquitous background ions (polysiloxanes) were excluded 
from fragmentation. The scan range was 300-1500 m/z, and ICC target was set to 30,000 
ions. The maximum accumulation time in the trap was set to 15 ms.  
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The first 33 minutes of each run was stored only in centroid mode to save storage space, 
since during this period no analyte is expected to elute from the chip. 
  
Database identification of proteins 
 
The data from each run was extracted using the Bruker Daltonik DataAnalysis software 
(version 3.2 build 121). The intensity threshold for exported fragment m/z values was set to 
5000 counts by using the export AutoMSn function in the software. The peak lists were 
analyzed using the Phenyx (https://phenyxonline.genebio.com) and Mascot 
(http://www.matrixscience.com) software platforms. Database search settings for both 
algorithms were as follows: 
 
Phenyx:  
Database: uniprot_sprot (version 55.3 29-april-2008) 
Taxonomy: mammalian 
Instrument type: ESI-ion trap 
Scoring Model: LCQ 
Default Parent Charge: 1,2,3,4 
Trust Parent Charge: medium 
Modifications: Oxidation_M (+16Da), variable  
Enzyme: Trypsin_KR_noP 
Missed Cleavage: 2 
Cleavage Mode: normal 
Parent Error Tolerance: 1000 ppm 
Turbo scoring (fragment tolerance) 
* tolerance 0.7 Da 
* coverage > 0.1 
* series b ; b++ ; y ; y++ 
Acceptance parameters:  
* peptide length 5 
* score 5.0 
* p-value individual peptides 0.05 
 
Mascot 
Exported spectra in the autoMSn spectra list were limited to 300 due to upload limitations 
on the online version of Mascot (http://www.matrixscience.com). 
 
Database: Swissprot (version 56.0) 
Taxonomy: mammalian 
Enzyme: Trypsin 
Allow up to 2 missed cleavages 
Variable modifications: oxidation (M) 




MS/MS tolerance: 0.7 Da 
Peptide charge 1+, 2+ and 3+ 
Instrument: ESI-TRAP 
 
After database search only peptides with an individual score corresponding to a 
significance level of p < 0.05 or higher are included. Redundant hits were manually 
examined. 
 
Results and discussion 
 
Introduction of strong anion exchange enrichment step 
 
To overcome the large volume difference between the eluate coming from the immobilized 
trypsin cartridge (at least 100  µL) and the dimensions on the HPLC chip (40 nL 
enrichment column), an additional trapping or enrichment step was introduced. The use of 
ion exchange in this case seemed logical, since this technique is orthogonal to the other 
separation methods used in the system (affinity and reversed phase chromatography). 
Traditionally strong cation exchange (SCX) is preferred as a complementary separation 
technique in proteomics, and is well described in literature (for instance the MuDPIT 2D 
LC-MS platform9) but since (most) peptides can only be efficiently trapped on a cation 
exchange column at acidic pH (leading to positively charged peptides) this phase is not be 
ideal, since the eluate coming from the trypsin reactor (the elution digestion buffer) is at pH 
8.7. Since most acidic residues in the peptides will be deprotonated at this pH and the 
primary amines only partially positively charged, the choice for anion exchange was made. 
An additional advantage of using ion exchange material for the trapping step is the fact that 
the non-ionic surfactants used in the extraction, and that are essential in keeping the active 
protease and the larger peptides in solution, will not be retained in this step. This should 
result in a cleaner sample being sent to the mass spectrometric step and reduced risk of ion 
suppression due to the surfactant in the electrospray ionization process. 
Preliminary experiments incorporating a strong anion exchange trapping step between the 
trypsin reactor and the Chipcube interface were carried out by simply incorporating an 8 µL 
polymer-based  monolithic high capacity SAX nano trap column (Styros HQ, Orachrom, 
Woburn, MA, USA). After trapping of the peptides in the flowthrough of the trypsin reactor 
the rightmost valve on the ACE (see figure 1) was switched to elute the trapped peptides 
using the capillary (loading) pump of the 1100 HPLC system. This approach seemed the 
“cleanest” option, since theoretically the pH switch from the elution digestion buffer (pH 
8.7) to the mobile phase of the capillary HPLC (water/acetonitril 97/3 with 0.1 % (v/v) 
formic acid, pH ~2.7) should be sufficient to introduce positive charge on the peptide 
leading to elution from the SAX cartridge. Using this approach the necessity to introduce 
additional solvent flows as make-up solvents could be avoided. Although the use of SAX in 
peptide analysis is rather rare, there are examples of this approach10,11. 
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Experiments using this setup to perform an automated analysis of 5 pmol (injected) of  
MMP-12 catalytic domain yielded somewhat disappointing results as compared to the 
original system setup. Only two peptides ((I55-R63)2+ and (I19-R36)3+ (see figure 4 for protein 
sequence) were detected, but yielded no significant database hits in either Mascot (Mowse 
scores resp. 27 and 23 with 43 corresponding to a significant hit at p=0.05) or Phenyx.  
 
The earlier described total analysis system12, on the contrary, was capable of yielding 70-
80% sequence coverage, although identification of the peptides was done manually by 
creating extracted ion chromatograms from LC-MS data of the peptides observed earlier in 
standard analyses of MMP-12 digests instead of automatically by MS2 with data-dependent 
precursor selection. Manual investigation of the data showed poor signal intensity for the 
two observed MMP-12 tryptic peptides (see figure 5) compared to earlier results with the 
first generation platform. Another problem was the high variability in the obtained results 
(observed peptides and intensity per run) after the introduction of the SAX cartridge into 
the system. 
 
Figure 4:  
Amino acid sequence and theoretical tryptic peptide map of recombinant MMP-12 catalytic domain 








Extracted ion chromatograms of the two detected peptides from MMP-12 in an automated 
PROSPEKT-LC-MS2 analysis of 5 pmol MMP-12 in 100 µL extraction buffer after the incorporation 
of an 8 µL polymer-monolithic SAX trapping column into the system. 
 
 
To evaluate to performance of the SAX column in trapping tryptic peptides, off-line 
extraction experiments were carried out using a tryptic digest of bovine serum albumin in 
elution-digestion buffer as a standard sample. The results of trapping and elution 
experiments revealed that the trapping itself was successful, although one peptide with a 
high pI of 8.75 (K437-S451 in BSA swissprot entry  P02769) did break through during 
washing steps. However, elution using only a pH switch was not very efficient. Using 
formic acid, trifluoroacetic acid or acetic acid at different concentrations (0.1-1% (v/v)) 
elution of the bound peptides from the SAX cartridge was not observed . This strong 
retention was probably based on ionic and not a non-specific hydrophobic interactions, 
since increasing the acetonitrile content of the elution buffer did not improve elution. Only 
when elution was performed using 1 M acetic acid, or when the column was seemingly 
saturated with BSA peptides detection of most BSA peptides was possible. This finding is 
in line with the irreproducible identification of the observed MMP-12 peptides in the first 
experiments using the new setup of the online system. 
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Traditionally ion exchange chromatography uses salt gradients to elute bound analytes, but 
this introduces the risk of precipitation and blockage, especially when analysing the 
samples with techniques that use small dimension capillaries and connections, such as 
nano- or chip-LC. Two volatile salts (ammonium acetate and ammonium formate) were 
tested for their efficacy in eluting bound peptides from a strong ion exchange column. To 
increase system compatibility the Orachrom column was replaced by a 1 mm ID (bed 
volume 8 µL) SAX (quartenairy ammonium, silica based trimethylaminopropyl phase) 
PROSPEKT cartridge by Spark housed in a stainless steel clamp. When using a 0.2 M 
solution of either salt adjusted to pH 5 elution of bound peptides was readily observed, with 
ammonium acetate resulting in a slightly better yield. This phenomenon may be explained 
by the higher ionic strength of acetate as compared to formate counter ions13.  
 
 
Automated analysis method 
 
Table 1 gives a point-by-point overview of the individual steps of the PROSPEKT method 
for the automated extraction-digestion-trapping of MMPs. The Triathlon autosampler is 
programmed separately from the ACE and HPD, and synchronisation is ensured by a series 
of cross-talking auxiliary signals (aux 1 of ACE and aux in autosampler programme). 
In step 1, the system is flushed with extraction buffer (ExB) with all cartridges offline. 
Flushing with the Sepharose-inhibitor cartridge not included in the flowpath enables higher 
flow rates without risk of damaging the pressure sensitive Sepharose material. 
Simultaneously, the autosampler performs a wash cycle to reduce carry-over between runs. 
In the second programme step the inhibitor cartridge is included in the flowpath by 
switching valve 1 into the 6-1 position. The cartridge is equilibrated with ExB and prepared 
for injection of the sample. At the same time, an aliquot of sample is aspirated from the 
sample vial. This volume can be modified depending on the desired injection volume. In 
step 3 the sample is loaded onto the inhibitor cartridge by switching the autosampler valve 
to the inject position while the µHPD delivers a flow of ExB to carry the sample to the 
cartridge. After washing the inhibitor cartridge with ExB (step 4) the system is filled with 
trypsin wash buffer (TWB) with all cartridges off-line in step 5. The next step is the 
washing of the trypsin reactor with TWB to ensure a clean trypsin cartridge before the 
elution step. After the cleaning step the system is filled with Trypsin equilibration buffer 
(TEB) and the trypsin reactor is conditioned with TEB to maximize trypsin activity. In 
steps 8 and 9 the system lines are filled with Elution digestion buffer (EDB), and the SAX 
cartridge on valve 3 of the ACE is equilibrated to pH 8.7 with EDB. This last step was 
included since in all previous steps the SAX column is in contact with the acidic mobile 
phase of the capillary LC pump. In step 10 both the inhibitor cartridge and the trypsin 
reactor are switched in the flowpath and elution of bound proteins is performed with EDB. 
This buffer contains EDTA which is capable of chelating the Zn2+ ions in the catalytic site 
of the MMPs and thereby eluting proteins that are bound via metal-chelation from the 
immobilized inhibitor cartridge. The eluate from the inhibitor cartridge is pumped over the 




(the lowest flow that the µHPD can deliver in this setup) to maximize digestion time to ~ 1 
min. Previously published results have shown that a contact time of 4 seconds is sufficient 
for tryptic digestion of cytochrome C at this pH3. The peptides resulting from the 
proteolytic cleavage in the trypsin reactor are subsequently trapped on the SAX cartridge 
which is situated on valve 3 of the ACE. After elution and digestion are complete, the ACE 
gives separate auxiliary signals to both the HPLC and the mass spectrometer. The signal 
from the ACE starts the HPLC methods described in tables 2-4 and the MS acquisition. The 
capillary loading pump switches from the standard acidic mobile phase to the SAX elution 
solvent B (200 mM ammonium acetate pH 5.0 with 3% acetonitrile). There is a 2 minute 
delay in the ACE method (step 12) to ensure a stable flow of solvent B and to avoid contact 
of the SAX column with the acidic mobile phase that is still present in the tubing 
connecting the pump to valve 3 on the ACE. The next steps comprise several washing steps 
of the injector loop, Sepharose-inhibitor cartridge and trypsin reactor to reduce carry-over 
between runs. Step 14 contains a delay to ensure synchronisation between the PROSPEKT 
method and the LC-MS analysis. By making the PROSPEKT method longer than the LC-
MS method, samples can be analysed in parallel, meaning that while the first sample is 
analyzed the next sample can already be introduced into the PROSPEKT system. The total 
analysis time for this method is 1h:40min per sample meaning that with a continuously 
running system on average 14 samples may be profiled in 24 hours. The overall analysis 
time is, however, dependent on the injection volume. An injection of 500 µL instead of 100 
µL under the same conditions will take 6 minutes longer. 
 
Figure 6 shows a representative chromatogram resulting from analysis of 2.9 pmol MMP-
12 catalytic domain in 100 µL of extraction buffer. Marked by arrows are the five peaks 
that correspond to MMP-12 derived tryptic peptides as identified by database search against 
the exported spectra of this run (Auto-MS2). This result demonstrates that the system is 
capable of performing fully automated activity-based analysis of MMP-12 at the low nM 
concentration level and that the inclusion of the anion exchange trapping step did not affect 
sensitivity and system performance adversely. The chromatogram in Fig. 6 (right panel) 
shows the result of an experiment where the SAX cartridge was taken out of the system, 
and the eluate from the immobilized trypsin reactor was directly loaded onto the chip 
enrichment column. The large peak that appears in the chromatogram is the result of the 
high surfactant load in the extraction and elution digestion buffer on the chip in this 
experiment and shows an additional positive effect of the inclusion of the SAX step. 
Because the surfactants that are present in the extraction and the elution-digestion buffer are 
non-ionic in nature their retention on the anion exchange material will be limited and the 
eluate is cleaned up before sending it to the LC-MS system. Surfactant addition to the 
extraction and elution buffer was found to be necessary at low concentration of target 
protease to avoid non-linear response and poor system sensitivity due to loss caused by 
non-sepcific adsorption of protein and peptide to  system tubing12. 






Left: LC-MS chromatogram obtained with 2.9 pmol MMP-12 catalytic domain in 100 µL ExB on the 
PROSPEKT-LC-MS/MS system with a SAX trapping step. MMP-12 peptides are indicated by arrows. 
Right: LC-MS chromatogram of 5.4 pmol MMP-12 catalytic domain in 100 µL ExB analysed on the 
PROSPEKT-LC-MS/MS system without a SAX trapping step. The eluate of the trypsin reactor was 
directly loaded onto the chip enrichment column.  
 
Figure 7 shows a similar experiment where recombinant MMP-9 was used as standard 
protease, and spiked into extraction buffer. From an injected amount of 5.4 pmol MMP-9 
catalytic domain in 100 µL extraction buffer two peptides were identified as resulting from 
MMP-9 by automatic precursor ion selection MS2. This result shows that the sensitivity of 
the system towards MMP-9 is slightly lower but that especially the F319-R334 peptide still 
gives a signal with good intensity. This is an interesting finding since MMP-9 as a 
gelatinase is a very well studied protease (along with its sister gelatinase MMP-2) and has 
been implicated in various disease states. MMP-9 has been described to be present at 
relatively high concentration in urine of bladder cancer patients and synovial fluid of people 
suffering from rheumatoid arthritis14. 
One interesting observation is that although the SAX step removes the majority of 
surfactant present in the EDB, there is still a significant signal at the end of the 
chromatogram. This may be a cause for concern since this detergent load could lead to 
breakthrough of (more hydrophilic) peptides on the chip enrichment column due to 
saturation, but unfortunately the addition of surfactants is unavoidable when analysing 
proteases at low concentrations due to non-specific adsorption. Contrary to the direct 
loading step, the detergent peak does no longer overlap the peptide elution region, so 






Figure 7:  
LC-MS chromatogram obtained after injection of 5.4 pmol MMP-9 catalytic domain in 100 µL 
extraction buffer on the PROSPEKT-LC-MS/MS system. Marked are two MMP-9-derived tryptic 
peptides that were identified by MS/MS. 
 
Incorporation of stable isotope labelled 15N-MMP-12 catalytic domain as internal 
standard  
 
When using mass spectrometry for quantitative analysis inclusion of an internal standard is 
advisable to correct for analytical variation between different analyses. Especially when 
analysing complex biological samples (prone to ionisation suppression) or when using 
nanoLC hyphenated to mass spectrometry between-run variation can complicate 
interpretation of the results, especially considering the multiple steps in the system 
described here, all contributing to total analytical variation. Stable isotope labelled 
compounds are preferred as internal standards for mass spectrometry, since the 
chromatographic behaviour of the analyte and the deuterated or 13C/15N labelled will be 
very similar or identical, thus correcting for variation in, for instance, ionisation efficiency. 
In the case of the activity-based analysis of proteases such as MMP-12 this is less obvious. 
To act as a good internal standard the target protease (MMP-12 in this case) and the internal 
standard need to be very similar and preferably be included in the original sample to correct 
for losses during the entire analytical process. The stable-isotope-labelled standard 
therefore needs to be the active metalloprotease itself. In the case of MMP-12 catalytic 
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domain the internal standard was created by metabolic stable isotope labelling, where the 
genetically modified organism (E. coli) is cultured in medium with an exclusively 15N-
containing nitrogen source. This process ensures (almost) complete incorporation of 15N 
into all proteins the organism produces yielding a proteolytically active, 15N-labeled version 
of the catalytic domain of MMP-12. The labelled protein is thus co-extracted on the 
inhibitor cartridge and follows the rest of the analytical steps of the automated system. The 
co-eluting peptides can be easily distinguished by mass spectrometry, since the mass 
difference between the natural and the stable isotope labelled peptides will be at least one 
mass unit per amino acid depending on the number of nitrogen atoms. 
 
Table 5:  
Relative standard deviation (in %; n=3) of the peak area of the three MMP-12 peptides with the 
highest intensity with and without inclusion of  15N-MMP-12 as internal standard (injection volume: 
100 µL). 
 
 With IS correction Without IS correction 
MMP12  
(pmol) 514 m/z 734 m/z 760 m/z 514 m/z 734 m/z 760 m/z 
0,15 29,9 22,4 21,5 52,4 57,0 44,4 
0,29 18,7 16,2 31,4 36,2 33,1 64,8 
0,59 15,7 21,1 4,4 59,4 115,3 48,1 
1,47 3,1 7,3 8,0 36,1 79,7 29,4 
2,94 3,1 26,8 7,8 30,0 56,7 34,3 
4,41 4,6 3,4 12,3 17,2 31,1 31,7 
5,88 9,9 12,9 11,8 14,5 24,4 35,0 
average RSD 12,1 15,7 13,9 35,1 56,8 41,1 
 
Table 5 shows the data obtained for calibration curves of MMP-12 catalytic domain in the 
integrated system. The results clearly show the beneficial effect of including the internal 
standard as opposed to “label-free” analysis, where the RSD may be as high as 100%. After 
correction of the peak area for the internal standard, variation is well below an RSD of 
20%, which is acceptable considering the complexity of the entire system. 
One problem that was encountered in the earlier version of the integrated system was the 
non-linear response at lower (sub pmol injected or low- to sub-nanomolar concentration) 
analyte concentrations. This effect was ascribed to losses due to non-specific adsorption to 
system components and could not be completely reversed by addition of the surfactant 
mixture to the extraction and elution-digestion buffer. This greatly limited the sensitivity of 
the system, since analysis of samples having sub-nM concentrations was very difficult. 
The addition of a relatively high amount of internal standard (2.9 pmol injected) probably 
helped to overcome this problem, since the sensitivity of the method improved notably with 




catalytic domain (with internal standard correction) in extraction buffer. The linearity of the 
response ratio is good over the investigated range. The amount of MMP-12 needed to yield  
a positive database hit in Mascot was found to be around 300 fmol injected (3 nM from 100 
µL). A similar curve was obtained when spiking MMP-12 CD in urine from a healthy 
human volunteer. When increasing the injected volume to 500 µL the required amount 
remained the same, indicating that the system is capable of identifying MMP-12 at sub-
nanomolar concentration in aqueous samples (0.8 nM) emphasizing its capability to enrich 




Calibration curve of MMP-12 catalytic domain in extraction buffer ( n=3 for each sample). The ratio 
of the area of the three peptides with the highest intensity of MMP-12 and 15N-MMP-12 is plotted 
against the amount of MMP-12 injected. The amount of 15N-MMP-12 added to each sample was 2.9 
pmol. 
 
Figure 9 shows smoothed EIC traces of the three peptides observed with the highest 
intensity after an injection of 59 fmol MMP-12 catalytic domain in 100 µL ExB on the 
online system. The sample was extracted on an inhibitor cartridge with TAPI-2 as a ligand, 
and although no database hit could be obtained by automatic MS/MS the peaks can still be 
identified and quantified after smoothing of the background. This indicates that this system 
may be used for targeted analysis of MMP-12 at concentrations of 0.6 nM using an ion trap 
mass analyzer in profile mode. It is likely that even lower concentrations can be reached 
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when using triple quadrupole mass analyzers in the SIR (Selective Ion Recording), SRM 




Extracted ion chromatograms (smoothed) of three MMP-12 peptides with the highest intensity 
obtained upon analysis of 59 fmol MMP-12 catalytic domain spiked into in 100 µL human urine with 
2.9 pmol 15N-MMP12 as internal standard. 
 
Analysis of active endogenous metalloproteases 
 
Since spiking experiments metalloproteases in biological matrices such as urine, total cell 
lysates and broncheo-alveolary lavage fluid (BALF) showed the possibility of analyzing 
active proteases in complex biological samples when resorting to Western blotting (see 
chapters 4 and 6), we performed multiple experiments for proving the applicability of the 
integrated analysis system to such complex samples. The main problem that was 
encountered in these experiments was the detection and identification of a large number of 
highly abundant non-metalloenzyme proteins that presumably interacted non-specifically 
with the inhibitor cartridge. When performing offline experiments, as described in the 
previous chapter, this non-specific binding was presumed to be low, since gel 
electrophoresis of the eluting fractions of several extraction experiments of biological 
samples showed almost no detectable protein. The high sensitivity of nanoLC-MS was, 
however, able to pick these proteins up, as shown in tables 6a and b and the chromatograms 
in figure 10. This table shows the identified proteins in a representative run of nephropathic 









Figure 10:  
TIC chromatograms obtained with a total analysis system run of 100 µL rat urine, using ML5 as 
immobilized inhibitor. The top trace shows the single MS signal, while the bottom trace shows the 
fragmentation signal obtained with data-dependent precursor selection. 
 
Table 6a:  
Top 30 proteins identified using the Phenyx algorithm in an extraction performed on 100 µL rat urine 
 
Protein Protein ID score unique 
peptides 
Alpha-1-antiproteinase precursor  A1AT_RAT 43,6 5 
Plasminogen precursor  PLMN_RAT 42,5 5 
Serine protease inhibitor A3N precursor  SPA3N_RAT 36,3 4 
Alpha-1-antitrypsin precursor  A1AT_HUMAN 34,1 4 
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Ceruloplasmin precursor  CERU_RAT 33,3 4 
Serotransferrin precursor  TRFE_RAT 33,1 4 
Ig gamma-1 chain C region. IGHG1_HUMAN 24,5 3 
Complement C3  CO3_RAT 23,5 3 
Serum albumin precursor ALBU_RAT 23,5 3 
Serine protease inhibitor A3L precursor  SPA3L_RAT 20,0 3 
Complement C3 precursor  CO3_HUMAN 19,8 2 
Pigment epithelium-derived factor precursor 
(PEDF)  PEDF_MOUSE 19,4 2 
Ceruloplasmin precursor  CERU_HUMAN 16,8 2 
Ceruloplasmin precursor  CERU_SHEEP 16,4 2 
Serine protease inhibitor A3K precursor  SPA3K_RAT 15,4 2 
Actin, cytoplasmic 1 ACTB_CERPY 15,1 2 
Apolipoprotein A-IV precursor  APOA4_RAT 14,4 2 
Macrophage metalloelastase precursor  MMP12_HUMAN 14,4 2 
Fibrinogen beta chain precursor  FIBB_RAT 14,0 2 
Ig kappa chain C region. KAC_HUMAN 11,4 2 
Complement component C9 precursor.  CO9_RAT 10,1 1 
Ig gamma-2 chain C region. IGHG2_HUMAN 9,3 1 
Liver carboxylesterase 1 precursor  EST2_RAT 9,1 1 
Ig alpha-2 chain C region. IGHA2_HUMAN 9,0 1 
Hibernation-specific plasma protein HP-55 
precursor  HP55_TAMSI 8,8 1 
Fetuin-B precursor FETUB_RAT 8,7 1 
Ig heavy chain V region MOPC 47A. HVM17_MOUSE 7,7 1 
Apolipoprotein A-II precursor  APOA2_RAT 7,5 1 
NMDA receptor-regulated 1-like protein NARGL_HUMAN 7,0 1 





Although the amount of high-confidence hits (when excluding “one-hit wonders” and 
interspecies duplicates) is relatively low, the total intensity on non-specific binding is rather 
high when evaluating the chromatogram in figure 10. One interesting observation is the 
presence of 2 MMP-12 peptides, which is likely the result of carry-over from previous 
experiments. This underlines the importance of system washing between runs, which has to 
be further optimized to avoid making false conclusions about the presence of MMPs in 
biological samples. 
 
Table 6b:  
Proteins identified using the Mascot algorithm in an extraction performed on 100 µL rat urine 
 
Protein Protein ID score unique 
peptides 
Ig gamma-1 chain C region IGHG1_human 144 4 
Alpha-1-antiproteinase A1At_rat 135 4 
Complement C3 CO3_rat 133 4 
Ig gamma-2 chain C region IGHG2_human 109 2 
Plasminogen PLMN_rat 107 4 
Alpha-1-antitrypsin A 1AT_human 103 3 
Serine protease inhibitor SPA3N_rat 90 1 
Apolipoprotein A-IV APOA4_rat 83 3 
Serum albumin ALBU_rat 81 2 
Serotransferrin TRFE_rat 69 2 
Pigment epithelium-derived factor PEDF_human 61 1 
Serine protease inhibitor A3L SPA3L_rat 61 2 
Complement component C9 CO9_rat 61 1 
Ceruloplasmin CERU_human 58 1 
Ig heavy chain V region MOPC 47A HVM17_mouse 56 1 
Ig alpha-1 chain C region IGHA1_human 55 1 
Complement C3 CO3_human 53 1 
Fibrinogen beta chain FIBB_rat 50 1 
Annexin A2 ANXA2_human 50 1 
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Actin, aortic smooth muscle ACTA_rat 49 1 
Glyceraldehyde-3-phosphate dehydrogenase G3P_human 48 1 
Liver carboxylesterase 1 EST2_rat 47 1 
Transthyretin TTHY_rat 47 1 
Macrophage metalloelastase MMP12_human 46 1 
Ig lambda chain C regions LAC_human 45 1 
Ig kappa chain C region IGKC_human 43 1 
Fibrinogen gamma chain FIBG_rat 42 1 
 
There are several options to reduce interference: A) Analyse the same sample on both an 
immobilized inhibitor cartridge as well as an (ethanolamine-inactivated) control cartridge 
and to use statistical classifiers to discriminate between peptides that are exclusively 
present or significantly increased in the inhibitor extracted sample. B) Optimize the loading 
and washing conditions to minimize non-specific binding. Earlier optimizations had the 
goal to maximize the binding of MMPs but this may have also lead to binding of non-
related proteins. The choice for Sepharose as carrier material for the affinity SPE step was 
based on the fact that this material showed the lowest non-specific interaction with 
biomolecules when compared to a range of silica-based or polymeric materials. 
The occurrence of this non-specific binding that is visualized by mass spectrometry and the 
fact that Sepharose as a non-pressure stable material is not ideal for online SPE has been 
the initiator for a search for pressure-stable materials with comparable properties to 
Sepharose with respect to non-specific interactions with proteins. Several supports were 
tested, but all displayed higher non-specific binding than Sepharose. One material, as 
described in offline experiments described in the previous chapter (ResQ aldehyde 
functionalized polymer with a hydrophilic coating from ResQ labs, Nijeveen, The 
Netherlands) seems to have favourable properties and may be a promising candidate for 
further testing.  
 
Another factor in MMP analysis that has surfaced as an important limitation when applying 
functional proteomics to clinical and other biological samples is the importance of proper 
handling and storage15. Since the described method depends on the presence of functional 
active protease, in contrast to earlier activity-based techniques such as zymography that 
also work when no activity is left in the sample because of the renaturation and reactivation 
step in the procedure, it is critical that all steps between the collection of the sample and the 
analysis are optimized with respect to maintaining enzyme activity. Alternatively, it may be 
best to collect a given sample directly on immobilized inhibitor beads to avoid further 









The integrated system for activity-based analysis of MMPs described in this chapter is an 
improved version of the system developed by Freije et al.12. The robustness and ease of use 
of the LC-MS component of the system was improved by replacing the capillary monolithic 
HPLC column and the in-house modified nano-ESI interface by a standardized microfluidic 
HPLC chip. Incorporation of a strong anion exchange column prior to the chip not only 
enabled transfer of a rather large volume of trypsin-digested proteins to the chip enrichment 
column, but also to remove surfactants that are necessary to keep the proteases in solution 
during the initial steps of the analysis. The improved automated analytical system showed a 
concentration sensitivity for MMP-12 catalytic domain that is within the expected 
biological  high picomolar to low nanomolar range.  Sluijter et al have for instance 
demonstrated that the level of MMP-2, -8 and -9 in atherosclerotic plaques lies around 5-10 
ng/mg plaque biopt which would correspond to around 75-150 fmol/mg16 and Demedts et 
al found up to 200 ng/mL (equals 10 nM of the fully processed form) of MMP-12 in 
induced sputum from patients suffering from COPD17. The question that remains to be 
answered is of course which fraction of this total protein amount is in fact the 
proteolytically active form, but the literature on quantitative analysis of active 
metalloproteases is very limited at best. 
The introduction of automated LC-MS2 with data-dependent precursor ion selection opens 
the possibility of profiling unknown active metalloproteases.  
Incorporation of a stable isotope labelled enzyme as internal standard demonstrated that the 
system gives quantitative results with a reproducibility of +/- 20% relative standard 
deviation in peak area. This technique is of course dependent on the availability of a 
suitable stable isotope labelled enzyme, but it remains to be investigated whether using one 
or two internal standards is sufficient to quantify a wide range of metalloproteases, 
provided that the stable isotope labelled peptides correct for variations along the entire 
length of the chromatogram.  
 
A factor that limits the use of this complicated, integrated analytical system on a routine 
basis at this stage of development is its limited robustness and the high level of expertise 
that is needed in its daily operation. While the start-up time is relatively long, the system is 
able to run at least 14 samples per day in an automated fashion, making this a viable 
approach for small clinical studies and target discovery. An advantage is that the method is 
not targeted or biased towards one metalloprotease when using broad-spectrum inhibitors 
such as TAPI-2 or ML5. It may thus lead to new insights into the roles of relatively 
unknown MMPs in a given biological process or pathology. The major challenge that needs 
to be overcome to prove the apllicability of this approach to clinical samples is the selection 
of suitable samples. While many clinical samples are available for analysis, conservation of 
proteolytic activity is often not taken into account in long-term storage of patient samples. 
Collaboration in early phases, and setup of clinical samples seems pivotal for future 
research. The uncertainty whether the concentration sensitivity reached in this study is 
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sufficient to identify active metalloproteases as marker for a given disease can only be 
solved by testing the system on diseases where the concentration of MMP in a certain 
biofluid is known to be rather high, combined with a high likelyhood of involvement of 
MMP activity in the disease pathology. The desired sensitivity may still lie around a factor 
10 lower than at present for widescale application, the suggested cut-off value for MMP-9 
in urine as a marker for bladder cancer for instance is reported to be 0.51 ng/mL, which 
would correspond to 6 pM for the mature form18. By continuing condensation of the 
analysis system on microfluidic devices (for instance inclusion of the trypsin reactor on-
chip) the relative loss of analyte that is inevitable in bioanalysis may be reduced. A further 
step that may be taken is selective mass spectrometric detection of the analyte when the 
MMP of interest is identified. Targetted MS/MS analysis or multi reaction monitoring is 
capable of maximazing the signal for a certain peptide. The application of suitable internal 
standards for profiling of multiple MMPs is a further issue that has to be considered. While 
it is theoretically possible to produce stable isotope labeled versions of any MMP, in 
practise this would amount to a disproportionate amount of work, and severely complicate 
profiling analyses. Approaches generally applied in proteomics like ICAT and iTRAQ 
labeling procedures for semi-quantitative work is likely not suitable for functional 
proteomics since the labeling procedure itself may have a detrimental effect of proteolytic 
activity, making enrichment by inhibitor-affinity difficult. Perhaps taking the middle road is 
advisable, by taking one or two stable isotope labeled active MMPs which are know to 
yield tryptic peptides that span the chromatographic range and use those peptides to correct 
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This thesis describes the development of novel methods for activity-based proteomics on 
zinc-dependent metalloproteases. The functional proteomics field can roughly be divided 
into two fields. The first approach uses labelling of active enzymes with functionalized 
probes (usually based on small synthetic inhibitor of the protease of interest) followed by 
detection or visualization via a fluorescent dye, radioactivity or a biotin moiety on the 
probe. The second approach focuses on selective enrichment of active proteinases by using 
immobilized protease inhibitors which can be used to fish out the protease of interest from 
an aqueous sample followed by detection or identification by Western blot or mass 
spectrometry. Both approaches were explored within this thesis. 
 
The development and testing of two novel photoactivatable probes for activity-dependent 
labelling of metalloproteases is described in chapter 3. The structure of the probes was 
based on optimization of the peptide-like backbone, yielding a novel inhibitor with a high 
inhibition efficacy even at low nanomolar concentrations (the basic structure for the probes 
was reversible inhibitor ML5). Addition of a trifluoroazirine photoreactive group for 
covalent crosslinking of the probe to the active site of the metalloprotease did decrease the 
affinity towards the tested metalloproteases (as tested by IC50 determination) but the 
inhibition constants were still within the nanomolar range. The photocrosslinking approach 
was chosen since, contrary to for instance serine and cysteine proteases the proteolytic 
cleavage is not mediated by an amino acid residue in the active site, but by an activated 
water-zinc (II) complex which is coordinated in the active site by three histidine residues. 
This makes labelling of the metalloproteases more difficult as is the case for the other 
protease classes, which are readily labelled by probes that attack the intramolecular 
nucleophilic group that is part of the active site residue (serine or cysteine). The latter 
approach has yielded several highly successful probes that are now at the point of being 
used in clinical research (see chapter 2 for references). The photocrosslinking approach is 
somewhat controversial since the labelling process is not initiated by actual proteolytic 
activity of the enzyme, but rather by irradiation with UV light. This makes the reaction 
possibly less efficient and less selective, and some investigators consider the technique not 
to be truly activity-based. On the other hand, since the labelling of both MMPs and 
ADAMs using the two novel probes has been demonstrated to be inhibited by TIMPs in a 
concentration dependent manner gives an indication that the interaction is at least 
dependent on the availability or accessibility of the catalytic cleft. This may be considered 
as a measure of activity since the catalytic pocket is not accessible in active metzincins, as 
it is shielded by the prodomain in the inactive zymogen, and by TIMP in the inhibited form. 
Preincubation of the enzymes with non-functionalized versions of the probes revealed that 
even a moderate excess was sufficient to inhibit labelling which is an indication that the 
labelling is site specific. Since the UV-mediated activation of the trifluoroazirine moiety 
and subsequent covalent attachment to the protein is by nature non-selective this efficient 
competition shows that there is at least a structural interaction which positions the probe in 
a certain part of the enzyme prior to UV irradiation, effectively limiting the possible 
binding sites. To assess the actual amino acid residue where the probe binds some 
experiments were performed to determine the labelling site by mass spectrometry. 
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Recombinant enzymes were labelled with the photoactivatable probe ML22, subsequently 
digested with trypsin and the tryptic peptides were analysed with LC-MS/MS. One problem 
that arose during the first attempts was the excess presence of unlabeled peptides, which 
seemed to indicate a low labelling efficiency. Experiments were further complicated by the 
primary structure of the proteases themselves, since the tested MMPs and ADAMs have a 
very low abundance of lysine and argentine residues in the catalytic region the resulting 
tryptic peptides containing the putative binding site are very large. This makes 
identification and sequencing by mass spectrometry challenging. The actual binding site 
has not been identified to date, but experiments are ongoing. 
Some attempts have been made to create an actual mechanism-based probe for the MMPs 
using the structure of the N-terminal generic MMP cleavage sequence Pro-Leu-Gly with a 
crosslinking group that is activated by cleavage and yields a highly reactive quinolimine 
methide group after proteolysis. The first generation inhibitor did unfortunately not show 
any covalent labelling of MMP-12 (data not shown).  
 
Although the first probe ML22 performed well in labelling ADAM proteases, and was 
actually the first ABP described in literature capable of labelling ADAMs, labelling of 
MMPs was considerably less efficient. Since an ideal probe for profiling purposes has a 
broad selectivity attempts were made to improve the labelling of MMPs by transfer of the 
photocrosslinking moiety from the P’2 site to the P’1 site. The resulting inhibitor PPG3 
demonstrated a family-wide selectivity in labelling both MMPs and ADAMs and labelling 
of the latter was even more efficient than for ML22. Attempt to identify the labelling site 
with mass spectrometry using the novel inhibitor probe are ongoing. 
Since in both probes the labelling of ADAM-10 was exceptionally strong and active 
ADAM-10 is known to be present in A549 cellular lysate (see figure 1 where the activity-
based extraction method was used, followed by Western blot detection of ADAM-10) 
labelling of endogenous ADAM-10 followed by pull down of biotinylated (endogenous or 
labelled) proteins with immobilized streptavidin beads was performed. Western blot 
analysis of the resulting extract showed that in the labelled fraction of the lysate a small 
extracted band was visible, corresponding to the molecular size of active ADAM-10, while 
in the non-incubated control lysate no extraction was observed. As observed in the results 
of ADAM-10 extraction by inhibitor ligand pull down the extraction of the mature form of 
ADAM-10 from cellular lysates is never complete (compare figure 1, considering the 
enrichment effect in the elution fractions by a factor of~8). This may imply that a 
considerable amount of ADAM-10 is present in an inactive, presumably TIMP-inactivated 
form. This finding is in line with the anticipated role of ADAM-10 in constitutative 
shedding events leading to a continuous turn-over of the protease. The low labelling 






Figure 1:  
Western blot of cartridge-extraction of an A549 lysate (2.5x106 cells) on an immobilized ML5 
cartridge FT: flowthrough; W: wash fraction; E1-3: 30 µL elution fractions 10 µM ML05; E4-5: 30 
µL elution fractions with 10 mM EDTA; SDS: final wash with SDS-PAGE sample buffer; 8% SDS-
PAGE, immunoblotted with anti-ADAM10 ectodomain antibody (R&D systems). 
 
As demonstrated in chapter 4, the activity-based enrichment technique can be used for 
extraction of active ADAM-17 from a complex proteome (lung carcinoma cell lysate). This 
report was the first example of application of this technique to ADAM proteases, with 
earlier being demonstrated for MMPs (recombinant MMP-12 and endogenous gelatinases 
in synovial fluid). The synthetic work on the first generation reversible inhibitors in Leiden 
resulted in the availability of an enantiomerically pure building block and the possibility to 
generate a large library of reversible hydroxamate-based inhibitors with variable amino acid 
residues in the peptide backbone. The amino acid residue on both the P’2 and P’3 position 
were demonstrated to have a substantial effect on the inhibition potential of the tested 
MMPs (MMP-9 and -12) and ADAM-17, with many inhibitors having a strong inhibitory 
effect on MMP-12, while some inhibitors had a preference for the gelatinase MMP-9 and 
one was found to exhibit the strongest inhibition towards ADAM-17. The introduction of a 
primary amine group attached to a spacer or linker enables the immobilization to a solid 
support by simple chemistry and the use of the novel material for activity-based solid phase 
extraction of metalloproteases from aqueous samples. The sample chosen for proof of 
principle was the lung carcinoma cell line A549, and inhibitor FF was selected since 
optimization experiments demonstrated that the extraction yield of ADAM-17 was still high 
even at lower concentrations of enzyme. By applying this screening technique, suitable 
inhibitors for immobilization may be selected and tested prior to application to biological 
samples, and may improve the extraction results (screening procedure is discussed in 
chapter 2).   
The SPE approach coupled to immunochemical detection by Western blot has proven to be 
applicable to analysis of endogenous metalloproteases, and attempts have been made to 
apply the technique to analysis of clinical samples. Sputum samples from an incidental 
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cigarette smoke exposure study (courtesy of Dr. N. ten Hacken, University Medical Center 
Groningen) were analyzed for the presence of active MMP-12.  Although the sputum of 
some volunteers contained considerable amount of MMP-12, and the putative active 22 
kDa isoform was detected on Western blot, no detectable extracted amount was observed in 
EDTA elution fractions. This may indicate that the majority of the MMP-12 is in fact 
complex with one of the endogenous inhibitors (TIMPs) or that prolonged storage of the 
samples has deteriorated the active protease. Analysis of the samples for MMP-9 revealed a 
strong presence of both the zymogen as the mature isoform of this protease in the original 
sample, but only a very minor extracted amount, which was unexpected since the original 
study 1 revealed an excess of MMP-9 over TIMP-1 in some of the selected samples.  
The issue of sample storage on MMP activity has just begun to be explored. First reports 
indicate that even storage at -80ºC under normal circumstances can have a detrimental 
effect after time2. This implies that for preservation of (dilute) samples containing 
metalloprotease activity care has to be taken. Addition of immobilized inhibitor beads 
immediately after sample acquisition may help to trap and enrich the active proteases for 
further storage. This approach may also overcome the problem of autoproteolytic 
degradation of MMPs as observed for e.g. MMP-9. Experimental work on this procedure is 
underway at present. 
The online analysis system described in chapter 5 is still a work in progress. Although the 
system has performed rather well in term of reproducibility and sensitivity for MMP-12 the 
identification of endogenous active MMPs has proven difficult. Several issues appear to 
have to be dissolved. Firstly the level of non-specific interaction that, although low when 
considering the high protein load on the extraction cartridge, is still at a level that makes 
identification and detection of very diluted active proteases difficult. Secondly sample 
handling has to be strictly regulated to conserve MMP activity prior to analysis. At present 
a study is underway where rat urine samples were incubated with the immobilized inhibitor 
beads immediately after sampling. A further project is planned focusing at use of 
alternative solid supports for the inhibitor. Preliminary results show that non-specific 
binding of proteins (e.g. albumin) in a novel functionalized solid support (ResQ) is 
comparable to Sepharose, but the pressure stability and solvent tolerance may lead to an 
improved washing procedure. 
 
When ADAM activity is to be analyzed some additional problems have to be faced. Since 
the majority of ADAMs is membrane-anchored in their mature, active form they require 
solubilisation prior to analysis by, for instance activity-based SPE. The usual method to 
achieve this is the use of (non-denaturing) surfactants in the lysis buffer, an approach that 
has been used throughout total proteome preparation within this thesis. Although many 
surfactants are reported to be non-denaturing, they may have an effect on protease activity 
as demonstrated by a decreased proteolytic activity of recombinant ADAM-17 in the 
presence of deoxycholate and Brij-35 (data not shown). Negative effects of surfactant in 
analysis are also described in chapter 3, where the photocrosslinking efficiency of probe 




dramatically reduced. Using CHAPS in stead of Triton was demonstrated to be sufficient to 
overcome this problem. 
When preparing total cell lysates, besides the obvious precautions like storing the samples 
on ice, addition of a protease inhibitor cocktail is advisable to avoid proteolytic degradation 
of the proteome by intracellular endopeptidases. Commercially available inhibitor cocktails 
usually contain inhibitors of all major subclasses of mammalian endopeptidases (serine, 
cysteine and aspartic proteases, aminopeptidases and depending on the cocktail a broad-
range metalloprotease inhibitor such as EDTA). The cocktail we used in early development 
of the activity-based extraction method in preparation of A549 lysate was from Merck, and 
when used at the recommended dilution contained the inhibitors in the concentration 
described in table 1. It was observed that addition of this cocktail had a negative effect on 
enrichment of active ADAM-17 from A549 lysate, and some experiments were carried out 
to assess the effect of the individual protease inhibitors on. One observation that is 
immediately clear from table 1 is that the concentration of the individual inhibitors at the 
recommended dilution is far higher than the minimal effective concentration, possibly 
giving rise to non-specific inhibition effects. As shown in an assay evaluating the effect of 
the used concentration of each individual inhibitor on the activity of recombinant ADAM-
17 and the total proTNFα convertase activity in  A549 lysate (measured by conversion of 
the standard  “ADAM-17”-fluorogenic substrate from R&D systems) most protease 
inhibitors have a small effect of proteolytic activity of the recombinant enzyme, but the 
cleavage of the substrate is almost completely abolished in lysate containing the 
recommended concentration of the serine protease inhibitor AEBSF (see figure 2). 
 







Figure 2:  
Residual proteolytic activity of rhADAM17 and endogenous metalloproteinase activity in an A549 
lysate in the presence of individual components of a standard protease inhibitor cocktail for 
mammalian cells (Merck). Concentration protease inhibitors: AEBSF 4 mM; Aprotinin 3.2 μM; E-64 
50 μM; Leupeptin 80 μM; Pepstatin 60 μM; Bestatin 160 μM. *: corrected for inhibition caused by 
solvent methanol. 













































































Table 1:  
Composition of the Merck protease inhibitor cocktail for mammalian cells without EDTA. For 
comparison the effective concentrations described in literature are included. 
 




AEBSF Serine 4 mM < 1 mM 
Aprotinin Serine 3.2 µM 0.09 – 0.3  μM 
Bestatin Metallo-aminopeptidase 160 µM 1 – 10 μM 
E-64 Cysteine  50 µM 1 – 10 μM 
Leupeptin Serine & Cysteine 80 µM 10 – 100 μM 
Pepstatin Aspartic  60 µM 1 μM 
 
The inhibitory effect of AEBSF on total ADAM activity was reduced to around 20% at 0.5 
mM, and to evaluate whether this decreased activity in cell lysate is caused by inhibition of 
post-lysis activation of ADAM zymogens by proprotein convertases like furin two 
proprotein convertase inhibitors were tested. The irreversible proprotein convertase 
inhibitor decanoyl-RVKR-chloromethylketone and the competitive furin inhibitor hexa-D-
arginine were shown to both inhibit the activity of recombinant TACE directly, but had a 
stronger effect on the proteolytic activity in cell lysate. These results illustrate the 
complexity of the biological system regulating ADAMs that has to be considered, and 
effort may be required to further investigate if the contribution of post-lysis zymogen 
conversion is existent and has a significant effect on levels of active metalloproteases. 
 
The experiments described in this thesis have demonstrated that activity-based profiling of 
ADAM proteases is possible, but practical limitations are obvious. Since in-situ ADAM 
activity is likely to have a better correlation with disease development and progression 
several groups have attempted to develop probes for in vivo imaging using near infrared 
fluorescence technology (recently reviewed in3). We evaluated the base inhibitor structure 
of ML5 as a potential probe for in vivo imaging by linking of 99m-technetium as a 
radiolabel, resulting in probe ML23. The freshly prepared 99mTc-inhibitor structure was 
evaluated in a binding assay to the human bronchial epithelial cell line 16HBE 14o- (a kind 
gift from Dr. D.C. Gruenert, University of California, San Francisco) and the effect of a 
competitive inhibitor (ML5) on the binding of the probe. 16HBE cells release TNFα upon 
stimulation which is an indication for ADAM activity on the cell surface, and this release 
can be (partially) blocked by 10 µM inhibitor ML5, indicating this inhibitor is suitable for 
competition regarding ADAM binding on living cells (figure 3). Figure 4 shows that the 
binding of the radioactively labelled ML23 to the cells is reversible by ML5, indicating that 
the interaction is selective. Further work on this probe is of course needed to demonstrate 




preliminary results show this approach may be worthwhile pursuing, as is being planned in 
future work. 
   
Figure 3:  
TNFα production by 16HBE after combined stimulation with PMA and LPS and the inhibitory effect 
















Figure 4:  

























On interesting question that was attempted to be tackled by using activity-based SPE was 
whether ADAM-33, a protein that is likely involved in asthma pathology, is present in its 
active form in lung epithelia cells. Cartridge extraction of A549 total cell lysates on an 
immobilized TAPI-2 cartridge followed by Western blot detection revealed a staining 
pattern similar to that observed by Powell in fibroblasts4, with selective enrichment of some 
of the lower molecular size bands on the TAPI-2 cartridge as opposed to the ethanolamine 
control cartridge. The reproducibility of these results with other columns and immobilized 
inhibitors was poor, leading to an impossibility of drawing distinct conclusion, but these 
findings may be worth further investigation, especially since the biological role of ADAM-
33 involvement in asthma and bronchial hyperresponsiveness may involve disturbed 
cellular adhesion by mutations in the disintegrin- or cysteine-rich domains but also 
dysfunctional activity of the metalloprotease domain. 
In conclusion the work described in this thesis shows that functional proteomics on zinc-
dependent proteases is a challenging field, an observation that is corroborated by the very 
limited amount of literature that has been published on this subject to date. The activity-
based SPE method seems to have crystallized to a point that it may be applied to the first 
clinical studies, but care has to be taken with respect to sample handling and storage. 
Gaining actual functional insight in metalloprotease activity in diseases may be essential in 
evaluating the role of these enzymes in development and progression of disease, and 
profiling results may aid pharmacological intervention by identifying (novel) targets and 
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Metalloproteinases zijn proteolytisch actieve enzymen die voor hun werking afhankelijk 
zijn van een metaalion in de actieve site. Dit proefschrift richt zich op de analyse van een 
subfamilie van zink (II) bevattende proteinases, de metzincins. Deze familie bestaat uit vier 
subgroepen, de matrix metalloproteinases (MMPs), de membraangebonden A Distintegrin 
And Metalloproteinases (ADAMs), de ADAMs met een thrombospodine motief 
(ADAMTSs) en een restgroep die proteinases zoals de meprins en de bacteriële serralysines 
bevat. 
De belangrijkste biologische functie van de metzincins is het reguleren van de cellulaire 
omgeving, de extracellulaire matrix (ECM). Dit gebeurt enerzijds direct door proteolytische 
afbraak van ECM eiwitten zoals collageen, en anderzijds door het vrijmaken van biologisch 
actieve eiwitcomponenten, een proces dat shedding wordt genoemd. Het bekendste 
voorbeeld van dit laatste proces is het vrijmaken van de oplosbare vorm van de cytokine 
TNFα uit de membraangebonden pro-vorm door ADAM-17 of TNF alpha converting 
enzyme (TACE). 
De proteolytische functie van de metzincins wordt sterk gereguleerd in vivo. De eiwitten 
komen tot expressie als inactieve enzymen (zymogenen) en worden pas functioneel na 
activatie door autoproteolytische activatie, of activatie door andere proteinases zoals furine. 
Naast deze transcriptionele regulatie heeft het lichaam de beschikking over een viertal 
endogene remmers, de tissue inhibitors of metalloproteinases (TIMPs) die ongewenste 
actieve MMPs en ADAMs inactiveren. 
Bij verstoring van deze protease-remmer balans kan de excessieve protease activiteit zorgen 
voor pathologische processen zoals destructie van weefsels, ontstekingsprocessen, 
ongewenste remodelling van weefsels en ontstaan en uitzaaiing van tumoren. 
Door de hoge mate van regulatie kan een eenvoudige analyse van de expressie van een 
metalloprotease (bijvoorbeeld met kwantitatieve PCR) of een bepaling van de totale 
hoeveelheid eiwit een vertekend beeld geven. Om dit probleem op te lossen zijn diverse 
analytische methoden ontwikkeld om selectief actieve proteinases te detecteren (zie 
hoofdstuk 2). Veel van deze methoden zijn gebaseerd op het monitoren van de omzetting 
van een endogeen of synthetisch substraat van het proteinase waarnaar onderzoek gedaan 
wordt. Een veelgebruikte variatie op dit thema is de zymografie; een substraat voor de 
proteinase wordt in een SDS-PAGE gel gegoten waardoor na electroforese en renaturatie 
van de eiwitten een proteolytische afbraak optreedt op de plaat waar de protease zich 
bevindt. Ook zijn activiteitsafhankelijke ELISA assays opgezet waar de proteinase uit het 
monster gevist wordt met een antilichaam waarna de activiteit kan worden bepaald door een 
geschikt substraat toe te voegen. 
Alle technieken die gebaseerd zijn op substraatomzetting zijn enerzijds elegant omdat de 
daadwerkelijke activiteit van de proteinases gemeten wordt, maar voor 
profileringsdoeleinden is deze aanpak minder geschikt. Aangezien er aanzienlijke overlap 
in substraatspecificiteit bestaat toont men in deze assays alleen de totale activiteit van een 
subfamilie aan, en is identificatie van de individuele enzymen niet mogelijk. Bij de 
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activiteitsafhankelijke ELISA is weliswaar het doeleiwit bekend, maar wordt ook slechts 
een enkele proteinase gedetecteerd. 
Om een daadwerkelijke profilering van de actieve proteinases in een monster te kunnen 
bereiken is begin deze eeuw begonnen met het ontwikkelen van de activity-based 
proteomics (ABP) waarbij de specifieke interactie van synthetische remmermoleculen met 
de katalytische site van een actief enzym wordt gebruikt om onderscheid te kunnen maken 
tussen actief en niet-actief (zymogeen en geremde actieve vorm). 
Deze aanpak bleek succesvol voor diverse proteasefamilies zoals de cysteine- en 
serineproteases, maar door het afwijkende proteolytische mechanisme (gemedieerd door het 
metaal ion dat een watermolecuul activeert) was voor de metalloproteinases nog geen 
succes behaald. 
Een mogelijke aanpak voor de activiteitsafhankelijke analyse van metalloproteinases wordt 
geschreven in hoofdstuk 3. Een nieuwe synthetische MMP-remmer, gebaseerd op een 
peptidenstructuur gekoppeld aan een zinkbindende hydroxamaat groep, werd uitgerust met 
een lichtreactie groep die zorgt voor een covalente binding van de remmer aan het enzym 
na bestraling met UV licht. Doordat de remmerstructuur ook een biotine groep bevat kan 
het gelabelde eiwit zichtbaar worden gemaakt met behulp van een biotine-streptavidine 
conjugatie. Deze zelfde interactie kan eveneens worden gebruikt om de gelabelde eiwitten 
uit het monster te vissen en na verrijking verder te analyseren. 
De resultaten beschreven in hoofdstuk 3 laten zien dat de eerste generatie probe een goede 
labeling laat zien van recombinant actief ADAM-9, -10 en -17, maar de labeling van de 
geteste MMPs bleef achter. De interactie tussen de probe ML22 en de ADAMs is selectief 
voor de actieve vorm van de proteinases, aangezien na denaturatie of preïncubatie met de 
endogene remmer TIMP-3 geen labeling meer optreedt. Ook preïncubatie met een kleine 
overmaat niet-gebiotinyleerde remmer laat een concentratieafhankelijke afname van de 
labeling zien, een indicatie dat de covalente crosslinking op een specifieke plaats in het 
eiwit plaats vindt. 
Labeling van eiwitten in een complex proteoom zoals een cellysaat van gekweekte 
longkankercellen laat een beperking zien van deze techniek. Aangezien de detectie is 
gebaseerd op visualisatie van biotine worden ook alle endogeen gebiotinyleerde eiwitten 
zichtbaar die in veel hogere concentratie aanwezig schijnen te zijn. Door een vergelijkbare 
probestructuur uit te rusten met een fluorescent (BODIPY-TMR) label te gebruiken kon dit 
probleem worden vermeden, maar de gevoeligheid van detectie was lager, iets dat 
problemen kan opleveren bij de vermoedelijk zeer lage concentraties waarin de 
metalloproteases aanwezig zijn.  
Om een probe te verkrijgen die zowel MMPs als ADAMs labelt is de lichtreactieve groep 
op een andere plaats in de remmerstructuur geplaatst. De probe met de crosslinker op de 
P’1 positie in plaats van de P’2 positie bleek een goede labeling te geven van zowel 
recombinante MMPs als ADAMs en de labeling lijkt effectiever te verlopen bij deze 
nieuwe probe (PPG3). Competitie-experimenten door preïncubatie met TIMP-1 en de niet-
gebiotinyleerde remmer laten zien dat ook de labeling van MMPs (zoals getest voor MMP-






Hoofdstuk 4 beschrijft een tweede mogelijke aanpak voor activiteitsafhankelijke 
proteomics van metalloproteases. Door reversibele remmermoleculen met een zeer hoge 
affiniteit te immobiliseren op een dragermateriaal kan een ligandmateriaal dat selectief is 
voor actieve proteinases gecreëerd worden. Dit materiaal kan vervolgens worden gebruikt 
om de actieve fractie niet alleen te scheiden van de niet-actieve eiwitten, maar ook om de 
actieve metalloproteinases te verrijken. Deze verrijking lijkt noodzakelijk voor detectie en 
vooral kwantificering omdat de concentratie aan actief proteinase in veel gevallen 
uitzonderlijk laag zal blijken te zijn. 
In dit hoofdstuk wordt de evaluatie van een set van 96 nieuwe remmers beschreven. Door 
de aminozuren in de peptidenstructuur van de remmer te variëren kunnen de remmers 
worden geoptimaliseerd voor een hoge affiniteit ten opzichte van de proteinases waarin 
men geïnteresseerd is. Een aantal interessante remmers is verder geëvalueerd waarbij 
enkele structuren een zeer goede remmingefficiëntie bleken te hebben met IC50 waarden 
onder de nM. Na immobilisatie bleek dat een lage remmingsconstante niet per definitie een 
garantie is voor een goede extractieopbrengst, waaruit te concluderen valt dat voor een 
efficiënte verrijking van de actieve metalloproteases optimalisatie op het niveau van de 
daadwerkelijke extractie, en dus de geïmmobiliseerde remmerstructuur wenselijk is. 
Eén geselecteerde remmer is gebruikt voor de extractie van endogeen ADAM-17 uit een 
complex proteoom, een cellysaat van A549 long carcinoma cellen. Na detectie door middel 
van Western blot liet de remmerextractie een verrijkte band van de actieve vorm van 
ADAM-17 zien terwijl een controlemateriaal zonder geïmmobiliseerde remmerligand geen 
extractie gaf. Door een stimulatie van de A549 cellen met een phorbolester te volgen met 
extracties op verschillende tijdspunten konden we laten zien dat de activatie van ADAM-17 
niet veroorzaakt wordt door een verandering van de hoeveelheid eiwit, maar waarschijnlijk 
een translocatie van actief enzym dat in een pool aanwezig is in rustende cellen. Na enkele 
uren stimulatie scheen de hoeveelheid actief ADAM-17 weer af te nemen, een observatie 
die bekend is uit de literatuur voor de totale hoeveelheid ADAM-17. 
 
In hoofdstuk 5 wordt de automatisering van de in het vorige hoofdstuk beschreven 
activiteitsafhankelijke extractie beschreven. Door het geïmmobiliseerde remmermateriaal in 
een cartridge te gieten kan het worden gebruikt in een systeem voor automatische solid 
phase extractie (PROSPEKT II). Door deze extractie te koppelen aan een in-line digestie 
van de geëxtraheerde proteinases met een trypsine reactor kan een volledig gesloten 
monstervoorbewerkingssysteem gecreëerd worden dat gekoppeld kan worden aan een 
geschikte detectiemethode. In dit hoofdstuk wordt de koppeling van het extractieplatform 
aan een vloeistofchromatografiechip met electrospray ionisatie gekoppeld waardoor 
koppeling aan een maasspectrometer en daarmee identificatie van de geëxtraheerde 
eiwitten, mogelijk is. Door de introductie van een verrijkingskolom met een 
anionenwisselaar kunnen de tryptische peptiden die uit de trypsine reactor komen 
opgevangen worden terwijl storende componenten zoals oppervlakteactieve stoffen uit het 
monster verwijderd worden. Elutie met een geconcentreerde oplossing van een vluchtig 
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zout (ammoniumacetaat) gecombineerd met een pH switch van basisch naar zuur bleek een 
goede elutie te geven van de anionenwisselaar naar de HPLC chip. 
De model MMP, MMP-12 is gebruikt voor het evalueren van het analysesysteem, en om te 
compenseren voor variatie is als interne standaard 15N-gelabeld MMP-12 toegevoegd aan 
elk monster. Door deze toevoeging kon een goede lineariteit worden bereikt en werd een 
detectielimiet onder de nM mogelijk. Het spiken van recombinant MMP-12 in diverse 
biologische monsters zoals urine (menselijk en rat) en long lavage vloeistof liet zien dat er 
geen storende matrix effecten optreden in het MMP-12 signaal, een indicatie dat de 
monstervoorbewerking effectief is. 
De applicatie van dit systeem op klinische en biologische monsters heeft tot op heden geen 
identificatie van endogene metalloprotease opgeleverd. Dit wordt enerzijds veroorzaakt 
door de aanwezigheid van sterk geconcentreerde niet-metalloprotease eiwitten die ondanks 
de sterke verrijking van de actieve metalloproteinases nog steeds een sterk signaal geven in 
de massaspectrometer en laat anderzijds het belang zien van de behandeling van de 
monsters voor de analyse. Zaken als vries-dooi cycli, monsters tijdelijk bewaren bij 
kamertemperatuur en de lage endogene concentratie kunnen de aanwezigheid van actieve 
metalloproteinases op den duur zeer negatief beïnvloeden.  
Hoofdstuk 6 beschrijft een aantal projecten waar preliminair werk aan is verricht, en wat in 
een volgend project verder uitgediept zou kunnen worden. De grootste beperking van de 
probes zoals beschreven in de voorgaande hoofdstukken is het feit dat er alleen een indirect 
beeld ontstaat van de situatie in het lichaam. Door vergelijkbare remmermoleculen met een 
radioactief (bv. 99m-technetium) label te synthetiseren kunnen de probes eventueel 
gebruikt worden voor in-vivo beeldvorming van metalloprotease activiteit en nuttig zijn om 
bijvoorbeeld actieve tumoren op te sporen. 
Dit hoofdstuk beschrijft verder een aantal experimenten die aantonen dat de 
monsterbehandeling cruciaal is in het correct analyseren van de actieve metalloproteinases 
in biologische monsters. De standaard proteaseremmer cocktail die wordt toegevoegd aan 
cellysaten om degradatie van eiwitten tegen te gaan blijkt een negatief effect te hebben op 
de activiteit en ABP analyse van ADAM-17, ondanks de afwezigheid van 
metalloproteaseremmers. Ook de keuze voor het detergens dat wordt gebruikt om de 
membraangebonden eiwitten in oplossing te krijgen tijdens cellysis bleek een groot effect te 
hebben op de activiteit van ADAM-17, waarbij Triton X-100 als een veilige keuze 
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